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BACKGROUND 
In 2015 there was an estimated 46.8 million people worldwide living with 
dementia. This number will almost double every 20 years, reaching 74.7 
million in 2030 and 131.5 million in 2050. Although much research focusses on 
the treatment, yet there is neither cure nor treatment that considerably slows 
or stops its progression. In the meantime, the average age of people is 
increasing worldwide and there are estimates of 9.9 million new cases every 
year [1].   
Dementia is a syndrome that results in cognitive decline, functional 
decline and often also neuropsychiatric symptoms (NPS). Different 
(manifestations of ) NPS are described in dementia, e.g. agitation, aggression, 
anxiety, apathy, delusions, depressive symptoms, hallucinations, 
sleeplessness, wandering, and are also referred to as behavioral and 
psychological symptoms in dementia (BPSD) [2]. NPS have been identified as 
an integral part of the disease from the earliest descriptions of dementia, 
described by Alois Alzheimer in the beginning of the 20th Century [3] [4]. Some 
research attributes NPS to neurotransmitter [5][6][7][8] or neuropathological 
changes [9] whereas others describe its etiology more on personality and 
psychosocial factors [10] [2]. In this context the last few years, the 
biopsychosocial model is used, that hypothesizes that the (extent of) the NPS 
is not only explained by the disease itself but also by the physical and 
psychosocial environment of the patients [11]. The prevalence of NPS, 
associated with dementia is estimated at 72%-80% [12][13]. NPS are 
associated with poor quality of life [14][15] of patients with dementia and 
burden for the caregiver [16]. 
In the Netherlands approximately 270.000 people have dementia, 
150.000 do not have a proper diagnosis, 52.000 of these cases are known by 
general practitioners and 70.000 patients reside in Dutch long-term care 
facilities. However, these figures are estimates based on dated research 
[17][18][19]. Nursing home care differs between countries [20]. The 
Netherlands is the only country in the world with specialized Elderly Care 
Physicians (ECP's)[21][22]. Among other types of care for the elderly, e.g. 
geriatric rehabilitation or palliative care, ECP’s provide dementia care to 
people that reside on Dementia Special Care Units (DSCUs). Most of the 
institutionalized patients with dementia reside on DSCUs [23][24]. On these 
units, care is provided by multidisciplinary teams consisting of ECP’s, 
pharmacists, psychologists and nurses, all of whom are employed by the 
nursing home. DSCUs are specialized in treating patients in Global 
Deterioration Stages 4 - 7 of dementia and unit sizes vary from 5 to 30 
patients, with typically 1 nurse per 5-6 residents. Usually patients have one 
nurse assigned as primary responsible caregiver, that is also involved in 
reporting NPS in patients and discussing the patients’(medical) treatment [25].
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Psychosocial interventions are the first choice of management for NPS 
[26][27][28], however, NPS are frequently a reason for prescription of 
psychotropic drugs (PDs) [25][29][30], i.e. antipsychotics, anxiolytics, 
hypnotics, antidepressants, anticonvulsants, and anti-dementia drugs. PD use 
rates in institutionalized patients with dementia vary from 63%-75% 
[12][31][30].   
PDs have considerable side effects. Antipsychotics are associated with 
increased occurrence of extrapyramidal symptoms, somnolence, increased 
risk for stroke and pneumonia and higher mortality rates [32][33][34], 
although controversy exists of the latter[35][36][37]. Anxiolytic and hypnotic 
drugs are associated with falls [38]. PDs in general [14] and antipsychotics in 
particular also have negative effects on quality of life [15]. It is also known 
that antipsychotic use varies among countries between 11% and 54% 
[30][39][40][41][42][43].  
Guidelines emphasize the restricted, short-term use [28]. However, 
long-term inappropriate use of PDs is common [44]; a recent study found that 
31% of the nursing home patients used PDs for a sustained period (≥2 years) 
[31] and in another study 74 % of dementia patients in nursing homes used 
PDs for 83% of their nursing home stay [45]. Many studies report that PDs are 
used too long [46] [44][31], with sometimes duplicate prescription [47][48], 
and without a proper indication [49][50]. This does not comply with available 
evidence on risks, side effects, limited evidence for efficacy of these drugs and 
long-term inefficacy [34][51]. 
In sum, there are many challenges physicians face in treating 
dementia patients for NPS appropriately. Moreover, there is an ever 
increasing interest in reducing PD use in nursing homes internationally 
[52][53]. However, with the initiatives to reduce the frequency of 
(inappropriate) PD use, there seem to be little attention for prescriptions that 
have appropriate indications and appear to be effective when evaluated. 
While that could be key for beneficial PD use, consequently improving its 
effectiveness and reducing inappropriate use. Potentially, intervening on the 
appropriateness instead of just reducing these prescriptions could lead to 
improved NPS treatment. 
 
APPROPRIATENESS OF PSYCHOTROPIC DRUG USE 
Many different definitions have been established to describe the 
appropriateness of drug prescriptions, that include indications [54], regularly 
evaluating the prescriptions [55], the administration and pharmaceutical 
aspects like dosage, drug-drug interaction, drug-disease interaction and 
therapy duration [56][57]. For many of these (individual) aspects there exist 
evidence based guidelines for PD use that formulated recommendations. 
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Aspects that relate to the broader concept of appropriateness, that integrates 
guideline adherence, have previously not been studied.  
 
AIM OF THIS THESIS 
PDs are prescribe too long and inappropriately for NPS, however, we do not 
exactly know what appropriate PD prescription in dementia is. Therefore, the 
first aim of this thesis is to investigate the appropriateness of PD prescriptions 
and its associations; a research index needs to be developed that is specialised 
in measuring all relevant indicators of the appropriateness of PDs for NPS in 
dementia.  
Using this index the current status of the appropriateness of these 
prescriptions can be calculated and factors associated to more or less 
appropriateness can be explored.     
The second aim of this thesis is to execute an intervention to improve 
the appropriateness of these prescriptions and measure its effect with the 
newly developed index. 
 
RESEARCH QUESTIONS AND GENERAL OUTLINE 
How to measure appropriateness of psychotropic drug prescriptions? 
Although there are different assessment instruments to objectify (potentially) 
inappropriate prescriptions, e.g. Beers criteria [58], Medication 
Appropriateness Index [59] and START and STOPP [60], none of these are 
specifically suited to measure the appropriateness of PD prescriptions for NPS 
in patients with dementia. Therefore a measure especially suited for this 
purpose needs to be developed.  
Chapter 3 gives an overview of the development of an instrument that 
is suited for measuring appropriateness of PD prescriptions for NPS in patients 
with dementia in nursing homes, and to test its reliability and validity.   
 
How appropriate are psychotropic drug prescriptions for neuropsychiatric 
symptoms? 
Chapter 4 concerns the assessment of the appropriateness of PD prescription 
for NPS in nursing home patients with dementia. The study design is described 
in chapter 2. Current status of the appropriateness of PD prescription for NPS 
in nursing home patients with dementia is explored, and more specifically the 
domains of appropriateness of PD prescription for NPS that contributed the 
most to appropriate use are investigated. Potential  differences between PD 
types in the appropriateness of use and association between the 
appropriateness of PD prescription and the number of PDs used (frequency of 
use) per patient, DSCU, and elderly care physician are studied.  
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What factors are associated with the appropriateness of psychotropic drug 
prescriptions? 
Although several studies [11][61][62][63][64][65] investigated factors 
associated with the frequency of PD use, we only found one study that reports 
about factors associated with the appropriateness of PD prescriptions in 
dementia; it was found that presence of behavioral symptoms and female sex 
were associated with more appropriate indications of benzodiazepines [54].  
Chapter 5 describes research on the appropriateness of PD 
prescription for NPS in nursing home patients with dementia and its 
associations, i.e. related to patients, physicians and nurses. The study design is 
also described in chapter 2. 
 
How to improve the appropriateness of PD prescriptions? 
The Dutch Healthcare Inspectorate advises to use national guidelines in the 
prescription of PDs and to biannually evaluate the effect of these prescriptions 
and if ineffective stop these prescriptions. 
Both systematic reviews [66][67] as well as individual studies [66][60][68] in 
different settings, i.e. hospital [66][60] and nursing homes [68], show that a 
multidisciplinary medication review with the involvement of a pharmacist [67] 
and the additional presence of a nurse [67] has beneficial effects on 
appropriate drug prescription. Although there is evidence to suggest that a 
medication review may result in the improved appropriateness of drug 
prescription in general [69][68], studies on psychotropic drug prescription in 
dementia are lacking thus far.  
This trial, the PROPER-II study, of which the design was described in 
chapter 6 and the outcomes in chapter 7, concerns the effect of a structured 
multidisciplinary medication review supported by education on the 
appropriateness of PD prescription for the treatment of NPS in nursing home 
patients with dementia.  
Finally in chapter 8 the main findings of this thesis are summarised and 
discussed. 
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ABSTRACT 
Background 
Nursing home patients with dementia use psychotropic drugs longer and 
more frequently than recommended by guidelines implying psychotropic 
drugs are not always prescribed appropriately. These drugs can have many 
side effects and effectiveness is limited. Psychotropic drug use between 
nursing home units varies and is not solely related to the severity of 
neuropsychiatric symptoms. There is growing evidence indicating that 
psychotropic drug use is associated with environmental factors, suggesting 
that the prescription of psychotropic drugs is not only related to (objective) 
patient factors. However, other factors related to the patient, elderly care 
physician, nurse and the physical environment are only partially identified. 
Using a mixed method of qualitative and quantitative research, this study aims 
to understand the nature of psychotropic drug use and its underlying factors 
by identifying: 1) frequency and appropriateness of psychotropic drug use for 
neuropsychiatric symptoms in nursing home patients with dementia, 2) 
factors associated with (appropriateness of) psychotropic drug use.  
 
Methods 
A cross-sectional mixed methods study. For the quantitative study, patients 
with dementia (n=540), nursing staff and elderly care physicians of 36 
Dementia Special Care Units of 12 nursing homes throughout the Netherlands 
will be recruited.  Six nursing homes with high average rates and six with low 
average rates of psychotropic drug use, based on a national survey about 
frequency of psychotropic drug use on units, will be included. Psychotropic 
drugs include antipsychotics, anxiolytics, hypnotics, antidepressants, 
anticonvulsants and anti-dementia drugs. Appropriateness will be measured 
by an instrument based on the Medication Appropriateness Index and current 
guidelines for treatment of neuropsychiatric symptoms. Factor associated to 
psychotropic drug use, related to the patient, elderly care physician, nurse and 
physical environment, will be explored using multilevel regression analyses. 
For the qualitative study, in depth interviews with staff will be held and 
analyzed to identify and explore other unknown factors.  
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Discussion 
This study will provide insight into factors that are associated with the 
frequency and appropriateness of psychotropic drug use for neuropsychiatric 
symptoms. Understanding  psychotropic drug use and its associations may 
contribute to better dementia care. 
 
Keywords 
Nursing home, dementia, neuropsychiatric symptoms, psychotropic drug use, 
environment.
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BACKGROUND 
In the Netherlands approximately 37.000 patients with dementia reside in 
Dementia Special Care Units (DSCUs) of nursing homes [1][2]. The prevalence 
of neuropsychiatric symptoms (NPS) associated with dementia is high, more 
than 80% [3], and frequently a reason for prescription of psychotropic drugs 
(PDs) [4][5][6]. However, psychosocial interventions and restraints are also 
commonly used in the management of NPS [7]. Psychotropic drug use (PDU) 
rates in institutionalized patients with dementia vary from 63%-75% [8][9][6].  
It is also known that antipsychotic use varies among countries between 11% 
and 52% [6][10][11][12].  
PDs have considerable side effects. Antipsychotics are associated with 
increased occurrence of extrapyramidal symptoms, somnolence, increased 
risk for stroke and pneumonia and higher mortality rates [13][14][15].  
Anxiolytic and hypnotic drugs are associated with falls [16]. PDs in general [17] 
and antipsychotics in particular also have negative effects on quality of life 
[18].  
Long-term or inappropriate use of antipsychotics is common [19], a 
recent study found that 31% of the nursing home patients used PDs for a 
sustained period of at least 2 years [9] and in another study 74% of dementia 
patients in nursing homes used PDs for 83% of their nursing home stay [20]. 
This does not comply with available evidence on risks, side effects, limited 
evidence for efficacy of these drugs and  long-term inefficacy [15][21][22]. 
That is why guidelines emphasize the restricted,  short-term use and thus the 
appropriateness of PDU [23].  
PDU varies considerably among nursing homes and DSCUs [24] [25]. 
This could partly be explained by different prevalence rates of NPS among 
patients on DSCUs [3]. However there is growing evidence that this inter-DSCU 
variation in PDU is not only related to the severity of patients’ NPS [6][26]. The 
PDU variation is also related to drug prescription policies of the Elderly Care 
Physician (ECP) [5], staff distress/workload [26], physical environmental 
factors [25], and the bed capacity of the nursing home [27](see figure 1). 
   
Although studies [26][27] investigated frequency of PDU and its 
associated environmental factors a large proportion, 80%, of the variation in 
PDU between DSCUs is unexplained [25]. The unexplained variation of PDU, 
the long-term use and the inter-DSCU variation raise questions not only about 
appropriateness of prescription, but also about factors associated with the 
variation in frequency and appropriateness of PDU. That is why we propose a 
conceptual framework of PDU and four categories of factors with which PDU 
is hypothesized to be associated: patient, ECP, nurse and physical 
environment. More specifically, possible other associations related to PDU 
are: 1. patients’ demographic characteristics and influence of psychosocial 
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environment (relatives and other patients) 2. physicians’ demographic 
characteristics and attitude to dementia care 3. nurses’ job satisfaction, 
experienced organizational culture, demographic characteristics and attitude 
to dementia care 4. the physical environment, e.g. nursing home 
characteristics and DSCU characteristics.   
 Depicted in the conceptual framework we hypothesize that PDU 
frequency and appropriateness are associated with these four categories of 
factors, the use of psychosocial interventions and restraints are seen as 
alternatives to PDU in the framework (see figure 1). To obtain full insight in 
(possible) associations mixed methods of quantitative and qualitative research 
will be used. 
We aim to study: 1. the frequency and appropriateness of PDU for 
NPS in nursing home patients with dementia 2. factors associated with 
frequency and appropriateness of PDU related to patient, ECP, nurse and 
physical environment. 
 
Figure 1. A conceptual framework on psychotropic drug use in nursing homes 
and its associations. 
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METHODS/ STUDY DESIGN 
Design and eligibility 
This study, the PROPER I study (PRescription Optimization of Psychotropic 
drugs in Elderly nuRsing home patients with dementia) is a cross-sectional 
mixed methods study and will be followed by the PROPER II study (Smeets et 
al., submitted), a multi-center cluster randomized controlled, pragmatic trial 
on the efficacy of structured repeated multidisciplinary review on 
psychotropic drugs. The eligibility of nursing homes is based on a survey 
among ECPs working in nursing homes that we will carry out among all 
members of Verenso, the Dutch association of ECPs and community 
geriatricians. ECPs will be asked to count the number of patients, living on the 
DSCU they are responsible for, that receive one or more PDs. Nursing homes 
will be eligible if their ECPs fill in the survey about PDU for at least 3 DSCUs. 
 
Study population and recruitment 
According to our calculations (see section on sample size), 36 DSCUs need to 
be recruited. Based on the results of the survey, 36 DSCUs will be divided over 
six nursing homes with high and six with low DSCU overall PDU rates. DSCUs 
with medium rates will be accepted if the nursing home’s overall rate is high 
or low on average; at least two out of three DSCUs need to score high or low 
within a nursing home. With this selection method the contrast in PDU among 
nursing homes is increased, which could facilitate finding relevant parameters 
of PDU, without loss of statistical dispersion for our analyses. No geographical 
considerations will be made in the recruitment process.   
 
Measurements          
The following instruments will be used to explore frequency and 
appropriateness of PDU and its associations, i.e. patient, ECP, nurse and 
physical environment related associations. Associations will be explored by 
quantitative and qualitative measures. 
Quantitative measures 
Frequency and appropriateness of PDU, primary outcome 
PDU will be classified using the Anatomical Therapeutical Chemical (ATC) 
classification [28] and grouped into antipsychotics, anxiolytics, hypnotics, 
antidepressants, anticonvulsants and anti-dementia drugs. 
For determining appropriateness of psychotropic drug use a screening tool 
will be developed, based on the Medication Appropriateness Index (MAI). The 
MAI was developed in 1992 [29] to determine the drug’s appropriateness for 
individual patients on 10 items and is proven to be reliable [30] and applicable 
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in the Dutch nursing home setting [31]. However, the MAI is not specifically 
developed as a tool to screen medical files for appropriateness of prescription 
of individual psychotropic drugs in dementia and thus does not sufficiently 
suit the needs for this study. We will therefore adapt the original MAI and 
develop an instrument that screens medical files for appropriateness of 
psychotropic drug prescription in dementia. The instrument will primarily 
screen PDs based on the Dutch association of ECP and community 
geriatricians (Verenso) guideline for problem behavior [23]. The instrument 
will also include information about interactions and contraindications that 
originates from the database of the Royal Dutch Association for the 
advancement of  Pharmacy  (KNMP) [32]. PD information that is not provided 
by the Dutch Verenso guideline, will be derived from ‘Farmacotherapeutisch 
Kompas’ [33], published by the Dutch Health Care Insurance Board (CVZ) and 
based on the summary of product characteristics (SPC)[34]. Items will be 
weighted by an expert panel of pharmacists and ECPs who categorize the 
relative contribution of each item to the level of drug appropriateness.  
Patient factors                
NPS will be assessed with the validated Dutch version of the 12-item 
Neuropsychiatric Inventory- Questionnaire (NPI-Q) [35] [36]. The NPI-Q 
assesses NPS in dementia and caregiver distress. The NPI-Q measures the 
occurrence and severity of NPS on a three-point Likert scale and associated 
caregiver burden on a five-point Likert scale.    
 Additionally, frequency of agitation and aggression will be assessed 
with the Cohen-Mansfield Aggression Inventory (CMAI) [37], of which the 
original and the translated Dutch version has been proven reliable and valid 
[38][39]. The CMAI consists of 29 individual items, each rated at a seven-point 
Likert scale, combined to 3 subscales of (physically) aggressive, physically non-
aggressive and verbally agitated behavior [38].   
 Information about other patient characteristics that will be derived 
from patients’ charts are: duration of institutionalization, dementia-type, 
number of falls, demographic characteristics (date of birth, sex), the use of 
activities, the use of psychosocial interventions (reality orientation training, 
reminiscence, validation, aromatherapy, music therapy, light therapy, 
psychoeducation, sensory activation/snoezelen, multisensory stimulation, 
cognitive stimulation and psychomotor therapy) and restraints (use of side 
rails, using a deep chair for patients, use of table stand or chair at table, forced 
or camouflaged administration of sedative medication, fixing patients with 
tools (tires, span sheets, tear suits, wristbands, swedish bands), seclude in 
room with/without the door locked, forced administration of fluid or food and 
use of electronic alerts). 
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ECP factors          
‘Attitude to dementia care’ will be measured by Approaches to Dementia 
Questionnaire (ADQ) [40]. The ADQ consists of 19 items, on a five-point Likert 
scale and measures hopefulness and person-centredness of professionals in 
dementia care.  Higher scores indicate positive attitudes. The total score 
ranges from 19-95, the 8-item sub score ‘Hope’ from 8-40, and the 11-item 
sub score ‘Person-centeredness’ from 11-55. Information about demographic 
characteristics of the physician/ECP will be collected: age, sex, years of work 
experience, number of years since education/specialization. 
Nurse factors         
Experienced organizational culture will be measured with the Competing 
Values Framework Scale (CVFS)[41], the validated Dutch version [42], a 6-item 
scale where four phrases need to be set in an order of personal relevance. The 
CVFS assesses the 6 dimensions of the competing values framework [43] : 
dominant organizational characteristic, administration, management style, 
organizational glue, strategic emphasis and criteria for success.  
Workload will be assessed with a workload questionnaire ‘werkdruklijst’ 
developed by De Jonge [44][45]. This scale consist of 10 items about unit 
workload, each item can be scored on a five-point Likert scale.     
Situations, feelings and thoughts about dementia care will also be 
administered, with a 29-item scale, which will be published as the Strain in 
dementia Care (SDC) scale (Michael Bird and Anna-Karin Edberg, personal 
communication 2013). There’s a four-point Likert scale for each item, also a 
score on another four-point Likert scale can be given for professional 
caregiver burden related to the item. Higher scores indicate high workload.   
Job satisfaction will be measured with the Maastricht Work 
Satisfaction Scale for Healthcare (MAS-GZ) [46][47]; a 21-item, five-point 
Likert scale that focuses on nursing staff satisfaction. It consist of seven 
subscales with three items each about satisfaction with: quality of care, 
opportunities of self-actualization/growth, supervisor, possibilities for 
promotion, clarity of tasks and rules, contact with colleagues and contact with 
patients. ‘Attitude to dementia care’ will be measured by the ADQ (see 
physician level) [40].  
Information about demographic characteristics of the nurse will be collected: 
age, sex, educational level, work experience, number of years since education.  
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Factors of the physical environment               
Physical environmental characteristics of the DSCU will be assessed using the 
Therapeutic Environment Screening Survey for Nursing Homes (TESS-NH)[48]. 
The TESS-NH contains 84 discrete items plus an open global scale that covers 
13 domains, i.e. number of patients on unit, exit control, maintenance, 
cleanliness, safety, orientation/cueing, privacy, unit autonomy, outdoor 
access, lighting, noise, visual/tactile stimulation, space/seating and 
familiarity/home likeliness [48].  
Other information about DSCU characteristics that will be collected 
are: number of staff per unit, number of staff during different shifts. 
 
Qualitative interviews, ECP and nurse level 
The ECP and 1-2 members of nursing staff will be interviewed about PDU. The 
qualitative interviews will be semi-structured and based on the Straussian 
grounded theory approach [49][50]. Interviews will be guided by a checklist of 
the following (relevant) topics:  influence of psychosocial environment 
(relatives and other patients), PD prescription in practice, own beliefs, beliefs 
of colleagues,  beliefs of patient’s family, PDU now and in the past, influence 
of the institution, best solutions for NPS, education, politics and media. 
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Table 1. Mixed methods research parameters/instruments 
 
Quantative  Parameters Instruments Registered by 
Patient level  Frequency of PDU ATC classification 
codes 
Researchers 
Appropriateness of PDU To be announced Researchers 
Neuropsychiatric 
symptoms 
NPI-Q  Nurse (web 
based) 
Agitation and aggression CMAI  Nurse (web 
based) 
Other patient 
characteristics 
Case report file Researchers  
Physician level 
 
 
 
Nurse level 
 
 
 
 
 
 
 
 
 
Physical 
environmental 
level 
Attitude to dementia 
care 
ADQ ECP (web based) 
Demographic 
characteristics 
Case report file ECP (web based) 
Organizational culture CVFS Nurse (web 
based) 
Workload/burnout SDC + Werkdruk 
(De Jonge) 
Nurse (web 
based) 
Work satisfaction MAS-GZ Nurse (web 
based) 
Attitude to dementia 
care 
ADQ Nurse (web 
based) 
Demographic 
characteristics 
Case report file Nurse (web 
based) 
Physical environment TESS-NH Researchers 
Other DSCU 
characteristics 
Case report file Researchers 
Qualitative Parameters Instruments Registered by 
Attitudes and 
beliefs 
Relevant qualitative 
factors ECP 
Semi structured 
interview 
Researchers 
Relevant qualitative 
factors nurse 
Semi structured 
interview 
Researchers 
Psychotropic drug use (PDU), Anatomical Therapeutical Chemical (ATC), Neuropsychiatric 
Inventory- Questionnaire (NPI-Q), Cohen-Mansfield Aggression Inventory (CMAI), Approaches to 
Dementia Questionnaire (ADQ), Elderly Care Physician (ECP), Competing Values Framework 
Scale (CVFS), Strain in dementia Care (SDC), the Maastricht Work Satisfaction Scale for 
Healthcare ’Maastrichtse Arbeidssatisfactie Schaal voor de Gezondheidszorg’ (MAS-GZ), 
Therapeutic Environment Screening Survey for Nursing Homes (TESS-NH).  
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Data analysis 
Quantitative (descriptive and multivariate) and qualitative analyses will be 
performed.     
For quantitative data analysis a multilevel model is built to investigate 
the potential associations with the frequency of PDU and with the 
appropriateness of PDU, taken into account that appropriateness of PDU is 
nested within DSCUs. 
Data collection and analysis of the qualitative semi-structured interviews will 
be conducted as an iterative process with saturation as a guiding principle[51], 
implying interviews will be carried out until knowledge saturation is reached.  
This is known as the constant comparative method, which is part of the 
grounded theory approach [51].  
 
Sample size 
According to the n/10 rule [52][53] 360 patients are sufficient to study the 
number of variables needed for this study. 67% of the patients are expected 
to use PDs, which means that in total 540 patients need to be recruited. 
Regarding good sampling and an average cluster size of 15 patients per DSCU, 
36 DSCUs of twelve different nursing homes will be recruited. 
 
Ethical approval 
The study is undertaken in accordance with the declaration of Helsinki and will 
be carried out in accordance with the applicable rules in the Netherlands. 
According to the Medical Ethics Committee of the region Arnhem-Nijmegen, 
the Netherlands, the study does not need to be conducted according to the 
Medical Research Involving Human Subjects Act (WMO), because patients will 
not be directly involved. Relatives, if not available other representatives, of 
patients will be informed and asked if they object to the collection of data. If 
the relatives or representatives object, patients will be excluded from the data 
collection.  
 
DISCUSSION  
The high rates of long-term PDU [9] in combination with the risk of major and 
hazardous side effects, limited evidence for efficacy, long-term inefficacy 
[15][21][22] and guidelines recommending to regularly evaluate PDU [23], 
make it crucial to study PDU appropriateness and its associations.  
It is hypothesized that the frequency as well as appropriateness of 
PDU varies between DSCUs, because of factors related to patient, ECP, nurse 
and physical environment, as described in a conceptual framework (figure 1). 
More specifically, it is expected that factors like workload and staff distress 
influence the appropriateness of PDU.    
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A strength of this study is that the recruitment focuses on nursing homes/ 
DSCUs with low versus those with high PDU. Knowledge about extreme, i.e. 
low or high, PDU and its associations is most important in dementia care. 
         
Although the instrument used for measuring appropriateness of PDU needs to 
be developed specifically for this study, no other instruments known are 
suitable to investigate the appropriateness of PDU for NPS. However, it should 
be taken into account that the instruments’ assessment of appropriateness of 
PDU relies on medical files, which may be subjected to bad reporting. Yet, in 
our view this procedure is considered to be more objective than personal 
reports of ECPs. 
Many of the instruments used for this study are well known in this field 
of research, and will contribute to giving clear insight in factors related to 
PDU, which can be used in improving nursing home patient care.  
The mixed design of the study is another strength of this study, 
interviewing ECPs and nurses can reveal relevant factors that are not 
measured with quantitative instruments. So, this study not only gives insight 
into frequency and appropriateness of PDU, but also into a diversity of 
possible associations, which can be used in future quantitative research. 
PROPER I will provide insight in associations of (appropriateness of) PDU and 
thus the barriers of optimal prescription, which is the first step towards safer 
PDU. 
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ABSTRACT 
Objective  
The aim of this study is to develop an index derived from the Medication 
Appropriateness Index (MAI) items that is suited for clinical studies evaluating 
appropriateness of psychotropic drug use (PDU) for neuropsychiatric 
symptoms (NPS) in patients with dementia in nursing homes, and to test its 
reliability and validity. 
 
Study design and setting  
An expert panel reviewed the MAI items in order to develop items for 
appropriateness of PDU; a second, independent, expert panel determined 
content validity of the items. An inter-rater reliability study was conducted 
(N=54) and a summated index score, based on weighted item scores, was 
developed to enhance the use in clinical studies. Construct validity was 
explored using a representative sample of 560 medical records. 
 
Results   
Five existing MAI items were used, the MAI item ‘indication’ was adjusted, a 
new item ‘evaluation’ was added and scoring rules were based on guideline 
recommendations, to create the Appropriate Psychotropic drugs use In 
Dementia (APID) index. The second expert panel concluded that all items 
contributed to the construct ‘appropriateness’. All items and the summated 
index score had moderate to almost perfect inter-rater reliability 
(ICCagreement 0.577-1). The summated index score showed promising 
construct validity, e.g. no multicollinearity issues were found. 
 
Conclusion 
The results of this study show that the APID index is reliable and valid for 
measuring appropriateness of PDU for NPS in dementia in nursing homes in 
clinical studies. 
 
Keywords 
Appropriate, psychotropic drug use, dementia. 
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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psychotropic drugs (PDs) are frequently prescribed in nursing homes [1] 
[2][3][4], in particular for the treatment of neuropsychiatric symptoms 
(NPS)[3][5], e.g. agitation/aggression, psychosis, depression and apathy [6]. 
Many different groups of PDs are prescribed for this purpose, i.e. 
antipsychotics, anxiolytics, hypnotics, antidepressants, anticonvulsants and 
anti-dementia drugs [7]. Although PDs are frequently prescribed, their efficacy 
is limited [8][9], especially for the long term [10]. PDs are not only used 
frequently but also persistently, for a period longer than 3 months [11][12], 
Given that antipsychotics prescribed for NPS in dementia should only be used 
for a  period of 3 months [13]anxiolytics and hypnotics for a period of 2-4 
weeks [13] this indicates that antipsychotics, anxiolytics and hypnotics in 
particular have inappropriate duration of therapy [7]. Additionally, Finkers et 
al. found that the majority of the patients in nursing homes have at least one 
drug prescribed of which the indication was unknown [14]. These findings 
point at inappropriate use.      
Furthermore, adverse drug events [15] and hospitalization have been 
related to inappropriate prescription [16][17]. Particularly, antipsychotics have 
been shown to cause adverse events, i.e. extra pyramidal symptoms, 
somnolence, increased risk of falls, stroke and mortality [18][19][20][21]. 
Pinpointing at inappropriateness of psychotropic drug use (PDU) may help 
optimizing it in the future, and may even reduce adverse events. 
What is new? 
 
Key findings  
 A research index is developed to measure appropriate psychotropic 
drug use in nursing home patients with dementia, with moderate to 
almost perfect inter-rater reliability and good construct validity. 
 
What this adds to what was known? 
 The newly developed index adds a method for medical file research in 
measuring appropriateness of psychotropic drug use for 
neuropsychiatric symptoms in dementia. 
 
What is the implication and what should change now? 
 With this instrument we are not only able to look at absolute 
prescription rates but also to its appropriateness, which helps 
clinicians to optimize and not just reduce psychotropic drug use. 
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The retrospective application of ‘appropriateness’ criteria to assess 
medication use is referred to as drug utilization reviews [22]. Based on this 
concept several tools and indexes have been developed for the measurement 
of inappropriate drug use [23]. One of these has been shown to be reliable 
[24] and applicable in the nursing home setting [25], the Medication 
Appropriateness Index (MAI) [26]. However, the MAI is an index to measure 
appropriateness of drug prescription in general, but it is not specifically 
developed for assessing appropriateness of PDU for NPS in dementia. 
Additionally, the MAI does not fit specific drug utilization formularies, which is 
preferable when drug utilization reviews are applied [27] [28]. Formularies 
that contain evidence-based international medication recommendations for 
physicians on when and how to use PDs for patients with dementia and NPS, 
should be applied.   
Hence, to estimate appropriateness of PDU for NPS in dementia, the 
MAI has to be adjusted [29].  
The aim of this study is to develop an index that is suited for 
measuring appropriateness of PDU for NPS in patients with dementia in 
nursing homes, and to test its reliability and validity.   
 
METHODS    
For the use in clinical research [30], an index to measure appropriateness of 
PDU, prescribed for NPS in patients with dementia in nursing homes, based on 
patient medical record inspection [31], was developed. To enhance its use for 
clinical studies a summated index score was constructed [32]. The 
development of the index was guided by a formative model [33]. This means 
that the items, or causal indicators in this case [34], together determine the 
construct ‘appropriateness’ instead of reflecting the underlying construct.  
This also implies that neither Classical Test Theory nor Item Response Theory 
are applicable [33]. In figure 1, an example is provided from other research. 
Similar use of these models can be applied in measuring drug use where, for 
example, drowsiness is a reflective measure for (in)appropriate psychotropic 
drug use and the correct indication is a formative measure for appropriate 
drug use.  
Index development was performed in the following step-by-step 
approach using measurement techniques according to the work of 
Diamantopoulos [35], Streiner and Norman[36], and de Vet [33] : 1) the index 
construction (see section 2.1); 2) the study of item inter-rater reliability (2.2); 
3) the construction of a summated index score (2.3); and 4) the study of 
construct validity (2.4).  
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Figure 1. Graphical representation of a reflective (a) and formative model (b). 
Source, reprinted with permission: De Vet H, Terwee C, Mokkink L KD. 
Measurement in Medicine: A Practical Guide. Cambridge; 2011. 
 
For this study we used two expert panels and three samples of nursing home 
patients with dementia. These will be described in the pertaining sections. All 
statistical analyses were performed using IBM SPPS Statistics version 20.0. 
 
Index development 
An expert panel of one pharmacist and four elderly care physicians (expert 
panel 1) developed the index by extensively reviewing the literature [30], and 
thus the constructs’ contextual domain [37]. All panel members are also 
scientists who have extensive knowledge in the field of dementia research. 
The development was validated by a second independent expert panel (expert 
panel 2). Expert panel 2 consisted of ten clinical and scientific experts in PDU 
and NPS in dementia, i.e. three clinical pharmacologists, one pharmacist, two 
geriatricians/pharmacologists, one psychiatrist and three elderly care 
physicians.  
The index development consisted of two parts; (2.1.1) selection of items for 
‘appropriateness of PDU for NPS in dementia’, (2.1.2) development of scoring 
rules and instructions for medical record inspection.  
 
Selection of items for ‘appropriateness of PDU for NPS in dementia’ 
To establish which items determine the construct ‘appropriateness of PDU for 
NPS in dementia’, expert panel 1 used the MAI items as a basis. The MAI 
consists of 10 items, i.e. indication, effectiveness, dosage, correctness of 
directions, practicality of directions, drug-drug interaction, drug-disease 
interaction, duplication, expense and duration of therapy [31]. The panel 
members were asked to identify which of these were relevant items and 
whether new items should be added for the construct ‘appropriateness of 
PDU for NPS in dementia’. Subsequently, expert panel 2 was asked if each of 
the preselected items was relevant, to determine content validity.  
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Development of scoring rules and instructions for medical record inspection 
The index has to focus on the appropriateness of PDU for NPS in nursing home 
patients with dementia. Therefore, PDs that had a clear indication for 
psychiatric disorders in the medical record were excluded from scoring. The 
expert panel considered sleeping disorder and delirium to be an exception, as 
these are frequently associated with dementia and are difficult to 
differentiate from NPS. Therefore, both were also included in the scoring. 
This resulted in the following inclusion criteria: a) PDs prescribed for 
NPS, b) PDs prescribed for sleeping disorder in dementia, c) PDs prescribed for 
delirium in dementia, based on the indication found in the medical record, d) 
when an indication for the PD was not found in the medical record, it was 
assumed that the PD was prescribed for NPS.  
 
First, three ordinal response categories were constructed: appropriate, 
marginally appropriate and inappropriate, scoring 0, 1 and 2 respectively.  This 
scoring structure makes it possible to add multiple PDs prescribed for one 
patient. Hence, a patient’ overall appropriateness score can be given.   
Second, expert panel 1 constructed scoring rules for these response 
categories, to unify the interpretation by different raters. The scoring rules 
were primarily based on the Verenso guideline for problem behavior (VGPB) 
[7]. This guideline, based on evidence from international research, includes 
recommendations for medical treatment of NPS in dementia. 
 Additionally, the scoring rules included information about drug-drug 
interactions and drug-disease interactions that originates from the database 
of the Royal Dutch Association for the advancement of Pharmacy (KNMP) [38]. 
Information about indication, dosage and duration of therapy of specific PDs 
that was not provided by the VGPB guideline, was derived from the 
‘Farmacotherapeutisch Kompas’ [39]. Both the KNMP and the 
‘Farmacotherapeutisch Kompas' are databases that derive their information 
from the summary of product characteristics (SmPC)[13]. The Medication 
Evaluation Board published the SmPC. Henceforth, these databases will be 
referred to as the SmPC.      
 Drugs were grouped using the Anatomical Therapeutic Chemical 
classification (ATC) [40], on ATC3 level, into antipsychotics (N05A) anxiolytics 
(N05B), hypnotics (N05C), antidepressants (N06A), anticonvulsants (N03A) and 
anti-dementia drugs (N06D) [3].  
 
The appropriateness of PDU was assessed for the used PDs per patient on the 
day of medical record inspection. Information was obtained from the patient’s 
medical records and pharmacist files. Expert panel 1 determined the medical 
record inspection periods per item and per drug group. These periods are the 
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dates in the medical record where the physician could have written down 
relevant information needed for the rater to score the item.    
Prior to data collection the scoring rules and instructions for medical 
record inspection were pilot tested twice, by three researchers, to test if the 
index was applicable and to adjust the medical record inspection periods 
where needed. In both pilot tests, the medical records of ten nursing home 
patients were rated.  
 
Item inter-rater reliability 
To study inter-rater reliability of the items, two independent raters assessed a 
random sample of 54 medical records and pharmacist files (sample 1), drawn 
from the PROPER-study I [30] sample. All subjects from the sample were 
patients residing in Dementia Special Care Units (DSCUs).    
  
Firstly, the inter-rater reliability analysis focused on absolute agreement and 
chance-adjusted agreement. Secondly, two sources of (dis)agreement 
between raters were addressed: the application of scoring rules and the 
selection of relevant text from the medical record.  
To obtain more insight into the influence of the selection of relevant 
text from the medical record on reliability, labeled as ‘medical record 
extraction factor’, and the quality of reporting by the elderly care physicians,  
a second reliability study on an independent sample (sample 2) was 
performed by three practicing elderly care physicians and a researcher. For 
this study a sample of 49 patient records from three DSCUs of two different 
care organizations that were not involved in the PROPER- study I was used.
   
Percentage of agreement was calculated and the Intraclass Correlation 
Coefficient for agreement (ICCagreement) was used for inter-rater reliability 
analysis [36] [41]. Considering  that the magnitude of the ICCagreement is 
associated with prevalence [42], the proportion of positive agreement (both 
raters scored the item ‘appropriate’, both scored ‘0’), and the  proportion of 
negative agreement (both raters scored the item ‘inappropriate, both scored 
‘1’ or ‘2’) per item were also calculated. The following interpretation of the 
ICCagreement was used: slight <0.20, fair 0.21-0.40, moderate 0.41-0.60, 
substantial 0.61-0.80, almost perfect 0.80-1.00 [43] [44].   
Construction of a summated index score             
To enhance the index’ use in clinical research a sum score for the index, i.e. a 
summated index score was constructed. A summated index score creates a 
summary measure for appropriate PDU and improves its utility in clinical 
research [32], so that both individual PDs or multiple PDs used by a single 
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patient can be scored. For example, groups of PDs and patients can easily be 
compared on a particular moment or prospectively in time.  The whole 
PROPER-study I sample, of 560 patients residing on DSCUs, was used for the 
construction of a summated index score (sample 3).   
Expert panel 2 was asked to weigh the relative importance of each of the 
items, on a scale of 1 to 10, which we used to create the summated index 
score. This way, the relative contribution of the items to a summated index 
score could be calculated using mean item weights. 
In applying a formative model inter-item correlations are not expected and 
internal consistency of the items is not implied [45][37]. However, excessive 
collinearity among items makes it difficult to separate the distinct influence of 
the items on the latent variable, the construct ‘appropriateness’[35]. 
Considering that the summated index score is a measure for this construct, 
excessive collinearity among items could make an item redundant for the 
summated index score. In particular, if two items represent the same variance 
in the construct, one could be excluded from the index [35]. Thereto, the 
items were analysed for multicollinearity [35]. A common cut off threshold of 
‘below 10’ of the Variation Inflation Factor (VIF) was used [46].  
Reliability of the summated index score was estimated with ICCagreement, 
using the above-mentioned interpretation: slight <0.20, fair 0.21-0.40, 
moderate 0.41-0.60, substantial 0.61-0.80, almost perfect 0.80-1.00 [43] [44].   
Construct validity                  
Sample 3 was also used for the study of construct validity. A gold standard for 
appropriateness of PDU for NPS is lacking, so that criterion validity could not 
be determined. Nevertheless, considering the above-mentioned 
multicollinearity analysis, each item’s contribution to the summated index 
score, which is a measure of the construct, can also be interpreted as a 
validity indicator of the items’ distinct influence on the construct [45]. In other 
words, high multicollinearity makes the individual contribution of an item to 
the construct’s variance abundant.      
 Although no structural validity can be explored in a formative model, 
the construct validity can be based on hypothesis testing [33]. Hence, the 
relative contribution of the items to the summated index score can be 
explored for consistency with hypothesized contributions to the mean 
summated index scores in a representative sample [33]. Assumed is that 
duration of therapy and indication will contribute the most to the mean 
summated index score, based on results found in previous studies which 
established that PDs are used persistently and indications are often missing 
[11][14].       
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Additionally, the assumed heterogeneity in the distribution of the summated 
index score was investigated. Similar to what was found in the summated 
score of the MAI [32] the summated index score is expected to be 
heterogeneous and positively skewed, in a representative sample. Skewness is 
assumed to be significant when the skewness divided by its standard deviation 
is above 1.96 (z-value). For this analysis the summated index score was 
divided into 7 categories, i.e. 0-10, 10-20, 20-30, 30-40, 40-50, 50-60 and 60-
70.  
RESULTS 
Index development 
Items for ’appropriateness of PDU for NPS in dementia’ 
Expert panel 1 excluded three of the ten MAI items, merged two into one and 
added one to develop the Appropriate Psychotropic drug use In Dementia 
(APID) index. Expert panel 1 made the following considerations:  
The fourth item ‘Are the directions correct?’ was excluded, because 
correct directions, the route of administration and the relationship to food or 
liquids are relevant for many drugs, but was considered less relevant for PDs. 
The fifth item ‘Are the directions practical?’  was excluded based on the 
expert panel’s opinion that the schedule and time of day of administration 
and its influence on the efficacy of the care are not regarded as a barrier in PD 
administration in nursing homes, since these are frequently discussed by 
physician and nurse, and hence adjusted. This makes the directions 
automatically practical. The item ‘Is this drug the least expensive alternative 
compared to others of equal utility?' was judged irrelevant in (Dutch) nursing 
homes, since costs are a marginal factor in PD prescription. The panel used  
data of the costs derived from the ‘Farmacotherapeutisch Kompas’ [39].
  
The MAI items ‘indication’ and ‘effectiveness’ were merged in one item 
‘indication’, given that the newly formed APID item ‘indication’ had guideline 
recommendations integrated. In other words, the item ‘indication’ scores 
appropriate when effective, i.e. according to the recommendations of drug 
utilization formularies.  
Finally, a new item ‘evaluation’ was added, considering that evaluation of 
medication use is an important item for appropriate PDU [7].This resulted in a 
seven-item index, i.e. indication, evaluation, dosage, drug-drug interaction, 
drug-disease interaction, duplication and duration of therapy. Expert panel 2 
deemed all seven items relevant for the construct. 
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Scoring rules and instructions for medical record inspection  
No structural changes in the initially formulated scoring rules were made 
based on the results of the pilot tests. The response categories of the seven 
items remained 0, 1 and 2. All items were scored based on the most recent 
medical charts during data collection, except for the items ‘indication’ and 
‘evaluation’; for these items expert panel 1 formulated relevant periods of 
medical record inspection. The periods were specified based on the 
performed pilots. 
Table 1 shows the general PD scoring rules and medical record inspection 
periods for each of the items; see Appendix A for an example.  
 
Table 1. General Psychotropic Drug scoring rules and medical record 
inspection periods per item. 
 
 Score 0 Score 1 Score 2 
Indication  
 
- Recommended by the 
VGPB and found in the 
medical record within 
2 months after start of 
PD. 
- Recommended by the 
VGPB and found within 
6 months after DSCU 
admission. 
 
The typical PD not 
recommended by the 
VGPB, but another PD of 
similar ATC3 level. 
Other or no 
indication 
found within 
the medical 
record 
inspection 
period. 
Evaluation 
 
- Within 2 weeks after 
starting medication? 
(for antidepressants 
within 8 weeks) 
- Within 6 months after 
DSCU admission 
Within 6 months after start 
of PD 
No evaluation 
found in the 
medical 
record 
inspection 
period. 
Dosage 
 
Recommend by VGPB 
or the SmPC. 
Too low Too high 
Drug-drug 
interaction 
No interaction 
indicated at the SmPC 
Indicated as interaction at 
the SmPC. Although not 
recommended, when 
adequately monitored 
administration is possible. 
Do not 
administrate, 
indicated at 
the SmPC. 
Drug-
disease 
interaction 
No interaction 
indicated at the SmPC 
Indicated as interaction at 
the SmPC. Although, not 
recommended, when 
adequately monitored 
administration is possible. 
 
 
Do not 
administrate, 
indicated at 
the SmPC. 
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Duplication No duplication in same 
grouped PD. 
Duplication, without 
exceeding the total 
maximum combined 
dosage.* 
Duplication, 
exceeding the 
total 
maximum 
combined 
dosage.* 
Duration of 
therapy  
- Recommended by the 
VGPB or SmPC. 
- Antipsychotics less 
than 3 months and 3 to 
6 months, if a 
documented dosage 
reduction period is 
found. 
Antipsychotics 3 to 6 
months. 
Exceeding 
recommendati
ons 
ATC3 level Anatomical Therapeutic Chemical classification 3 level / same grouped psychotropic 
drugs, DSCU Dementia Special Care Unit, PD Psychotropic Drug, SmPC Summary of Product 
Characteristic, VGPB Dutch association of ECP and community geriatricians (Verenso) guideline 
for problem behavior. 
 
*The total maximum combined dosage was calculated based on each of the PDs percentage of 
their individual maximum dosage. The percentage was then summed up; if this exceeded a total 
of 100% a score 2 was given. 
 
Item inter-rater reliability 
The inter-rater reliability study (on sample 1), was conducted in September 
2012 on 54  medical records from nursing home patients living on DSCUs, of 
which 18 males (33.3%) and 36 females (66.7%), with a mean age of 83 (62-96 
years).  
The inter-rater reliability of the seven individual items was moderate 
to almost perfect (ICCagreement 0.577-1), see Table 2.  
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Table 2. Inter-rater reliability study. 
 
Item Positive 
agreement 
Dis-
agreement 
Negative 
agreement 
Missing Total 
Agreement 
ICC 
agreement 
Indication 
 
.28 .23 .44 .05 .72 .775 
Evaluation 
 
.19 .30 .42 .09 .61 .577 
Dosage 
 
.86 .07 .07 0 .93 .698 
Drug-drug 
interaction 
.95 .05 0 0 .95 * 
Drug-disease 
interaction 
.84 .05 .07 .04 .91 .843 
Duplication .95 0 .05 0 1 1 
Duration of 
therapy 
.44 0 .53 .03 .98 .805 
Positive agreement= proportion of positive agreement, both raters scored 0. Disagreement= 
proportion of disagreement,  rater A and B disagreed, i.e. scored 0 and 1, 0 and 2 or 1 and 2. 
Negative agreement= proportion of negative agreement, both raters scored 1 or 2. Missing= 
proportion of missing data. Total agreement= proportion of total agreement, positive plus 
negative agreement. Interclass correlation coefficient for agreement (ICCagreement). 
*No variance in ratings, so no ICCagreement can be estimated.  
 
Data analysis was performed to identify the cause of disagreement between 
two raters. It was found that for the items ‘indication’ and ‘evaluation’, 
respectively 61,5%  and 82.4% of the disagreement between raters was due to 
different information extraction from the medical records. For the items 
‘dosage’, ‘drug-drug interaction’ and ‘drug-disease interaction’ all 
disagreements were due to medical record extraction factors. No 
disagreement was found for the items ‘duplication’ and ‘duration of therapy’, 
see Table 3.   
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Table 3. Cause of disagreement inter-rater reliability study. 
Item Indication Evaluation Dosage Drug-drug 
interaction 
Medical record extraction 
factor 
61.5% 82.4% 100% 100 % 
Application of scoring rules 38.5% 17.6% 0 0 
 
Item Drug-
disease 
interaction  
Duplication Duration of  
therapy 
Medical record extraction 
factor  
100%  No disagreement  No disagreement  
Application of scoring rules 0 No disagreement No disagreement 
 
An independent reliability study (using sample 2) was done to obtain insight 
into the medical record extraction factor, i.e. in differences between three 
practicing physicians and a researchers using the APID index. This study was 
conducted from September to November 2013. The average age of the 
subjects in sample 2 was 84 (20 males; 29 females), 64% used one or more 
PDs. It was found that there was one physician who scored the PDs 
significantly more appropriate than the researcher did on the item ‘indication’ 
(r =-0.13, p<0.1). No other significant differences were found. The specific 
physician had ready knowledge about the patient; both other physicians 
needed to use the medical record similar to the researcher to score the APID 
index and their indication score did not differ significantly. 
 
Construction of a summated index score 
Expert panel 2 weighted the items on a scale of 1 to 10. The items’ mean 
weights are, in descending order; evaluation, indication, duplication, dosage, 
drug-disease interaction, duration of therapy and drug-drug interaction (see 
Table 4). Considering that the scores per item have a maximum of 2, the sum 
of the total weighted items, and thus the summated index score, had a range 
from 0 to 102.8, with higher scores indicating inappropriate use. 
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Table 4. Item weighting. 
 
Items Mean weights experts  
Evaluation 9.6 
Indication 9.4 
Duplication 7.2 
Dosage 6.7 
Drug-disease interaction 6.6 
Duration of therapy 6.1 
Drug-drug interaction 5.8 
 
For the multicollinearity analysis a sample of nursing home patients with 
dementia was used, the PROPER I sample 3. This study was conducted from 
January to June 2012. The sex distribution is 147 male (26.3%) and 413 female 
(73.8%), with a mean age of 85 (range 62-100 years). Three individual item 
scores were missing, therefore these PDs were excluded for the analysis of the 
summated index score. 
All seven items were analysed for multicollinearity, the variance 
inflation factor (VIF) came to a maximum of 3.966, which is below the cut off 
threshold of 10. Hence, no multicollinearity issues were found and all seven 
items remained included in the index (see Table 5).  
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Table 5. Multicollinearity APID index. 
 
VIF Indication Evaluation Dosage Drug-drug 
interaction 
Drug-
disease 
interaction 
Duplication Duration 
of 
therapy 
Indication  1.993 3.966 3.966 3.966 3.966 2.985 
Evaluation 1.499  2.983 2.984 2.983 2.983 2.984 
Dosage 1.009 1.009  1.008 1.008 1.008 1.006 
Drug-drug 
interaction 
1.026 1.026 1.024  1.002 1.025 1.025 
Drug-
disease 
interaction 
1.028 1.027 1.026 1.004  1.026 1.028 
Duplication 1.004 1.004 1.003 1.004 1.003  
 
1.004 
Duration of 
therapy 
1.504 1.998 1.991 1.998 1.998 1.998  
VIF = Variation Inflation factor  
 
Using the newly formed summated index score, sample 1 (N=53) was used, as 
described above, to calculate the inter-rater reliability of the summated index 
score. It was found that this was substantial (ICCagreement 0.693). Absolute 
agreement was 37.2%. 
 
Construct validity 
As mentioned above, multicollinearity did not pose a problem for the 
construction of a summated index score based on the seven items, which also 
contributed to the importance of each of the seven items to the construct and 
thus the validity of the index.  
For the items’ contribution to the summated index score, as well as 
the distribution of the summated index score, sample 3 (N=560) was used, see 
description above. 
As shown in Table 6 ‘indication’, ‘evaluation’ and ‘duration of therapy’ 
contribute the most to the summated index score.  
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Table 6. Items mean weights, mean scores and mean weighted item scores.  
Items Mean weights 
experts  
Mean score Mean weighted 
item scores 
Indication 9.4 1.07 10.06 
Evaluation 9.6 0.89 8.54 
Dosage 6.7 0.19 1.27 
Drug-drug interaction 5.8 0.01 0.06 
Drug-disease interaction 6.6 0.11 0.73 
Duplication 7.2 0.09 0.65 
Duration of therapy 6.1 0.83 5.06 
Sum   26.4 
 
The summated index score had a mean of 26.4 and a standard deviation of 
15.7. Absolute scores range from 0 to 68.6, of which 10.4% of the PDs scored 
optimal, i.e. absolute zero. The summated index score was positively skewed 
(skewness= .280; standard deviation= .102; Z=2.75). The distribution of the 
single summated score was categorized in 7 ranges, see Table 7. Apparently, 
the summated index score shows a heterogeneous distribution; 18.2% had a 
score between 0-10, 20.5% between 10-20, 16.8% between 20-30, 24.8 % 
between 30-40 and 19.6% above 40. 
 
Table 7. Distribution of summated index score. 
 
  
 
 
 
 
Single summated score Percentage Cumulative percentage 
0-10 18.2 18.2 
10-20 20.5 38.7 
20-30 16.8 55.6 
30-40 24.8 80.4 
40-50 9.5 89.9 
50-60 8.9 98.8 
60-70 1.2 100.0 
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DISCUSSION 
Nursing home patients with dementia use PDs frequently and persistently, in 
particular for NPS. This study describes the development and validation of the 
first medication index specified to measure the appropriateness of this PDU. 
The MAI was adjusted for this purpose: relevant items of the MAI were 
selected based on the opinion of two independent expert panels. This study 
shows that all seven newly developed APID index items have good content 
validity and moderate to almost perfect inter-rater reliability.  
The constructed summated index score is a summation of 7 weighted items 
that range from 0-102.8 per rated PD, from appropriate to inappropriate 
respectively. Furthermore, the summated index score is a good representation 
of the construct ‘appropriateness of PDU for NPS in dementia’, that shows 
promising construct validity. 
 
Outcomes of the index development show that all seven items constructed by 
expert panel 1 were indicated as relevant for the construct ‘appropriateness’ 
by expert panel 2. Based on this result the APID index seems to be a valid 
measurement instrument for measuring appropriateness of PDU for NPS in 
dementia.  
 
Results of the inter-rater reliability analyses show promising agreement on the 
individual items. The ICCagreement of the items are moderate to almost 
perfect. However, the proportion of positive and negative agreement should 
also be considered to make an informed assumption about the magnitude of 
the ICCagreement, given that it is related to the item’s prevalence [42]. For 
example, although the item ‘dosage’ shows higher ‘absolute’ agreement than 
the item ‘indication’, the latter item has a higher ICCagreement. Hence,  the 
items ‘indication’ and ‘evaluation’ have considerably lower ‘absolute’ 
agreement than the other items, but still have satisfactory ICCagreement, 
given that for these items the distribution of negative and positive agreement 
is balanced.  
The results of the analysis of the cause of disagreement between two 
raters show that differences in information extraction are the major cause of 
disagreement. This implies that results of intra-rater reliability analysis are 
bound to be higher [36], considering that in repetitive measures by one rater 
the extraction of information is more consistent. 
Hanlon et al. found a higher inter-rater reliability for the MAI [31]. However, 
this could be due to the fact that the MAI was administered using medical 
record abstracts in that study, provided by the same independent person. 
Other studies of the MAI’s reliability found similar but also considerably lower 
reliability than what was found for the individual APID items [26]. Hence, the 
inter-rater reliability of the APID index items is promising, which could be 
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explained by the straightforwardness of its scoring rules; medical record 
content can be directly matched with formulary content and its corresponding 
scores. 
Given that the APID index uses medical record reports for measuring 
appropriateness of PDU, this measure could also, next to a medical record 
extraction bias, be biased by the reporting quality. However, the independent 
reliability study found minimal differences between the researcher and the 
practising elderly care physician’s administration of the APID index, which 
supports the concept of using medical records for an appropriate PDU for NPS 
index. Nevertheless, the results also show that the physician could have 
additional information about patients’ PD indications that could influence the 
index’ score.  
  
The results of mean weights by expert panel 2 and the score range per 
individual item, i.e. 0-2, resulted in a summation of 7 weighted items that can 
range from 0-102.8 per rated PD, from appropriate to inappropriate, 
respectively. Additionally, it was found that all seven items contribute to the 
summated index score and that there were no multicollinearity issues. The 
reliability of the summated index score is substantial, however, it should be 
taken into account that this is not the same as the ‘absolute’ agreement 
between raters [41], which is important to consider if the index is to be used 
in clinical practise.  
 
There is no gold standard to validate the index as a good measure for the 
construct ‘appropriateness of PDU for NPS in dementia’. Nevertheless, the 
results of the expert panel 2 judgement and of the multicollinearity analyses 
show that all items contribute to the construct, indicating that the summated 
index score resembles the construct to be measured. 
As predicted by the literature on appropriateness indicators 
[11][14][12], the results show that the items ‘indication’, ‘duration of therapy’ 
and ‘evaluation’ show a large contribution to the mean summated index score 
on a large group of patients, thus the overall  inappropriateness of PDU.  
These results are in line with the mean weighting by expert panel 2 for items 
‘indication’ and ‘evaluation’, combined with results of a multi-intervention 
study on all drugs used by elderly people that found that the items indication, 
duration and expense where most inappropriate using the MAI [47].  
Furthermore, in the used data pool, the positive skewness found for 
the summated index score and its heterogeneous distribution makes the index 
applicable for the use in clinical research.  
 
A limitation of this study involves the reliability of the ‘clinical items’ indication 
and evaluation, both have high disagreement between raters, largely due to 
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medical file extraction bias. Particularly, considering that these items have the 
highest weight in the summated index score.  However, as mentioned before, 
a minimal difference between the researcher and the practising elderly care 
physician’s administration of the APID index was found. This could imply that 
bad reporting results in inappropriate indications and evaluation scores. 
Nevertheless, without good reports about effectiveness (indications and 
evaluations) it is difficult for physicians to prescribe appropriately. Studies 
show that indications for antipsychotics are often unknown and can be used 
as a measure for its appropriate use [14][48]. Recently, indications are also 
added to the medication chart, what could improve reporting of indications. 
Although the contextual domain of the construct,  its hypothesised 
contributions to the average summated index score and the absence of 
multicollinearity are promising considering the validity of the index, further 
validity analysis should be explored in the future combining different types of 
validity and accumulating evidence when hypotheses are confirmed [33] [37]. 
Freeze describes two more steps, next to multicollinearity analysis, that can 
be taken in the study of nomological validity, i.e. the degree to which a 
construct should behave in relation to other constructs and the construct in 
isolation measured by reflective measures [37]. Additionally,  in future 
research the MAI, which is not specified for PDU for NPS in dementia, could 
very well be used to investigate discriminant validity [37]. 
Furthermore, future research could study the APID index in relation to 
presence of NPS.  
In addition, it should be taken into account that the APID index’ content, i.e. 
the formularies for medication prescription and the SmPCs, are subject to 
revisions [26].In an ever-changing drug policy, nationally and internationally, 
formularies and the SmPCs are often revised, that is why the APID index 
should also be updated before every research trial. If items differ between 
nations, e.g. costs in the US, and are found relevant by local experts, these 
should also be added. Additionally, in the revisions mentioned above, validity 
should also be reconsidered. 
 
Considering that the APID index is directly based on specific drug utilization 
formularies it could also be suited for clinical practise. However, that needs to 
be further explored.   
 
CONCLUSION 
The APID index and its individual items appear to be reliable and valid in 
clinical research. The summated index score and its item weights can be used 
in clinical research. Additionally, if one patient uses multiple PDs, individual PD 
scores can be added to create a patient’s overall appropriateness of PDU 
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score. This also makes the APID index an applicable index to use in 
longitudinal research.  
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ABSTRACT  
Background 
This study explores the appropriateness of psychotropic drug (PD) use for 
neuropsychiatric symptoms (NPS) in nursing home patients with dementia.  
 
Method 
A cross-sectional study on 559 patients with dementia residing on dementia 
special care units in Dutch nursing homes was conducted. Appropriateness of 
PD use was assessed using the Appropriate Psychotropic drug use In Dementia 
(APID) index. The APID index score is calculated using information about 
individual PDs from patients’ medical records. The index encompasses seven 
(different) domains of appropriateness, i.e. indication, evaluation, dosage, 
drug-drug interactions, drug-disease interactions, duplications and therapy 
duration.  
 
Results 
A total of 578 PDs were used for NPS by 60% of the nursing home patients. 
Indication, evaluation and therapy duration contributed the most to 
inappropriate use. Ten per cent of the PDs scored fully appropriate according 
to the APID index sum score, 36% scored fully appropriate for indication, 46% 
scored fully appropriate for evaluation and 58% scored fully appropriate for 
therapy duration. Antidepressants were used the most appropriately, and 
antiepileptics the most inappropriately.  
 
Conclusions 
The minority of the PD use was fully appropriate. The results imply that PD use 
for NPS in dementia can be improved; the appropriateness should be 
optimised with a clinical focus on the appropriate indications, evaluations and 
therapy duration. 
 
Keywords 
Behavioral and psychological symptoms of dementia (BPSD), dementia, 
psychopharmacology. 
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INTRODUCTION 
Psychotropic drugs (PDs) have limited evidence of efficacy for the treatment 
of neuropsychiatric symptoms (NPS) in dementia [1] [2] and there is 
substantial evidence on the risks, side effects and long-term inefficacy of PDs 
[3][4][5]. Antipsychotics, in particular, have been shown to cause adverse 
events, i.e. extrapyramidal symptoms, somnolence, increased risk of falls, 
stroke and mortality [3][6][7][8]. Anxiolytics and hypnotic drugs are associated 
with falls [9]. Therefore, the guidelines recommend psychosocial interventions 
as a first choice for treating NPS in dementia [10].  
 Despite this [10], psychotropic drugs (PDs) are frequently prescribed 
[11][12][1][13]. This concerns many different PDs, i.e. antipsychotics, 
anxiolytics, hypnotics, antidepressants, anti-dementia drugs and 
antiepileptics, the latter also being prescribed for NPS in dementia in the 
Netherlands [10].   
The frequent use of PDs may raise questions about the 
appropriateness of prescription. There is some literature available supporting 
the hypothesis that PDs are used too long [14] [15][16], in duplicate 
prescription [1], and without proper indication [17][18]. Other aspects relating 
to a broader concept of appropriateness [19] are not available for PDs. This is 
important because appropriateness itself (and not frequency only) was found 
to be associated with a higher mortality [19]. 
Recently, we developed an instrument with seven domains of 
appropriateness [20] that gives us the opportunity to investigate the different 
domains of appropriateness simultaneously. Exploring appropriateness into 
more detail is imperative because a high frequency of psychotropic drug use 
(PDU) does not necessarily imply suboptimal drug therapy; to our knowledge, 
no studies relate the frequency and appropriateness of PDU.   
The aim of this study is to assess the appropriateness of PDU for NPS 
in nursing home patients with dementia. More specifically, the research 
questions are: 1) How appropriate is the PDU for NPS in nursing home 
patients with dementia? 2) Which domains of appropriateness of PDU for NPS 
contribute the most to appropriate use? 3) Are there differences between PD 
types in the appropriateness of use? 4) Is there an association between the 
appropriateness of PDU and the number of PDs used per patient, dementia 
special care unit (DSCU), and elderly care physician?  
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METHODS 
Study design 
This study is part of the PROPER I study (PRescription Optimisation of 
Psychotropic drugs in Elderly nuRsing home patients with dementia); a cross-
sectional study on the appropriateness of PDU for NPS in nursing home 
patients with dementia. The study was conducted from January to June 2012 
and the data were collected from the medical records of Dutch nursing home 
patients with dementia residing in DSCUs. Data about PD prescriptions 
(dosage, drug-drug interactions, drug-disease interactions, duplications and 
therapy duration) was derived from the pharmacy part of the medical record; 
data about indications for the PD prescriptions and evaluation of effect/side 
effects of PD prescriptions was derived from the physician and nurse medical 
records in the time period PDs were started. The full study design is described 
elsewhere [21]. 
In this study, the unit of analysis is the prescribed PDs for NPS in a 
sample of nursing home patients. We did not include pro re nata use because 
the rationale for prescription may be different. Analyses were performed for 
the appropriateness (in general and per domain) of PDU in total, per PD group 
and per individual PD. Furthermore, the association of the appropriateness of 
PDU and the number of PDs used was analysed by investigating the 
association of appropriateness of PDU with the number of PDs used. 
 
Assessment of appropriateness 
The appropriateness of PDU was extracted from medical records and assessed 
using the Appropriate Psychotropic drug use In Dementia (APID) index [20]. 
The APID index is developed based on the items of the Medication 
Appropriateness Index [22] and is specifically suited for clinical studies 
evaluating the appropriateness of PDU for NPS in patients with dementia in 
nursing homes. Only medication administered for behaviour associated with 
dementia, sleep disturbance and delirium were scored with the APID index. 
Therefore, PDs that had a clear indication for psychiatric disorders other than 
dementia in the medical record, i.e. sleep disturbance and delirium, were 
excluded from scoring. If no clear indication was found in the medical record, 
it was assumed it was prescribed for NPS [20]. 
The APID index encompasses seven items corresponding with the 
seven different domains of appropriateness, i.e. indication, evaluation, 
dosage, drug-drug interactions, drug-disease interactions, duplications and 
therapy duration. Recommendations from national (Dutch) and international 
drug formularies are applied in order to score information about individual 
PDs; see the Appendix B for an example. The response categories of the seven 
domains are 0, 1 and 2 for fully appropriate, marginally appropriate and fully 
inappropriate prescribing. At the time of index development, an expert panel 
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weighted the relative importance of each of the domains on a scale from one 
to ten. This resulted in different theoretical ranges per domain as follows: 
indication (range 0-18.8), evaluation (range 0-19.2), dosage (range 0-13.4), 
drug-drug interactions (range 0-11.6), drug-disease interactions (range 0-
13.2), duplication (range 0-14.4) and therapy duration (range 0-12.2). This 
way, the relative contribution of the domains could be incorporated into a 
sum score using mean weights. The APID sum score ranges from 0 (fully 
appropriate) to 102.8 (fully inappropriate) on individual PDs [20].  
Psychotropic drugs were grouped using the Anatomical Therapeutic 
Chemical classification (ATC) [23]. Different PD groups had different 
theoretical sum score ranges, considering that antidepressants, as well as anti-
dementia drugs, do not have a maximum therapy duration according to drug 
formularies. Therefore, these PDs cannot score as inappropriate for therapy 
duration. Moreover, other PD groups do not have a fully inappropriate drug-
drug interactions score according to the APID index. This implies that there is a 
difference between the theoretical maximum sum score ranges of the 
different PD groups: antiepileptics (0-96.2), antipsychotics (0-102.8), 
anxiolytics (0-96.2), hypnotics (0-96.2), antidepressants (0-90.6) and anti-
dementia drugs (0-84.8)[20].  
 
Statistical analyses 
First, the appropriateness of PDU in the total sample was determined by 
calculating the APID indexes mean sum scores (including range) and the 
percentage of PDs being prescribed fully appropriate (APID sum score = 0).  
 Second, the mean scores and their standard deviations per PD group 
and APID domain were calculated. The amount of use per PD group was also 
determined. The APID domains that contributed the most to the mean 
inappropriateness in the total sample, thus are the least appropriate, were 
analysed; the percentage of fully appropriate scores (score 0) was calculated 
for all APID domains taken together (APID sum score) and for each of these 
domains separately.   
Third, the different outcomes were ranked using ranking (League) 
tables [24], i.e. outcomes are ranked according to the 95% CI of the mean 
APID sum score. Within the interval, the minimum ranking and maximum 
ranking were calculated for the different PD groups and ranked in ascending 
order. Additionally, per individual PD the amount of use in the total sample, 
the observed score ranges and mean APID sum scores were calculated. The 
percentages of fully appropriate scores were also calculated per individual PD 
for all domains taken together (APID sum score = 0), and for the least 
appropriate domains separately. 
Fourth, to analyse the association between the appropriateness of PDU and 
the number of PDs used, the following calculations were performed: the 
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number of PDs used by individual patients, the average number of patients 
who receive one or more PDs per individual DSCU and the average number of 
patients who receive one or more PDs prescribed by individual elderly care 
physicians. When patients used more than one drug, the APID sum scores 
were averaged. The association was determined by calculating the 2-tailed 
Pearson correlation coefficient between the average number of use 
(percentage) and the mean APID sum score on patient, DSCU and elderly care 
physician level. A p-value <0.05 was considered statistically significant. 
Descriptive statistics and correlation calculations were performed by using 
IBM SPSS Statistics version 20.0. Ranking tables were created using Microsoft 
Excel, 2010 version (Microsoft Corporation, Redmond, WA, USA). 
 
RESULTS 
Participants’ characteristics 
The sample consisted of 559 patients living in 44 different DSCUs, cared for by 
25 different elderly care physicians, of 12 Dutch nursing homes with 21 
locations. There were 146 males (26.3%) and 413 females (73.8%) in the 
sample who had a mean age of 84 years (range 62-100). From the 559 
patients, 338 used one or more PDs. These 338 patients used 578 PDs 
prescribed for NPS in total; three PDs were excluded from the analyses 
because of an incomplete APID-index score resulting in 575 PDs for the 
analyses.  
 
1. Appropriateness of total PDU  
The mean APID sum score for all 575 PDs was 26.6, ranging from 0 to 68.6; 
9.6% of the PDs scored fully appropriate on the APID sum score.  
 
2. Appropriateness of PDU per domain and PD group 
The domains that contribute the most to the mean inappropriateness in the 
total sample are indication and evaluation for the PD groups antidepressant 
and anti-dementia drugs; indication, evaluation and therapy duration for 
anxiolytics, antipsychotics and hypnotics; and indication, evaluation and 
duplication for antiepileptics (Table 1). The domains indication, evaluation and 
therapy duration contributed to 89.5% of the mean inappropriateness, i.e. the 
APID sum score, in the total sample (not in Table). Therefore, these domains 
were further explored on their fully appropriate scores (score 0) per PD group 
and per individual PD. 
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Table 1. Appropriateness of use, defined by APID-scores, per domain and per psychotropic drug group, higher scores mean 
that they are less appropriate. 
 SD= Standard Deviation. 
* This psychotropic drug group could only score fully appropriate in this specific domain.  
 
Psychotropic drug 
group  
Indication 
Mean [SD] 
Evaluation 
Mean [SD] 
Dosage 
Mean [SD] 
Drug-drug 
Interactions 
Mean [SD] 
Drug- disease      
interaction 
Mean [SD] 
Duplication 
Mean [SD] 
Therapy 
duration 
Mean [SD] 
Sum score 
Mean [SD]  
Antidepressants 
N=167  
10.9 [8.4] 9.2 [8.8] 0.4 [1.7] 0.1 [0.8] 1.3 [2.9] 0.4 [1.7] 0 [0]* 22.5 [14.5] 
Anti-dementia drugs 
N=86  
12.7 [8.9] 10.0 [9.2] 0.7 [2.9] 0 [0] 0.5 [1.7] 0.3 [2.2] 0 [0]* 24.7 [15.6] 
Anxiolytics 
N=85  
6.6 [9.0] 7.6 [8.4] 0.9 [3.5] 0 [0] 0 [0] 0.7 [2.4] 11.1 [3.6] 26.9 [14.6] 
Antipsychotics 
N=147  
9.0 [6.8] 7.7 [8.2] 1.7 [3.2] 0.2 [1.2] 1.0 [2.9] 0.7 [2.5] 8.8 [5.2] 29.1 [16.5] 
Hypnotics 
N=76  
10.3 [8.9] 7.6 [7.9] 3.5 [5.6] 0 [0] 0 [0] 1.0 [3.3] 8.3 [5.8] 30.8 [14.7] 
Antiepileptics 
N=14  
18.8 [0] 13.0 [8.1] 1.9 [3.1] 0.4 [1.6] 0.9 [2.4] 2.6 [3.6] 1.7 [4.4] 39.4 [10.1] 
Total 
N=575  
10.2 [8.4] 8.6 [8.6] 1.3 [3.4] 0.1 [0.8] 0.7[2.3] 0.7 [2.4] 5.0 [5.9] 26.6 [15.5] 
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3. Appropriateness of PDU per PD group and per individual PD 
Antidepressants are the most appropriately prescribed (95%CI, rank 1-3) and 
antiepileptics the most inappropriately (95%CI, rank 5-6) (Table 2). From all 
PDs, 36.1% had a fully appropriate score for indication, 45.6% a fully 
appropriate score for evaluation and 57.7% had a fully appropriate score for 
therapy duration. Further exploration of the scores showed that in 35.8% of 
the prescribed PDs no indication and in 52.7% no evaluation were found in the 
medical records (not in Table). Indications that were not registered accounted 
for 66.7% of the fully inappropriate indication scores, evaluations that were 
not registered accounted for 100% of the fully inappropriate evaluation scores 
(not in Table). 
 
Table 2. Appropriateness of use, defined by APID-scores, per psychotropic 
drug group; higher scores mean that they are less appropriate. 
 
Psychotropic drug 
group 
[theoretical range] 
Sum score 
Mean [SD] 
[observed 
range] 
N Rank 
[95 % CI] 
Sum score 
% sum 
score  0 
% score 0 
indication 
% score 0 
evaluation 
% score 0 
therapy 
duration 
Antidepressants 
[0-90.6] 
22.5 [14.5] 
[0- 51.2] 
167 
1 
[1-3] 
14.4% 31.1% 43.7% 100%* 
Anti-dementia 
drugs 
[0-84.8] 
24.7 [15.6] 
[0-52.4] 
86 
2 
[1-5] 
19.8% 27.9% 43.0% 100%* 
Anxiolytics 
[0-96.2] 
26.9 [14.6] 
[0-50.2] 
85 
3 
[1-5] 
4.7% 64.7% 50.6% 9.4% 
Antipsychotics 
[0-102.8] 
29.1 [16.5] 
[0-68.6] 
147 
4 
[2-5] 
5.4% 28.4% 48.3% 23.6% 
Hypnotics 
[0-96.2] 
30.8 [14.7] 
[0- 63.6] 
76 
5 
[2-6] 
2.6% 39.5% 46.1% 31.6% 
Antiepileptics 
[0-96.2] 
39.4 [10.1] 
[0-50.4] 
14 
6 
[5-6] 
0% 0% 21.4% 85.7% 
Total 
[575], [0-102.8] 
26.6 [15.5] 
[0-68.6] 
  9.6% 36.1% 45.6% 57.7% 
I= Confidence Interval, SD= Standard Deviation. * This psychotropic drug group could only score 
fully appropriate in this specific domain. 
 
The observed score range and the mean sum score per individual PD are 
shown in ascending order, only PDs that were used five times or more are 
shown (Table 3). The prescription of more than half of the shown individual 
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PDs scored not fully appropriate on all domains of appropriateness taken 
together, i.e. the APID sum score. Almost half of the shown individual PDs did 
not have a prescription that had a fully appropriate score on indication, i.e. 
score 0. 
 
Table 3. Appropriateness of individual psychotropic drugs, defined by APID-
scores, higher scores mean that they are less appropriate. 
 
Individual psychotropic 
drugs, [observed range]  
Sum 
score 
mean 
N % score 0 
sum 
score 
% score 0 
indication  
% score 0 
evaluation  
% score 0 
therapy 
duration 
Citalopram [0-51.2] 19.1 83 28.9% 60.2% 45.8% 100%* 
Zuclopentixol [9.4-47.5] 20.5 6 0% 0% 66.7% 66.7% 
Haloperidol [0-50.2] 20.5 41 7.3% 42.9% 56.1% 40.5% 
Memantine [0-38.0] 21.7 32 28.1% 43.8% 40.6% 100%* 
Escitalopram [9.4-38.0] 21.9 7 0% 0% 42.9% 100%* 
Trazodone [0-38.0] 22.3 17 0% 0% 58.8% 100%* 
Oxazepam [0-50.2] 23.2 60 6.7% 78.3% 53.3% 8.3% 
Rivastigmine [0-44.6] 23.7 34 23.5% 29.4% 55.9% 100%* 
Mirtazapine [9.4-45.2] 25.4 26 0% 0% 38.5% 100%* 
Risperidone [0-64.6] 25.6 27 18.5% 70.4% 55.6% 22.2% 
Venlafaxine [9.4-38.0] 26.1 9 0% 0% 55.6% 100%* 
Temazepam [0-50.2] 27.9 37 2.7% 64.9% 45.9% 2.7% 
Pipamperon [9.4-57.4] 30.8 36 0% 0% 50.0% 8.3% 
Paroxetine [9.4-44.6] 31.0 14 0% 0% 21.4% 100%* 
Galantamine [9.4-52.4] 31.1 20 0% 0% 25.0% 20.0% 
Melatonin [0-51.4] 32.4 19 5.3% 21.1% 47.4% 100%* 
Midazolam [18.8-55.2] 35.5 6 0% 0% 33.3% 50.0% 
Lorazepam [12.2-50.2] 36.6 19 0% 42.1% 36.8% 5.3% 
Olanzapine [13.3-50.2] 36.8 5 0% 20.0% 40.0% 20.0% 
Valproate [18.8-45.2] 37.3 6 0% 0% 16.7% 100%* 
Quetiapine [16.3-68.6] 38.7 19 0% 10.5% 31.6% 10.5% 
Clozapine [15.5-63.4] 42.0 10 0% 10.0% 30.0% 20.0% 
Total [0-68.6] 26.6 575 9.6% 36.1% 45.6% 57.7% 
* This psychotropic drug could only score fully appropriate in this specific domain.  
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4. Association of the number of PDs used with the appropriateness of 
PDU 
No significant association between the number of PDs used per patient and 
the mean APID sum score per patient was found (Pearson Correlation -0.016, 
Sig. (2-tailed) 0.769, N=338). Furthermore, no significant association was 
found between the average number of patients on a specific DSCU who 
received one or more PDs and the mean APID sum score on that DSCU 
(Pearson Correlation 0.030, Sig. (2-tailed) 0.582, N=44), nor between the 
average number of patients of the individual physician who receive one or 
more PDs and the mean APID sum score for that elderly care physician 
(Pearson Correlation 0.059, Sig. (2-tailed) 0.283, N=25).  
 
DISCUSSION 
To our knowledge, this is the first study to explore a broad range of relevant 
domains of appropriateness of PDU for NPS in nursing home patients with 
dementia. 
We found that only ten per cent of the PDs scored as fully appropriate 
and that appropriateness was the least for the domains indication, evaluation 
and therapy duration. Dosage, drug-drug interactions, drug-disease 
interaction and duplications scored more appropriately. A potential 
explanation for this difference could be that, in Dutch nursing homes, domains 
such as drug-drug interactions are controlled by computerised processes and 
domains such as indication are dependent on the physicians’ prescription 
policy. For instance, it appeared that in more than one-third of the 
psychotropic drugs no indication was found in the medical records. This 
confirms earlier findings that the majority of the patients in nursing homes 
have at least one drug prescribed of which the indication was unknown [17].    
Antidepressants were prescribed the most appropriately, whereas 
antiepileptics were prescribed the most inappropriately. Another study [25] 
found that 18% of antipsychotics had appropriate indications and evaluations 
based on the prescription criteria. Our results showed low appropriateness 
rates regarding indications and evaluation not just for antipsychotics but also 
for all other PDs. 
Furthermore, appropriateness was not associated with the number of 
PDs used per patient, the percentage of use on the separate units patients 
resided, nor the percentage of prescription of the individual physicians. Many 
studies describing the frequency of use [1][2] and prescription policies 
[14][26] focussed on reducing PDU [27]. However, our study suggests that the 
appropriateness and frequency of PDU may be unrelated; high rates of PDU 
do not necessarily reflect the inappropriate use of individual PDs. Therefore, it 
seems imperative not only to focus on absolute PDU, but also on its 
appropriateness. Nevertheless, both concepts are conjoined, two 
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inappropriate prescriptions still add up to less appropriate use than one 
inappropriate prescription. Implementation of tools that evaluate 
appropriateness in clinical practice may, therefore, lead to prescriptions that 
are more appropriate. The appropriateness of prescription might be improved 
by the implementation of tools such as the APID index in daily practice, which 
may, next to increased appropriateness, also reduce the frequency of use. 
Thereto, the APID index could be revised into a (self-) evaluation tool. 
  
The absence of an association between frequency and appropriateness may 
also imply that the underlying factors of these constructs may differ. Factors 
related to frequency of use next to patient factors have been studied, e.g. bed 
capacity, under staffing, mindset and staff experience [28][29]. However, little 
is known about factors related to the appropriateness of PD prescription. This 
could be subject of further study. 
 A limitation of this study is that the results are based on medical 
record research, so that inappropriateness scores partly reflect a lack of 
reporting. However, as our former study shows, prescribers need good 
reporting to accurately review their own prescriptions [20], which implies that 
good reporting is a prerequisite for appropriateness and its measurement. 
Another limitation of this study could be that the APID index does not 
detect under-prescription, thus this criterion was not included in our study 
results.   
 
CONCLUSION  
The appropriateness of the prescription of PDs for NPS in nursing home 
patients with dementia is rather poor; it should be optimised with a clinical 
focus on appropriate indications, evaluations and therapy duration. 
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ABSTRACT  
Background 
We studied the patient and non-patients factors of inappropriate psychotropic 
drug (PD) prescription for neuropsychiatric symptoms (NPS) in nursing home 
patients with severe dementia.  
 
Methods  
In a cross-sectional study, the appropriateness of prescriptions was explored 
using the Appropriate Psychotropic drug use In Dementia (APID) index sum 
score. This index assesses information from medical records on indication, 
evaluation, dosage, drug-drug interactions, drug-disease interactions, 
duplications, and therapy duration. Various measurements were carried out 
to identify the possible patient and non-patient factors. Linear multilevel 
regression analysis was used to identify factors that are associated with APID 
index sum scores. Analyses were performed for groups of PDs separately, i.e. 
antipsychotics, antidepressants, anxiolytics, and hypnotics.  
 
Results  
The sample consisted of 338 patients with a PD prescription that used 147 
antipsychotics, 167 antidepressants, 85 anxiolytics, and 76 hypnotics. It was 
found that older patients and more severe aggression, agitation, apathy, and 
depression was associated with more appropriate prescriptions. Additionally, 
less appropriate prescriptions were found to be associated with more severe 
anxiety, dementia diagnoses other than Alzheimer dementia, more physician 
time available per patient, more patients per physician, more years of 
experience of the physician, and higher nurse’s workload.  
 
Conclusions 
The association of more pronounced NPS with more appropriate PD 
prescriptions implies that physicians should pay more attention to the 
appropriateness of PD prescriptions when NPS are less manifest. Non-patient 
related factors are also associated with the appropriateness of PD 
prescriptions. However, especially considering that, some of these findings are 
counter-intuitive; more research on the topic is recommended. 
 
Keywords 
Dementia, psychopharmacology, neuropsychiatric symptoms.
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INTRODUCTION 
Psychotropic drugs (PDs) are prescribed for the treatment of neuropsychiatric 
symptoms (NPS) in dementia [1][2]. However, there is substantial evidence on 
the risks, side effects and long-term inefficacy of PDs [3][4]. That is why 
guidelines recommend a restricted, short-term use of PDs [5]. There is some 
literature available supporting the hypothesis that the duration of PD 
prescription is too long [6], with sometimes duplicate prescriptions [1][7], and 
without a proper indication [8]. Other aspects that relate to the broader 
concept of appropriateness have previously not been studied.   
     
Different appropriateness measurement instruments that relate to the 
broader concept have been developed, e.g. STOPP/START criteria [9] and 
Medication Appropriateness Index (MAI) [10]. However, these are not 
specifically developed to measure the appropriateness of PD prescriptions for 
NPS in dementia.    
Recently, we developed the Appropriate Psychotropic drug use In 
Dementia (APID) index, which was derived from the MAI and was validated on 
a sample of (Dutch) nursing home patients with dementia [11]. The APID index 
measures the appropriateness of PD prescriptions for NPS in patients with 
dementia with a sum score that encompasses seven different domains of 
appropriateness: indication, evaluation, dosage, drug-drug interactions, drug-
disease interactions, duplications and therapy duration. The APID index sum 
score showed to be reliable and valid for measuring appropriateness of PD 
prescriptions for NPS in dementia in nursing homes. Using the APID, we also 
found that the appropriateness of PD prescriptions and the frequency of PD 
use are unassociated, and thus independent concepts [12]. 
Frequency of PD use varies considerably among nursing homes and 
units [13][14], which is only partly explained by the different prevalence rates 
of NPS among patients [15] [16]. The variation in PD use is also found to be 
related to differences in drug prescription policies [17], staff distress/workload 
[16], physical environmental factors, and the bed capacity [14].  
  
Although several studies [16][18] investigated factors associated with PD use, 
we only found one study that reports about the factors associated with the 
appropriateness of PD prescriptions in dementia; it was found that the 
presence of behavioral symptoms and female gender were associated with 
more appropriate indications of benzodiazepines [19].  
Recently, we formulated a conceptual framework with four categories 
of factors with which the frequency and/or appropriateness of PD prescription 
were hypothesized to be associated, i.e. factors related to patient and non-
patient factors (physician, nurse, and physical environment) [20]. 
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Furthermore, in a previously conducted analysis about the appropriateness of 
PD prescriptions, the results indicated that the appropriateness of use differ 
per class of PD [12], and thus the factors related to appropriateness may also 
differ per class of PD, which compelled us to analyze antipsychotics (AP), 
antidepressants (AD), anxiolytics, and hypnotics separately. Some guidelines 
do not recommend benzodiazepine use (e.g. NICE guideline, 2016) and others 
do (e.g. BPSD guidance- NHS Cumbria; [21]). Benzodiazepines (oxazepam and 
lorazepam) are recommended for a maximum duration of four weeks in the 
Dutch guideline for NPS in patients with dementia, i.e. for agitation, anxiety 
and as adjuvant in case haloperidol has an insufficient effect on delirium. In 
addition, temazepam and zolpidem are recommended for sleep disorder for a 
maximum duration of two weeks [5]. The aim of the study was, therefore, to 
identify which patient and non-patient factors were associated with the 
appropriateness of prescriptions regarding four groups of psychotropic drugs. 
 
METHODS 
Design, setting, and sample 
This study is part of the PROPER I study (Prescription Optimisation of 
Psychotropic drugs in Elderly nuRsing home patients with dementia) which is a 
cross-sectional mixed methods study that aims to identify the prevalence and 
appropriateness of PD prescriptions and its underlying factors. The study was 
conducted from January to June 2012. Thirty-six Dementia Special Care Units 
(DSCUs) divided over twelve nursing homes were needed based on our sample 
size calculations. The full study design is described elsewhere [20].  
The local Medical Ethics Review Committee ‘CMO Region Arnhem-
Nijmegen’ reviewed the study (number 2012/226) and pronounced that it was 
in accordance with the applicable rules in the Netherlands concerning the 
review of research ethics committees and informed consent. The study was 
conducted in accordance with the Declaration of Helsinki. 
 
Measurements 
Appropriateness of psychotropic drug prescriptions 
Appropriateness was explored using the APID index. This index sum score 
ranges from 0-102.8 where a lower score indicates a more appropriate PD 
prescription. The APID index sum score is based on seven domains, i.e. 
indication, evaluation, dosage, drug-drug interactions, drug-disease 
interactions, duplications and therapy duration, which are weighted for their 
contribution to the construct [11].  
PD prescription was grouped according to the Anatomical Therapeutic 
Chemical (ATC) classification into: antipsychotics (APs) (N05A), 
antidepressants (ADs) (N06A), anxiolytics (N05B), and hypnotics (N05C)(Nordic 
Council on Medicines, 1990). 
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Factors associated with appropriate psychotropic drug use  
The PROPER-I dataset contained 115 possible variables (including subscores) 
associated with frequency and/or appropriateness. Because it was estimated 
that a maximum of 28 factors could be included in the analyses, 28 variables 
were selected as guided by our framework [20]. Based on the existing 
evidence for the factors being associated with the appropriateness of PD 
prescriptions and on their clinical expertise, the authors rated the relevance of 
the factors and reached consensus on what would be the 28 most relevant 
factors. It appeared that factors were selected from three of the four 
categories of the framework, i.e. patient-related factors, physician-related and 
nurse-related factors. There were no physical environment-related factors 
selected as these factors showed lack of variation in the participating nursing 
homes. 
The following instruments were used to assess information about these 
factors clustered within three categories:  
 
1) Patient-related factors 
Twelve patient-related factors were selected. We collected data about age, 
sex, length of stay at DSCU and dementia type (i.e. Alzheimer’s dementia (AD), 
Vascular Dementia (VaD), mixed AD/VaD, and other dementia (including ‘not 
otherwise specified’). 
The severity of NPS was assessed using the Neuropsychiatric Inventory 
Questionnaire (NPI-Q)[23]. The 12-item NPI-Q evaluates the severity of 12 NPS 
in the previous month on a 4-point scale ranging from 0 (absent) to 3 (severe). 
Symptoms were grouped into five clinically meaningful categories similar to 
what was done for this instrument’s nursing home version [24], i.e. psychosis 
(hallucinations and/or delusions), agitation (agitation, disinhibition, and/or 
irritability), depression, anxiety and apathy. 
Agitation/aggression was further assessed with the Cohen-Mansfield 
Agitation Inventory (CMAI)[25][24]. The CMAI consists of 29 agitated 
behaviors to be scored for the frequency of occurrence in the previous 2 
weeks on a 7-item scale ranging from 1 (never) to 7 (several times per hour). 
We grouped the symptoms into 3 categories: physical aggression (range 8 to 
56), physically nonaggressive behavior (range 7 to 49), and verbally agitated 
behavior (range 4 to 28)[25]. 
 
2) Physician-related factors 
Five physician-related factors were selected. The attitude of physicians toward 
caring for people with dementia was measured with the Approaches to 
Dementia Questionnaire (ADQ)[26]. The ADQ contains 19 statements to be 
scored on a 1 to 5 Likert scale, resulting in a total score ranging from 19 
(negative attitude) to 95 (positive attitude). Additionally, we registered the 
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number of years working as a physician. The physician’s availability in minutes 
per patient per week, the number of patients per physician and the 
physician’s reported time spent weekly on patient care. 
 
3) Nurse-related factors 
Eleven nurse-related factors were selected. The experienced nurse distress 
was assessed with the 12-item NPI-Q, which measures distress and NPS 
simultaneously, in the previous month on a 4-point scale ranging from 0 
(absent) to 3 (severe). The symptoms were, again, grouped into the above-
mentioned five clinically meaningful categories. The staff strain with regard to 
caring for patients with dementia was measured with the Strain in Dementia 
Care Scale (SDCS) [27]. The SDCS consists of 27 items on personal situations, 
thoughts or feelings. Items are weighted in terms of frequency (on a 4-point 
scale), multiplied by the amount of stress (on a 4-point scale); the total score, 
which was used for this study, is calculated by dividing the total summarized 
score with the amount of items included (possible range: 1–16). In addition, 
the Satisfaction with Patient Contact subscale from the Maastricht Work 
Satisfaction Scale for Healthcare (MAS-GZ) was assessed [28], which consists 
of 3 items on mutual liking between patients and nurse, each ranging from 1 
(very unsatisfied) to 5 (very satisfied) and a mean subscore (range 1 to 5). To 
measure the attitude of nurses toward caring for people with dementia, the 
above-mentioned ADQ was used. The nurses’ workload was assessed with a 
Dutch scale on job strain (Werkdruk de Jong) [29]. This instrument consists of 
8 statements regarding the presence of demanding aspects of the job with a 
5-point response scale resulting in a total score ranging from 1 (never) to 5 
(always).  
Furthermore, we obtained the nurse/patient ratio during the day 
(morning, afternoon, and evening) and the total number of different 
caregivers (e.g. nurses, supporting personnel) at the DSCU for assessing 
continuity in care. 
 
Procedures 
Variables were either collected per individual patient (PD prescriptions, 
patient characteristics, NPI-Q and CMAI) or per DSCU (all other variables). PD 
prescriptions were retrieved from the actual medication list, patient 
characteristics from the patient’s charts, and nursing home characteristics 
(nurse/patient ratio, number of patients per DSCU, and number of different 
caregivers) were retrieved from the DSCU’s team manager. All other data 
were collected web-based and completed by physicians or nurses. The 
maximum time window between the appropriateness measurement of PDs 
and the measurement of possibly related factors was 6 weeks. 
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Statistical analyses 
Sample characteristics were calculated, i.e. age, sex, number of patients that 
had a PD prescription, DSCUs, nursing homes and physicians, dementia 
diagnosis, number of PDs used in total and range of APID index sum score. 
Both unilevel and multilevel multivariate linear regression analyses 
were performed with the APID sum score as a dependent variable. Prior to 
analyses, to control for (problems of) multicollinearity (in analysis and 
interpretation), factors were analyzed for multicollinearity and if so, factor 
analysis was applied to find underlying latent variables.  
The APID sum score was calculated separately for the four different 
PD groups. If patients used more than one prescription in one of the four PD 
groups, the APID index sum score was averaged.  
Using all 28 preselected variables in a multivariate multilevel modeling would 
result in overfitting for each of the PD groups (i.e. results would likely be too 
specific for this dataset and hence not generalizable). To avoid overfitting, we 
used the 10-patients-per-predictor (N=10) rule of thumb [30] to determine, 
for each type of PD,  the maximum number of predictors to be used.  
To reduce the 28 preselected variables to this maximum number of 
variables, the following pragmatic approach was taken, for all four types of PD 
separately, with multivariate unilevel preselection:   
Step 0) We fitted a model with all 28 predictors (‘the benchmark 
model’), acknowledging that this would result in an overfitted model (and 
should therefore not be interpreted), but would at least give the maximum 
amount of variance (‘the benchmark’) that could be explained for the type of 
PD considered. In subsequent steps we tried to come as close as possible to 
this benchmark, while keeping the number of predictors below the maximum 
allowed by the N=10 rule of thumb.  
Step 1a) We preselected independent variables with the most 
influence in a unilevel (i.e. on patient-level) linear regression model via 
stepwise backward likelihood ratio selection with entry p<0.05, removal 
p<0.10. If step 1a resulted in a model with too many variables according to the 
N=10 rule of thumb or if step 1a resulted in a model with a significantly worse 
fit compared to the ‘benchmark model’ we then applied step 1b). The 
occurrence of a worse fit was guided by a more than 10% lower R2 (explained 
variance) compared to the benchmark (model) and/or statistical significant 
worse fit by using the 2-loglikelihood ratio test. 
Step 1b) Best subset unilevel linear regression was used to choose a 
selected number of variables not based on the p-value of individual variables 
but by comparing the fit of subsets (combinations of the 28 variables). For 
each amount of variables (1, 2, …, 28 variables), the combination (subset) with 
that number of variables that has the highest R2 was identified (‘best subset’ 
with that amount of variables). Out of the best subsets with 1, 2, .., 28 
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variables, the smallest subset of variables explaining 90% or more of the R2 
from the benchmark model (see step 0) was considered as a model having 
good fit and no overfitting.   
Step 2) The preselected variables were put together in the final 
multilevel linear regression model.  
For all analyses, we used IBM SPSS Statistics, Version 22.0 and SAS 9.2 
(SAS Institute, Inc., Cary, NC). Variables that had 10% or more missing cases 
were excluded from the analyses. 
 
RESULTS 
Table 1. Sample characteristics. 
 
Characteristics of nursing home patients  
  
Mean age in years (range) 84 years (range 62-100) 
Sex, female in percentage 73.8% 
Number of patients that had a psychotropic drug 
prescription 
338 
Number of DSCUs 44 
Number of nursing homes 
12 organizations with 21 
locations 
Number of physicians 25 
Diagnosis of dementia (percentage) 
Alzheimer’s dementia 186 (33.3%) 
Vascular dementia 92 (16.5%) 
Mixed Alzheimer’s/vascular dementia 62 (11.1%) 
Other dementia 219 (39.2%) 
 
Number of psychotropic drug prescriptions 
Antipsychotics 147  
Antidepressants 167  
Anxiolytics 85 
Hypnotics  76 
 
PDs were prescribed to 338 patients (see Table 1 for sample characteristics) in 
duplicate prescriptions: 147 APs, 167 ADs, 85 anxiolytics, and 76 hypnotics 
were used [12]. When applying the N=10 rule of thumb (1 factor/determinant 
per 10 incident cases) on the prescriptions per patient [31], 14, 16, 8, and 7 
variables could be used in the final models, respectively. In table 2, the 
abovementioned multivariate unilevel preselection method of variable 
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reduction was described, the final models are shown in bold. The APID index 
sum score ranged from 0 to 68.6. 
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Table 2. Unilevel preselection method of variable reduction in a multivariate regression model. 
Based on unilevel linear regression modelling via stepwise backward selection (step 1a) and best subset regression (step 1b) a 
selection of variables for multilevel analyses were made for four psychotropic drug group models (final models are shown in 
bold with asterisk). ¹ 
*Final model, R
2
= explained variance, S= significant, NS= not significant, no. =number.  
¹ For the four different models R
2 
and 2-loglikelihoods were calculated and analyzed for significant difference with the hypothetical full models with all 28 
variables: 
- For antipsychotics, stepwise backward selection resulted in a model that was significantly different from the hypothetical full model and, therefore, best 
subset regression was performed; that resulted in a model with 13 variables and was found not significantly different from hypothetical full model.  
- For antidepressants, stepwise backward selection resulted in a model with 3 variables, which was found to be not significantly different from the 
hypothetical full model.  
Model All the 28 
variables  
2-loglikelihood/ 
R
2
 
Step 1a: Backward 
selection 
No. variables/                        
2-loglikelihood/ R
2
 
Significant 
difference backward 
selection with all 28 
variables model 
Step 1b: Best 
subset regression 
No. variables/ 2-
loglikelihood/ R
2
 
Significant difference 
best subset with all 28 
variables model 
Antipsychotics 
 
1084.62 
R
2
= 0.29   
5/ 1128.06/ 
R
2
= 0.18   
Difference = 43.44   
 S (df 23, Χ²  = 
p<0.01) 
13/ 1092.28/ 
R
2
= 0.27 * 
Difference = 7.66 
NS (df 15, Χ² =  p>0.25) 
Antidepressants 
 
1259.10 
R
2
= 0.24   
3/ 1283.54/ 
R
2
= 0.15  * 
Difference = 24.44 
NS (df 25, Χ² =  
p>0.25) 
- - 
Anxiolytics 
 
638.15 
R
2
= 0.36   
5/ 658.06/ 
R
2
= 0.25  * 
Difference = 19.91  
NS (df 23, Χ² = p>0.25) 
- - 
Hypnotics 
 
535.27 
R
2
= 0.49   
A model with 9 variables was found; this is too 
many according to the rule of thumb (N=10). The 
best subset of 7 was used. 
7/ 567.96/  
R
2
= 0.35 *  
Difference = 32.69 
S (df 21, Χ² = p<0.05) 
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- For anxiolytics, stepwise backward selection resulted in a model with 5 variables, which was found to be not significantly different from the hypothetical 
full model.  
- For hypnotics, a model with 7 variables was chosen considering the 10-patients-per-predictor rule of thumb, but this model was significantly different 
from the hypothetical full model. 
CHAPTER 5 
82 
 
Multilevel analyses 
No multicollinearity was found between variables. Multilevel analyses with 
levels DSCU and location (step 2) were performed for antipsychotics, 
antidepressants, anxiolytics, and hypnotics.  
In the antipsychotics group, the following statistically significant 
associations were found: High CMAI physical aggression and older patient age 
were associated with low APID index sum scores; high NPI anxiety severity and 
physician patient care in minutes per week with high APID index sum scores. 
For the antidepressants group: High NPI apathy severity and high NPI 
depression severity were associated with low APID index sum scores. For the 
anxiolytics group: High CMAI physical aggression was associated with low APID 
index sum score; type of dementia other than Alzheimer’s dementia and high 
job strain of nurses were associated with high APID index sum scores. Finally, 
for the hypnotics group: High NPI agitation severity was associated with low 
APID index sum score; high number of patients per physician and more years 
of experience for physicians were associated with high APID index sum scores 
(Table 3). 
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Table 3. Multilevel models on the factors of the appropriateness of psychotropic drug use for antipsychotics, antidepressants, 
anxiolytics, and hypnotics. Variables are presented by patient-related, physician-related and nurse-related from top to 
bottom. More indicates a lower APID index sum score, thus a factor associated with more appropriateness. Less indicates a 
higher APID index sum score, thus a factor associated with less appropriateness. 
 Antipsychotics p-value Antidepressants p-value Anxiolytics p-value Hypnotics p-value 
1 Patients’ age 
More 
p 0.02* 
NPI category 
apathy severity 
More 
p 0.00* 
Type of dementia 
Mixed AD/VaD in 
comparison to AD 
Less 
p 0.04* 
Time (months) on this 
DSCU 
Less 
p 0.16 
2 Patients’ sex 
More 
p 0.26 
NPI category 
depression 
severity 
More 
p 0.01* 
CMAI (physical) 
aggression 
More 
p 0.03* 
NPI category 
agitation severity 
More 
p 0.01* 
3 
Time (months) on 
this DSCU 
Less 
p 0.26 
Nurse ADQ Total 
score 
Less 
p 0.08 
Number of patients 
per physician 
Less 
p 0.37 
NPI category apathy 
severity 
More 
p 0.07 
4 
NPI category 
anxiety severity 
Less 
p 0.01* 
  
Nurse SDC Total  
score 
More 
p 0.10 
CMAI Verbal agitation 
Less 
p 0.09 
5 
NPI category 
depression 
severity 
More 
p 0.14 
  Nurse job strain 
Less 
p 0.04* 
Number of patients 
per physician 
Less 
p 0.03* 
6 
CMAI (physical) 
aggression 
More 
p 0.00* 
    
Physicians experience 
(years) 
Less 
p 0.01* 
7 
CMAI motor 
agitation subscale 
More 
p 0.17 
    
Nurse_patient_ratio_
daytime 
More 
p 0.13 
8 
Physician ADQ 
Total score 
More 
p 0.20 
      
9 
Physician pt. care 
in minutes per 
week 
Less 
p 0.03* 
      
10 
Number of 
patients per 
physician 
Less 
p 0.09 
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 Antipsychotics p-value Antidepressants p-value Anxiolytics p-value Hypnotics p-value 
11 
Nurse ADQ Total 
score 
Less 
p 0.30 
      
12 
Nurse WDJ Total 
score 
More 
p 0.24 
      
13 
Nurse_patient_rat
io_daytime 
Less 
p 0.42 
      
In bold with asterisk = a significant effect was found, Neuropsychiatric Inventory- Questionnaire (NPI-Q), Cohen-Mansfield Aggression Inventory (CMAI), 
Approaches to Dementia Questionnaire (ADQ), Strain in dementia Care (SDC), the Maastricht Work Satisfaction Scale for Healthcare ‘Maastrichtse 
Arbeidssatisfactie Schaal voor de Gezondheidszorg’ (MAS-GZ), AD= Alzheimer disease, VaD= Vascular Dementia, DSCU=Dementia Special Care Unit. 
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DISCUSSION 
Main findings 
To our knowledge, this study is the first that investigates the factors 
associated with the appropriateness of PD prescriptions for NPS in nursing 
home patients with severe dementia on a broad range of appropriateness 
indicators summarized in one index score. We found that patient factors 
particularly influence appropriateness. Psychotropic drugs were more 
appropriately prescribed in patients with higher levels of NPS, older age, and 
other types of dementia than Alzheimer’s dementia. Patient factors accounted 
for eight out of twelve of the found associations in the four different PD 
groups. 
Regarding antipsychotics, the severity of aggression was associated 
with appropriate prescriptions, in antidepressants this was the severity of 
apathy and depression, in anxiolytics it was the severity of aggression, and in 
hypnotics it was the severity of agitation. Since the inappropriateness of a 
prescription is mainly based on poor indications, evaluations, and therapy 
durations [12], these findings signify that when NPS were less pronounced, 
appropriate indications for these symptoms were missing, while evaluations 
of these prescriptions are lacking and the therapy continues. 
 
Next to patient factors, of the several non-patient factors, one physician- and 
one nurse-related factor appeared to be associated with the appropriateness 
of PD prescriptions.    
In the hypnotic group, prescriptions were less appropriate when the 
prescribing physician had a higher caseload. In the anxiolytic group, we found 
that prescriptions were less appropriate when nurses experienced more 
workload. This latter finding is in line with previous studies indicating that 
physicians feel more pressure to prescribe when the burden of nurses is high 
[14][15], which may result in less appropriate prescriptions. Additionally, 
when the workload is high, the pharmacological treatment of NPS compared 
to psychosocial treatment, which is the recommended intervention [5][32], 
could be considered as less time consuming. Therefore, pharmacological 
treatment is often preferred, while there is less time to appropriately evaluate 
and stop these prescriptions.   
 
Nevertheless, other factors associated with the appropriateness of PD 
prescription were counter-intuitive, and possibly a result of multiple testing: 
In the antipsychotics group, severe anxiety and physicians’ time available per 
patient were associated with less appropriate prescriptions. Moreover, it was 
found that the more experience a physician had the less appropriate the 
hypnotics were prescribed. 
 
CHAPTER 5 
86 
 
As mentioned before, little was known on this topic. Recently more relevant 
research has been published and it was found that large numbers of 
physicians working in one organization could result in an inappropriate 
prescription of antipsychotics [33]. Another study found that after long-term 
care admission, new antipsychotic use was just as strongly associated with 
social factors as clinical factors [34]. However, these studies did not address a 
large variety of potential patient and non-patient factors associated with the 
broader concept of appropriateness, i.e. on multiple items of appropriateness 
and in different PD groups. 
 
Methodological considerations  
A limitation of this study was that including all the possibly relevant factors, as 
collected for the PROPER-I study [20], led to a large number of factors 
compared to the number of patients, which could lead to an overfit of the 
statistical models. In order to control for this, we had to make a selection. Due 
to this selection, 28 of the in total 115 collected factors were used for 
analyses. Many of the for PROPER I collected factors were not included, 
considering that these were less relevant or were covered by other measures 
based on a conceptual framework. In this process relevant factors might have 
been lost, e.g. physical environment-related factors. Additionally, this 
selection was performed by a sample of clinical experts from one single 
country, which can also be concerned as a limitation. 
Furthermore, as mentioned before, we used multiple tests on the 
selected variables, which could have resulted in factors found coincidentally. 
Therefore, these associations might be clinically irrelevant and should be 
interpreted with caution. 
 
This Dutch study was performed on so called DSCUs with trained elderly care 
physicians as the responsible physician, therefore the results should be 
generalized to other health care systems with carefulness. In addition, the 
dependent variable was the APID index sum score. Prior to this study, the 
same patients’ records were used, by the same research team, in the 
development and validity study of the APID index. Therefore, uncertainty 
exists about the generalizability of the results to other samples, which could 
be considered as a limitation of the study; the APID index should be used in 
other samples to test the external validity of the results. 
Furthermore, DSCUs are specialized in treating patients in advanced 
stages (Global Deterioration Stages 4 - 7, primarily 6 - 7) of dementia. In this 
study only patients residing on these units were included, therefore, patients 
included in this study all had severe levels of cognitive impairment. Although 
inappropriate prescriptions are likely to affect cognition [35]. Due to the 
assumed floor effect (insufficient variance) we did not include an instrument 
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to detect cognitive impairment and therefore did not obtain information 
about the association between cognitive impairment and the appropriateness 
of PD prescriptions. Moreover, the stage of dementia and thus the level of 
cognitive impairment is unlikely to predict the appropriateness of PD 
prescriptions independent of behavior, which compelled us to obtain 
information about the extent of NPS.  
This study was conducted in single country and 12 nursing homes, that 
only involved people with severe dementia, which is typical for Dutch nursing 
homes. However, the appropriateness of PD prescriptions is a worldwide 
challenge [36][37], potentially, these results may be generalizable to other 
countries with similar health care systems. 
 
CONCLUSIONS AND CLINICAL IMPLICATIONS 
We found that there is an association between more pronounced NPS and 
more appropriate PD prescriptions in patients with severe dementia, which 
implies that physicians should be especially aware of the appropriateness of 
prescription when NPS are less manifest. Carefully recording and regularly 
evaluating these prescriptions could prevent inappropriateness. Obviously, 
patient factors influence PD prescription. Physician and nurse factors seem to 
also influence the appropriateness of PD prescriptions, and thus guideline 
adherence regarding appropriate indications, evaluations, and therapy 
durations. However, some of these findings are counter-intuitive and thus 
unclear; more research on the topic is recommended. 
To minimize these influences, standardization and thus guideline adherence is 
advised.  
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ABSTRACT  
Background 
Neuropsychiatric symptoms are highly prevalent in nursing home patients 
with dementia. Despite modest effectiveness and considerable side effects, 
psychotropic drugs are frequently prescribed for these neuropsychiatric 
symptoms. This raises questions whether psychotropic drugs are 
appropriately prescribed. The aim of the PROPER (PRescription Optimization 
of Psychotropic drugs in Elderly nuRsing home patients with dementia) II study 
is to investigate the efficacy of an intervention for improving the 
appropriateness of psychotropic drug prescription in nursing home patients 
with dementia.  
             
Methods/Design 
The PROPER II study is a multi-center cluster randomized controlled, 
pragmatic trial using parallel groups. It has a duration of eighteen months and 
four six-monthly assessments. Six nursing homes will participate in the 
intervention and six will continue care as usual. The nursing homes will be 
located throughout the Netherlands, each participating with two dementia 
special care units with an average of fifteen patients per unit, resulting in 360 
patients. The intervention consists of a structured and repeated 
multidisciplinary medication review supported by education and continuous 
evaluation. It is conducted by pharmacists, physicians, and nurses and consists 
of three components: 1) preparation and education, 2) conduct, and 3) 
evaluation/guidance. The primary outcome is the proportion of patients with 
appropriate psychotropic drug use. Secondary outcomes are the overall 
frequency of psychotropic drug use, neuropsychiatric symptoms, quality of 
life, activities of daily living, psychotropic drug side effects and adverse events 
(including cognition, comorbidity, and mortality). Besides, a process analysis 
on the intervention will be carried out.             
 
Discussion 
This study is expected to improve the appropriateness of psychotropic drug 
prescription for neuropsychiatric symptoms in nursing home patients with 
dementia by introducing a structured and repeated multidisciplinary 
medication review supported by education and continuous evaluation. 
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Trial registration 
Netherlands Trial Registry (NTR): NTR3569. 
 
BACKGROUND 
Neuropsychiatric symptoms (NPS) are highly prevalent in and burdensome for 
nursing home patients with dementia. Studies show prevalence rates of 
clinically relevant NPS of over 70% [1][2], and a cumulative two-year 
prevalence of even 97% [3]. NPS comprise a wide range of heterogeneous 
symptoms including delusions, hallucinations, agitation/aggression, 
depression, apathy, euphoria, anxiety, disinhibition, irritability, and aberrant 
motor behavior, which are frequently treated with psychotropic drugs. It is 
known that the efficacy of psychotropic drugs is limited and that their use is 
associated with considerable side effects such as extrapyramidal symptoms, 
somnolence, and increased risk for stroke, pneumonia, and mortality [4-7]. 
 
Nevertheless, the prevalence of psychotropic drug use (PDU) among nursing 
home patients with dementia is high with rates ranging from 48 to 66% [8-10]. 
Moreover, there is a risk for long-term use of psychotropic drugs whereas 
prescription for only a short period of time is recommended [4][11]. For 
instance, 74% of the nursing home patients with dementia use antipsychotics, 
anxiolytics, hypnotics, or sedatives for 83% of the duration of their stay [12], 
and 31% continue the use of antipsychotics, antidepressants, anxiolytics, 
hypnotics, anticonvulsants, or anti-dementia drugs throughout a 2-year period 
[9]. The contradiction of widely prescribed psychotropic drugs despite side 
effects and limited evidence for (long-term) effectiveness, suggests that 
psychotropic drugs may be prescribed inappropriately.  
 
Systematic reviews on the effect of education, the involvement of 
pharmacists, and/or a multidisciplinary team show that these interventions 
may improve drug prescription in the elderly [13] or in nursing homes 
specifically [14][15]. For instance, improvements of about 30% in the 
prescription of drugs in nursing home residents [16][17], and discontinuation 
or dose reduction of antipsychotics in 61% of patients with dementia [18] 
have been found. Since the above-mentioned systematic reviews also include 
high quality studies not showing an effect, the authors suggest to focus in 
future studies on for example combining methods, multidisciplinary 
cooperation and direct communication between pharmacist, physician, and 
nurse, ways to improve the intervention, continuous education, and explicit 
procedures and routines for medication review. This encouraged us to 
develop an intervention integrating these elements into a new method of 
medication review. This medication review will be conducted face-to-face by a 
multidisciplinary team including not only the physician and pharmacist but 
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also a member of nursing staff. Further, it will be supported by education on 
practical, organizational, and medical aspects, continuous evaluation, and will 
be repeated every six months. It is expected that the education and 
continuous evaluation offered to all participants gives each of them additional 
knowledge and structure for proper medication review with a specific 
emphasis on psychotropic drugs. Furthermore, the participation of nurses, 
through their daily observations representing the patient, and the face-to-face 
setting is expected to improve the quality of the review.  
 
The PROPER II study (PRescription Optimization of Psychotropic drugs in 
Elderly nuRsing home patients with dementia) aims to study the effect of a 
structured and repeated multidisciplinary medication review supported by 
education and continuous evaluation on the appropriateness of PDU for 
treatment of NPS in nursing home patients with dementia. Secondary 
objectives are to investigate NPS, quality of life, activities of daily living, side 
effects and adverse events (including cognition, hospitalizations, and 
mortality). 
 
METHODS/DESIGN 
Design and eligibility 
The study is a multi-center, cluster randomized controlled, pragmatic trial 
using parallel groups, with a duration of eighteen months, and four six-
monthly assessments. Six nursing homes will participate in the intervention 
and six will continue care as usual. Randomization will be conducted on the 
level of nursing homes to prevent contamination bias within the nursing 
home. The nursing homes will be located throughout the Netherlands, and 
each will participate with two dementia special care units (DSCUs). In the 
Netherlands, dementia patients usually reside on DSCUs, and medical care 
including prescription of psychotropic drugs is provided by an elderly care 
physician employed by the nursing home [19]. In an investigation preceding 
the PROPER II study, the observational PROPER I study, the same twelve 
nursing homes will participate. Nursing homes will be selected based upon 
their responses on a questionnaire regarding the proportion of patients using 
psychotropic drugs per individual DSCU. In order to maximize variation in the 
use of psychotropic drugs in the PROPER II study, those nursing homes, more 
specifically, those DSCUs with either high or low rates, will be approached for 
participation. Ideally, six nursing homes with high PDU, and six with low PDU 
will be included. Since the sample size needed for PROPER II (see below) is 
lower than for the PROPER I study (Van der Spek et al., submitted), two DSCUs 
from each participating nursing home will be randomly included in the current 
study. 
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In total, 360 patients with a chart diagnosis of dementia will be included, i.e. 
on average fifteen patients of each of two DSCUs of twelve nursing homes. 
From DSCUs with more than fifteen patients, a random selection of fifteen 
patients will be included, regardless of their PDU. For DSCUs with less than 
fifteen patients, additional DSCUs will participate to retrieve the warranted 
number of patients per nursing home. Patients who die or are discharged 
from the DSCU, will be replaced during the study period. Physicians and 
nurses who are directly involved in the medical treatment and care for the 
patients will collect the patient data. 
 
This study is a collaboration between the sections for elderly care medicine of 
three Dutch university Medical Centers and the Dutch Institute for Rational 
Use of Medicine [20], and is supported by the Dutch association for residential 
and home care organizations (ActiZ), and the Dutch Health Care Inspectorate. 
 
Intervention 
The intervention consists of a structured and repeated multidisciplinary 
medication review supported by education and continuous evaluation. It 
consists of three components: 1) preparation and education, followed by a 
cycle of 2) conduct and 3) evaluation/guidance (figure 1). A local project 
coordinator will be assigned to ensure appropriate planning and organization 
of these components. The first component takes place within one month after 
the baseline assessment of the trial; the second occurs within one month after 
the first component, or within one month after the evaluation/guidance 
meeting of the third component; the third component takes place within one 
month after the six- and twelve-month trial-assessments. 
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Figure 1. Intervention of the structured and repeated multidisciplinary 
medication review supported by education and continuous evaluation, 
consisting of three components. 
 
 
 
Component 1: Preparation and education 
The first component includes all preparations prior to the actual conduct of 
the medication review. The major part consists of an educational session. The 
education includes both the practical and organizational aspects of the 
medication review, as well as training about the efficacy and side effects of 
psychotropic drugs. It will be provided locally at each intervention nursing 
home and is to be attended by physicians, pharmacists, and nurses. The 
content is based upon the Guideline for problem behavior of the Dutch 
Association of Elderly Care Physicians and Social Geriatricians (Verenso) [21], 
and the Multidisciplinary guideline Polypharmacy in the elderly [22]  including 
the STRIP method and Dutch versions of the START and STOPP tools [23]. The 
STRIP is the Systematic Tool to Reduce Inappropriate Prescribing and is a 
guidance for conducting structured medication reviews, the START is the 
Screening Tool to Alert doctors to Right Treatment, and the STOPP is the 
Screening Tool of Older Person's potentially inappropriate Prescriptions. This 
education will be provided by the Dutch Institute for Rational Use of Medicine 
(IVM), which is specialized in the distribution of information and solutions for 
the proper, safe, affordable and effective use of medicine. The education is 
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developed by the IVM in cooperation with the authors. Next to the education, 
this component comprises assigning responsibilities of the physicians, 
pharmacists, and nurses involved, timelines to be followed, and defining those 
sources of information that each of the participants will use for the 
medication review. 
 
Component 2: Conduct 
The second component includes the actual conduct of the medication review 
and follow-up per individual patient. The structure is largely based on the 
STRIP [22]. The conduct of medication reviews per individual patient is a 
process of preparation, discussion on medication during the medication 
reviews, execution of the actions proposed, and evaluation of changes. The 
medication review will be conducted by a team consisting of an (elderly care) 
physician, pharmacist, and a nurse (assistant). Each of the participants will 
prepare the medication review. The physician is responsible for collecting 
medical data of the patient relevant for the discussion, such as type of 
dementia, comorbidity, and contraindications. The pharmacist is accountable 
for the actual medication list, knowledge on drug-drug interactions, and 
dosages. Whereas the STRIP involves the patient in the preparation of the 
medication review, the patient is in this study represented by the nurse. The 
nurse is therefore responsible for collecting information about the patient’s 
current behavior and potential PDU-related side effects and adverse events by 
means of completing a checklist per patient prior to the medication review. 
The medication review focuses on the appropriate prescription of 
psychotropic drugs for NPS, but also includes review of other drugs. During 
the discussion, the team determines whether (psychotropic) drugs must be 
additionally prescribed, tapered, discontinued, dose-adjusted, or replaced, 
and whether other actions are needed. These encompass additional 
diagnostics such as blood checks or electrocardiography, further observations 
of side effects and adverse events or NPS, referral to a psychologist or to a 
medical specialist, and use of psychosocial interventions by nursing staff in 
behavioral management. Proposed changes and actions will be registered and 
implemented after obtaining consent from the patient’s representative. 
(Non)compliance to the proposed actions is also registered. Further, changes 
in medication will be followed-up continuously by the physician and nurse.  
 
Component 3: Evaluation/guidance 
Evaluation meetings regarding the conduct of the medication reviews will be 
organized to provide continuous evaluation by guiding and counseling in the 
process of medication review. These meetings will be provided by the IVM and 
are to be attended by physician, pharmacist and nurse. Moreover, a help desk 
provided by the IVM is available for questions.  
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Outcomes 
Primary outcome 
The primary outcome is the appropriateness of PDU defined as the proportion 
of patients with appropriate PDU. Assessment of appropriateness in this study 
is limited to antiepileptics, antipsychotics, anxiolytics, hypnotics/sedatives, 
antidepressants, and anti-dementia drugs prescribed for treatment of NPS in 
dementia, for sleep disturbances, and for delirium. Based on the Medication 
Appropriateness Index [24], a scale will be developed specifically for those 
psychotropic drugs used for treatment of NPS in nursing homes. Information 
will be included from the Guideline for problem behavior of the Dutch 
Association of Elderly Care Physicians and Social Geriatricians (Verenso) [21], 
the Guideline for diagnostics and medical treatment of dementia of the Dutch 
Geriatrics Society [25], the drug database of the Royal Dutch Pharmacists 
Association [26], and the ‘Farmacotherapeutisch Kompas‘ [27], a reference of 
drugs available in the Netherlands published by the Dutch Health Care 
Insurance Board (CVZ). 
 
Secondary outcomes 
Secondary outcomes are the overall frequency of PDU, NPS, quality of life, 
activities of daily living, psychotropic drug side effects and adverse events 
(including cognition, hospitalizations, and mortality).  
 
The overall frequency of PDU will be collected from the patients’ medical files 
or from (prints of) the electronic pharmacist information system and 
categorized using the Anatomical Therapeutic Chemical (ATC) classification 
[28] into the following therapeutic subgroups: antiepileptics (N03A), 
antipsychotics (N05A), anxiolytics (N05B), hypnotics and sedatives (N05C), 
antidepressants (N06A), and anti-dementia drugs (N06D). 
 
NPS will be assessed using the Neuropsychiatric Inventory – Questionnaire 
(NPI-Q), the Cohen-Mansfield Agitation Inventory (CMAI), the Nijmegen 
Observer-Rated Depression scale (NORD), and the Minimum Data Set 
Depression Rating Scale (MDS-DRS). The NPI-Q [29] is a brief version of the 
Neuropsychiatric Inventory, which was developed for measuring NPS in 
dementia [30]. The NPI-Q consists of twelve items on NPS, each scored for 
occurrence (yes/no format), severity (three-point Likert scale), and associated 
caregiver distress of NPS (six-point Likert scale). A validated Dutch version will 
be used [31]. The CMAI is a questionnaire on 29 agitated behaviors reflecting 
physical aggression, physically nonaggressive behavior, and verbally agitated 
behavior. All items regard frequency of behavior using a seven-point Likert 
scale [32]. The (construct) validity of the Dutch version [33][34] and reliability 
[35] have been extensively studied. The NORD is a recently developed and 
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promising Dutch questionnaire on occurrence (yes/no format) of five 
observable depressive symptoms, for screening of depression in nursing home 
residents with or without dementia [36]. The MDS-DRS is a seven-item 
observational instrument consisting of seven items on depression derived 
from the Minimum Data Set of the Resident Assessment Instrument (MDS-
RAI) [37][38]. Each item is scored for frequency on a three-point scale. The 
Dutch version of this instrument was studied for validity and reliability and 
considered suitable for research in nursing homes [39]. 
 
Quality of life will be assessed using the Qualidem, a 37-item observational 
instrument consisting of nine subscales for measuring quality of life, each item 
is scored for frequency on a four-point scale. It was developed for Dutch 
nursing home patients with dementia and proven reliable and valid [40][41]. 
In order to allow proper interpretation of the Qualidem scores, the severity of 
dementia will be assessed using the Global Deterioration Scale, a staging 
instrument indicating cognitive deterioration in dementia [42]. Additionally, 
the Revised Index of Social Engagement (RISE) [43] will be assessed. This is an 
observational instrument with six dichotomous items on social behavior, 
which is considered to contribute to quality of life. The RISE is a revised 
version of the Index of Social Engagement [44], and is derived from the MDS-
RAI [37][45]. 
 
Activities of daily living will be assessed using a questionnaire also derived 
from the MDS-RAI [46], of which validity and reliability of the Dutch version 
were established [39]. This scale has been adapted for the Dutch nursing 
home situation and scoring was simplified, resulting in a scale of twelve items 
to be scored on a four-point scale for level of independence, and a thirteenth 
item regarding change compared with the previous month (Joke Smallenburg, 
personal communication 2011).  
 
Psychotropic drug side effects and adverse events will be assessed by 
symptoms and disorders related to PDU, cognition, hospitalizations, and 
mortality. A scale representing common symptoms and disorders related to 
PDU will be developed for this study, based upon the Udvalg for kliniske 
undersogelser side effect rating scale (UKU) [47]. Cognition will be assessed 
using the Severe Impairment Battery-8 [48], a brief version of the Severe 
Impairment Battery [49]. It was developed as a brief instrument for patients 
with severe Alzheimer’s disease and is sensitive to change over time. The SIB-8 
was translated into Dutch for this study. Hospitalizations will be assessed by 
the number, indication, and duration as reported by the physicians, and 
mortality will be derived from the patients’ medical files. 
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All assessments will take place at baseline, six months, twelve months and 
eighteen months. An overview of the outcomes is shown in Table 1. 
 
Table 1. Overview of outcomes, instruments, and assessor at baseline, six, 
twelve, and eighteen months. 
Outcome  Instrument  Assessor  
Appropriateness of PDU  To be developed  Researcher  
Frequency of PDU  Generic name and ATC 
code  
Researcher  
NPS   
 NPS NPI-Q  Nurse  
 Agitation/aggression  CMAI  Nurse  
 Depression  NORD  Nurse  
 Depression  MDS-DRS  Nurse  
Quality of life    
 Quality of life  Qualidem  Nurse  
 (For interpretation of Qualidem)  GDS  Physician  
 Social engagement  RISE  Nurse  
Activities of daily living  Instrument derived 
from MDS-RAI  
Nurse  
Psychotropic drug side effects and 
adverse events    
 Symptoms and disorders related to 
PDU  
Instrument derived 
from UKU  
Physician  
 Cognition  SIB-8  Physician/ 
representative  
 Hospitalizations  Number, indication, and 
duration  
Physician  
 Mortality  Occurrence  Researcher  
Abbreviations: PDU: psychotropic drug use, ATC: Anatomical Therapeutic Chemical, NPS: 
neuropsychiatric symptoms, NPI-Q: Neuropsychiatric Inventory – Questionnaire, CMAI: Cohen-
Mansfield Agitation Inventory, NORD: Nijmegen Observer-Rated Depression scale, MDS-DRS: 
Minimum Data Set Depression Rating Scale, GDS: Global Deterioration Scale, RISE: Revised Index 
of Social Engagement, MDS-RAI: Minimum Data Set Resident Assessment Instrument, UKU: 
Udvalg for kliniske undersogelser side effect rating scale, SIB-8: Severe Impairment Battery-8. 
 
Baseline characteristics 
Other characteristics collected at baseline will be: age, sex, duration of nursing 
home admission, type of dementia as documented in the patients’ files, and 
comorbidity. Comorbidity will be assessed using a checklist on 25 chronic 
diseases considered most prevalent in a nursing home population. This 
checklist is a selection of those International Classification of Primary Care 
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(ICPC) chronic diseases and comorbidities that are most prevalent in general 
practice [50], and adapted for the PROPER II study. 
 
Process analysis 
Also, a process analysis will be carried out on the actual use of the 
intervention and the factors determining its implementation, especially 
regarding facilitators and barriers. In addition, reasons for non-compliance 
with the intervention and time spent on medication review will be assessed, 
and the meetings guided by the IVM will be evaluated. Separate checklists for 
nurses, physicians, pharmacists, as well as for the nursing home’s local project 
coordinator will be used. 
 
Sample size 
Assuming an increase in the proportion of patients with appropriate PDU from 
60% to 80% in the intervention group and equal randomization to the 
intervention or control group, a significance level (alpha) of 0.05, a power of 
80%, an average cluster size of fifteen patients per DSCU, and an ICC of 0.05 
[51], a sample size of 21 clusters is sufficient to detect a statistically significant 
difference applying Russ Lenth software [52] and calculation methods 
according to Twisk [53]. Allowing for a DSCU drop-out of ten percent, in total 
23 clusters are needed, resulting in the inclusion of  two DSCUs in each of 
twelve nursing homes. 
 
Statistical analysis 
Multilevel analysis will be applied to study the change in the proportion of 
patients with appropriate PDU between baseline and the average at six, 
twelve, and eighteen months on intervention DSCUs and control DSCUs, after 
correction of relevant covariates, such as baseline PDU and NPS. The use of a 
multilevel model will be applied for a number of reasons: patient PDU is 
hypothesized to be dependent on the prescription policy of the physician and 
thus to be nested within DSCUs, the longitudinal design and cluster 
randomization, and the replacement of drop-outs. 
 
Ethics approval 
The local Medical Ethics Review Committee ‘CMO Regio Arnhem-Nijmegen’ 
rated the study (number 2012/226) and pronounced that the study is in 
accordance with the applicable rules in the Netherlands concerning the review 
of research ethics committees and informed consent. Representatives of all 
selected patients will be approached in writing to inform them about the 
study and to give them the explicit opportunity to refrain from participation of 
the patient in the study. The study will be conducted in accordance with the 
Declaration of Helsinki [54]. 
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DISCUSSION 
This protocol presents the design of a cluster randomized controlled trial 
evaluating the effectiveness of a structured and repeated multidisciplinary 
medication review supported by education and continuous evaluation to 
improve appropriate prescription of psychotropic drugs for NPS in nursing 
home patients with dementia.  
 
The strength of this study’s intervention is the multidisciplinary three-
component approach of involving professionals who are educated to carry out 
a structured and repeated medication review. By including not only the 
pharmacist and physician but also the nurse, the multidisciplinary team is 
expected to bring optimal knowledge from different perspectives. In this 
setting, not only medical and pharmaceutical expertise is taken into account, 
but also insight into the patients’ NPS, for which the psychotropic drugs are 
prescribed. Besides, the nurse has close contact with the representative of the 
patient, which further allows input on wishes regarding treatment or 
acceptation of NPS for the individual patient to be included in the medication 
review. Moreover, this study is a broad collaboration between several Dutch 
parties. Aside from the sections for elderly care medicine of three Dutch 
university Medical Centers, which have close connections with numerous 
nursing homes, the Dutch Institute for Rational Use of Medicine, the Dutch 
association for residential and home care organizations (ActiZ), and the Dutch 
Health Care Inspectorate are actively involved in this project. This has not only 
contributed to the design of the study and structure of the intervention, but 
will also facilitate the knowledge transfer of the results to daily practice after 
completion of the study. In case effectiveness of this three-component 
intervention is shown, this medication review method will be used on a 
broader scale to increase awareness of physicians, pharmacists and nurses of 
proper psychotropic drug use. 
 
The study may have some limitations. Firstly, the involvement of a pharmacist 
for medication review is currently starting to become part of usual care, also 
in the control nursing homes. However, these medication reviews are most 
likely not introduced in a similar education-based, structured, and 
multidisciplinary fashion. Secondly, the turn-over of pharmacists, physicians, 
and/or nurses will affect the knowledge regarding the proposed conduct of 
the medication reviews, in case new staff did not attend the education 
sessions. However, due to the pragmatic design, the study will have a large 
external validity and it is expected that a potential effect is at least not 
overestimated.  
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Concluding, in the PROPER II study we target to improve the quality of 
pharmacological treatment of NPS of nursing home patients with dementia, 
by implementing a sound intervention of a structured and repeated 
multidisciplinary medication review supported by education and continuous 
evaluation. 
 
COMPETING INTERESTS 
The authors declare that they have no competing interests.  
 
AUTHORS' CONTRIBUTIONS 
SZ designed the study, DG and MS co-designed, and RK assisted in designing 
the study. The Dutch Institute for Rational Use of Medicine in cooperation 
with the authors designed the intervention. CS wrote the paper, and MS, DG, 
MN, RW, KS, SZ, and RK co-wrote the paper. All authors read and approved 
the manuscript. 
 
ACKNOWLEDGEMENTS 
This study was funded by the The Netherlands Organisation for Health 
Research and Development (ZonMw). 
 
 
 
 
 
 
 
 
CHAPTER 6 
104 
 
REFERENCES 
1. Zuidema S, Koopmans R, Verhey F: Prevalence and predictors of 
neuropsychiatric symptoms in cognitively impaired nursing home patients. 
Journal of geriatric psychiatry and neurology 2007, 20(1):41-49. 
2. Seitz D, Purandare N, Conn D: Prevalence of psychiatric disorders among 
older adults in long-term care homes: a systematic review. International 
psychogeriatrics / IPA 2010, 22(7):1025-1039. 
3. Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT: Course of 
neuropsychiatric symptoms in residents with dementia in nursing homes 
over 2-year period. Am J Geriatr Psychiatry 2010, 18(12):1054-1065. 
4. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, 
Lyketsos CG: Management of agitation and aggression associated with 
Alzheimer disease. Nature reviews Neurology 2009, 5(5):245-255. 
5. van Iersel MB, Zuidema SU, Koopmans RT, Verhey FR, Olde Rikkert MG: 
Antipsychotics for behavioural and psychological problems in elderly people 
with dementia: a systematic review of adverse events. Drugs & aging 2005, 
22(10):845-858. 
6. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical 
antipsychotics for dementia: meta-analysis of randomized, placebo-
controlled trials. Am J Geriatr Psychiatry 2006, 14(3):191-210. 
7. Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC: 
Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr 
Soc 2008, 56(4):661-666. 
8. Eggermont LH, de Vries K, Scherder EJ: Psychotropic medication use and 
cognition in institutionalized older adults with mild to moderate dementia. 
International psychogeriatrics / IPA 2009, 21(2):286-294. 
9. Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT: Prescribing 
pattern of psychotropic drugs in nursing home residents with dementia. 
International psychogeriatrics / IPA 2011, 23(8):1249-1259. 
10. Nijk RM, Zuidema SU, Koopmans RT: Prevalence and correlates of 
psychotropic drug use in Dutch nursing-home patients with dementia. 
International psychogeriatrics / IPA 2009, 21(3):485-493. 
11. Ballard C, Corbett A, Chitramohan R, Aarsland D: Management of agitation 
and aggression associated with Alzheimer's disease: controversies and 
possible solutions. Current opinion in psychiatry 2009, 22(6):532-540. 
12. van Dijk KN, de Vries CS, van den Berg PB, Brouwers JR, de Jong-van den Berg 
LT: Drug utilisation in Dutch nursing homes. European journal of clinical 
pharmacology 2000, 55(10):765-771. 
13. Kaur S, Mitchell G, Vitetta L, Roberts MS: Interventions that can reduce 
inappropriate prescribing in the elderly: a systematic review. Drugs & aging 
2009, 26(12):1013-1028. 
14. Verrue CL, Petrovic M, Mehuys E, Remon JP, Vander Stichele R: Pharmacists' 
interventions for optimization of medication use in nursing homes : a 
systematic review. Drugs & aging 2009, 26(1):37-49. 
CHAPTER 6 
105 
 
15. Forsetlund L, Eike MC, Gjerberg E, Vist GE: Effect of interventions to reduce 
potentially inappropriate use of drugs in nursing homes: a systematic review 
of randomised controlled trials. BMC geriatrics 2011, 11:16. 
16. Stuijt CC, Franssen EJ, Egberts AC, Hudson SA: Appropriateness of prescribing 
among elderly patients in a Dutch residential home: observational study of 
outcomes after a pharmacist-led medication review. Drugs & aging 2008, 
25(11):947-954. 
17. Patterson SM, Hughes CM, Crealey G, Cardwell C, Lapane KL: An evaluation of 
an adapted U.S. model of pharmaceutical care to improve psychoactive 
prescribing for nursing home residents in northern ireland (fleetwood 
northern ireland study). J Am Geriatr Soc 2010, 58(1):44-53. 
18. Child A, Clarke A, Fox C, Maidment I: A pharmacy led program to review anti-
psychotic prescribing for people with dementia. BMC psychiatry 2012, 
12:155. 
19. Schols JM, Crebolder HF, van Weel C: Nursing home and nursing home 
physician: the Dutch experience. Journal of the American Medical Directors 
Association 2004, 5(3):207-212. 
20. Instituut voor Verantwoord Medicijngebruik. 
http://www.medicijngebruik.nl/. 
21. Smalbrugge M, Boersma F, Kleijer BC, Kok RM, Sival RC, Verburg D, Verheij 
FRJ, Zuidema SU: Guideline problem behavior, NVVA. 2008. 
22. Nederlands Huisartsen Genootschap - Multidisciplinaire richtlijn Polyfarmacie 
bij ouderen. https://www.nhg.org/themas/artikelen/mdr-polyfarmacie-bij-
ouderen. 
23. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D: STOPP (Screening Tool 
of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to 
Right Treatment). Consensus validation. International journal of clinical 
pharmacology and therapeutics 2008, 46(2):72-83. 
24. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, 
Cohen HJ, Feussner JR: A method for assessing drug therapy appropriateness. 
Journal of clinical epidemiology 1992, 45(10):1045-1051. 
25. Van Gool WA, Hagemeijer, A., Barkhof, F., Brouwer, K.J., Eefsting, J.A., 
Eikelenboom, P., Jonker, C., Olde Rikkert, M.G.M., Sanders, J.B., Scheltens, 
Ph., Schmand, B.A., Sival, R.C., Stam, C.J., Steenhoek, A., Verhey, F.R.J., Wind, 
A.W.: Richtlijn Diagnostiek en medicamenteuze behandeling van dementie; 
2005. 
26. KNMP Kennisbank. http://www.kennisbank.knmp.nl/index.asp. 
27. Farmacotherapeutisch Kompas. http://www.fk.cvz.nl/. 
28. Nordic Council on Medicines: Guidelines for ATC classification. In. Oslo: WHO 
Collaborating Center for Drugs Statistics Methodology; 1990. 
29. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, 
DeKosky ST: Validation of the NPI-Q, a brief clinical form of the 
Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000, 12(2):233-
239. 
CHAPTER 6 
106 
 
30. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein 
J: The Neuropsychiatric Inventory: comprehensive assessment of 
psychopathology in dementia. Neurology 1994, 44(12):2308-2314. 
31. de Jonghe JF, Kat MG, Kalisvaart CJ, Boelaarts L: [Neuropsychiatric inventory 
questionnaire (NPI-Q): A validity study of the Dutch form]. Tijdschrift voor 
gerontologie en geriatrie 2003, 34(2):74-77. 
32. Cohen-Mansfield J, Marx MS, Rosenthal AS: A description of agitation in a 
nursing home. Journal of gerontology 1989, 44(3):M77-84. 
33. de Jonghe JF, Kat MG: Factor structure and validity of the Dutch version of 
the Cohen-Mansfield Agitation Inventory (CMAI-D). J Am Geriatr Soc 1996, 
44(7):888-889. 
34. Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT: Agitation in Dutch 
institutionalized patients with dementia: factor analysis of the Dutch version 
of the Cohen-Mansfield Agitation Inventory. Dementia and geriatric cognitive 
disorders 2007, 23(1):35-41. 
35. Zuidema SU, Buursema AL, Gerritsen MG, Oosterwal KC, Smits MM, 
Koopmans RT, de Jonghe JF: Assessing neuropsychiatric symptoms in nursing 
home patients with dementia: reliability and Reliable Change Index of the 
Neuropsychiatric Inventory and the Cohen-Mansfield Agitation Inventory. Int 
J Geriatr Psychiatry 2011, 26(2):127-134. 
36. Leontjevas R, Gerritsen DL, Vernooij-Dassen MJ, Teerenstra S, Smalbrugge M, 
Koopmans RT: Nijmegen Observer-Rated Depression scale for detection of 
depression in nursing home residents. Int J Geriatr Psychiatry 2011. 
37. Morris JN, Hawes C, Fries BE, Phillips CD, Mor V, Katz S, Murphy K, Drugovich 
ML, Friedlob AS: Designing the national resident assessment instrument for 
nursing homes. The Gerontologist 1990, 30(3):293-307. 
38. Burrows AB, Morris JN, Simon SE, Hirdes JP, Phillips C: Development of a 
minimum data set-based depression rating scale for use in nursing homes. 
Age Ageing 2000, 29(2):165-172. 
39. Gerritsen D, Ooms M, Steverink N, Frijters D, Bezemer D, Ribbe M: [Three 
new observational scales for use in Dutch nursing homes: scales from the 
Resident Assessment Instrument for Activities of Daily Living, cognition and 
depression]. Tijdschrift voor gerontologie en geriatrie 2004, 35(2):55-64. 
40. Ettema TP, Droes RM, de Lange J, Mellenbergh GJ, Ribbe MW: QUALIDEM: 
development and evaluation of a dementia specific quality of life instrument-
-validation. Int J Geriatr Psychiatry 2007, 22(5):424-430. 
41. Ettema TP, Droes RM, de Lange J, Mellenbergh GJ, Ribbe MW: QUALIDEM: 
development and evaluation of a dementia specific quality of life instrument. 
Scalability, reliability and internal structure. Int J Geriatr Psychiatry 2007, 
22(6):549-556. 
42. Reisberg B, Ferris SH, de Leon MJ, Crook T: The Global Deterioration Scale for 
assessment of primary degenerative dementia. Am J Psychiatry 1982, 
139(9):1136-1139. 
43. Gerritsen DL, Steverink N, Frijters DH, Hirdes JP, Ooms ME, Ribbe MW: A 
revised Index for Social Engagement for long-term care. J Gerontol Nurs 2008, 
34(4):40-48. 
CHAPTER 6 
107 
 
44. Mor V, Branco K, Fleishman J, Hawes C, Phillips C, Morris J, Fries B: The 
structure of social engagement among nursing home residents. The journals 
of gerontology Series B, Psychological sciences and social sciences 1995, 
50(1):P1-P8. 
45. Hirdes JP, Fries BE, Morris JN, Steel K, Mor V, Frijters D, LaBine S, Schalm C, 
Stones MJ, Teare G et al: Integrated health information systems based on the 
RAI/MDS series of instruments. Healthcare management forum / Canadian 
College of Health Service Executives = Forum gestion des soins de sante / 
College canadien des directeurs de services de sante 1999, 12(4):30-40. 
46. Morris JN, Fries BE, Morris SA: Scaling ADLs within the MDS. J Gerontol A Biol 
Sci Med Sci 1999, 54(11):M546-553. 
47. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect 
rating scale. A new comprehensive rating scale for psychotropic drugs and a 
cross-sectional study of side effects in neuroleptic-treated patients. Acta 
Psychiatr Scand Suppl 1987, 334:1-100. 
48. Schmitt FA, Saxton JA, Xu Y, McRae T, Sun Y, Richardson S, Li H: A brief 
instrument to assess treatment response in the patient with advanced 
Alzheimer disease. Alzheimer Dis Assoc Disord 2009, 23(4):377-383. 
49. Saxton J, McGonigle-Gibson, K.L., Swihart, A.A., Miller, V.J. and Boller, F: 
Assessment of the severely demented patient:  Description and validation of 
a new neuropsychological test battery. Psychological Assessment:  A Journal 
of Consulting and Clinical Psychology 1990, 2:298-303. 
50. van Oostrom SH, Picavet HS, van Gelder BM, Lemmens LC, Hoeymans N, 
Verheij RA, Schellevis FG, Baan CA: [Multimorbidity and comorbidity in the 
Dutch population--data from general practices]. Ned Tijdschr Geneeskd 2011, 
155:A3193. 
51. Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT: Psychotropic drug 
prescription in nursing home patients with dementia: influence of 
environmental correlates and staff distress on physicians' prescription 
behavior. International psychogeriatrics / IPA 2011, 23(10):1632-1639. 
52. Java applets for power and sample size. 
http://homepage.stat.uiowa.edu/~rlenth/Power/. 
53. Twisk JWR: Applied Multilevel Analysis. USA: Cambridge University Press; 
2006. 
54. WMA Declaration of Helsinki - Ethical Principles for Medical Research 
Involving Human Subjects. 
http://www.wma.net/en/30publications/10policies/b3/index.html. 
 
 
CHAPTER 6 
108 
 
 
 
 109 
 
CHAPTER 7 
The effect of biannual medication reviews on 
the appropriateness of psychotropic drug use 
for neuropsychiatric symptoms in patients 
with dementia: a randomised controlled trial 
 
CHAPTER 7 
110 
 
Klaas van der Spek, Raymond T. C. M. Koopmans, Martin Smalbrugge, 
Marjorie H. J. M. G. Nelissen-Vrancken, Roland B.Wetzels, Claudia H.W. 
Smeets, Erica de Vries Steven Teerenstra, Sytse U. Zuidema and Debby L. 
Gerritsen  
Submitted 
 
ABSTRACT  
Introduction 
We studied the efficacy of biannual structured medication reviews to improve 
the appropriateness of psychotropic drug (PD) prescriptions for 
neuropsychiatric symptoms (NPS) in nursing home patients with dementia.  
 
Trail, study design and setting 
The intervention encompassed a structured multidisciplinary medication 
review by physician, pharmacist and nurse. During this eighteen-month study, 
the patient’s medical files were assessed every six months.  
The primary outcome was the appropriateness of PD prescriptions defined by 
the Appropriate Psychotropic Drug use In Dementia (APID) index sum score, 
lower scores indicating more appropriate use. 
 
Results 
At baseline, 380 patients were included, of which 222 were randomised to the 
intervention group. Compared to the control group, the APID index sum score 
in the intervention group improved significantly for all PD prescriptions (-5.28, 
p = 0.005). 
 
Conclusion 
We advise the implementation of a structured, repeated medication review 
with the essential roles of pharmacist, physician and nurse, into daily practice. 
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INTRODUCTION 
Many nursing home residents with dementia have neuropsychiatric symptoms 
(NPS) which are frequently treated with psychotropic drugs , e.g. 
antipsychotics, antidepressants, anxiolytics and hypnotics [1][2]. However, 
there is substantial evidence for the existence of risks, side effects and long-
term inefficacy of psychotropic drugs [3][4], which is why the guidelines 
recommend the restricted and short-term use [5]. Nevertheless, there is some 
literature available reporting that psychotropic drugs are being used for 
excessively long periods [6][7][8], simultaneously [1], and without a proper 
indication [9][10]. These findings suggest inappropriate psychotropic drug 
prescriptions, thereby emphasising the need for optimisation strategies. 
Systematic reviews [11][12][13] as well as individual studies 
[11][14][15] in different settings, i.e. hospital [11][14] and nursing homes [15], 
show that a multidisciplinary medication review with the involvement of a 
pharmacist [12] and the additional presence of a nurse [12] has beneficial 
effects on appropriate drug prescription. Although there is evidence to 
suggest that a medication review may result in the improved appropriateness 
of drug prescription in general [16], studies on psychotropic drug prescription 
are unclear [15].  
In the current study, we aim to study the impact of a structured 
repeated multidisciplinary medication review on the appropriateness of 
psychotropic drug prescriptions. Recently, we developed the Appropriate 
Psychotropic drug use In Dementia index (APID index) [17]. This instrument is 
based on the Medication Appropriateness Index (MAI) [18] and makes it 
possible to specifically measure the appropriateness of psychotropic drug 
prescription for NPS in dementia on seven different domains, i.e. indication, 
evaluation, dosage, drug-drug interactions, drug-disease interactions, 
duplications and therapy duration. 
 Based on an earlier study [19], we hypothesise that the 
appropriateness-domains indication, evaluation and therapy duration 
contribute the most to the inappropriateness of psychotropic drug 
prescription [19] and will improve the most by this intervention. 
 
METHODS 
Trial design 
The PROPER II study (PRescription Optimisation of Psychotropic drugs in 
Elderly nuRsing home patients with dementia), investigated the effects of a 
newly developed medication review intervention in a multi-centre, cluster 
randomised controlled pragmatic trial using parallel groups [20]. The 
intervention group performed a structured, repeated (psychotropic) drug 
review, and the control group continued care as usual [20]. The study was 
conducted for eighteen months, with four biannual assessments.  
CHAPTER 7 
112 
 
Sample size 
Allowing for a cluster drop-out of ten per cent, in total 23 clusters (i.e. 
dementia special care units), with 15 patients on average, would provide 
>80% power to detect an absolute difference of 20% in the appropriateness of 
psychotropic drug prescriptions, as detailed in the study design paper [20]. 
 
Recruitment and randomisation 
The nursing homes recruited for PROPER II [20] were those already recruited 
for PROPER I, a cross-sectional mixed methods study that aimed to investigate 
(the appropriateness of) psychotropic drug prescriptions and its associations. 
For PROPER I twenty-seven long-term care organisations were contacted in 
order to include the necessary 13 nursing homes, located throughout the 
Netherlands. In the Netherlands, nursing homes are part of long-term care 
organisations and have dementia special care units that differ in size between 
5 and 30 patients. Usually, individual patients have one registered nurse and 
an elderly care physician assigned that is primarily responsible for their care 
[21]. A random selection of the dementia special care units that participated 
in PROPER I [22] was included in PROPER II. On average, 30 patients per 
location were included, residing in two or more dementia special care units 
depending on the size of the units. Randomisation was blinded, i.e. computer-
generated, and conducted on the level of nursing homes to prevent 
contamination bias within the nursing home. Seven nursing homes 
participated in the intervention and six continued care as usual.  
 
Patient involvement and ethics 
Patients were not directly involved in the study, information about 
psychotropic drug prescriptions were obtained from medical records. 
Physicians and nurses who were directly involved in the medical treatment 
and care for the patients collected data about the patients [20]. The inclusion 
criteria of PROPER II were (1) a chart diagnosis of dementia, (2) not terminally 
ill and (3) admitted for long stay. Patients who died or moved from the 
dementia special care unit were replaced by newly admitted patients on that 
units during the study. Representatives of all selected patients were 
approached in writing to inform them about the study and to give them the 
explicit opportunity to refrain from the participation of the patient in the 
study.   
The local Medical Ethics Review Committee ‘CMO Regio Arnhem-
Nijmegen’ judged/reviewed the study (number 2012/226) and pronounced 
that the study is carried out in accordance with the applicable rules in the 
Netherlands concerning the review of research ethics committees and 
informed consent.  
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PROPER II Intervention 
A newly developed method of structured and repeated multidisciplinary 
medication review was introduced for nursing home patients with dementia 
with the focus on psychotropic drugs prescribed for NPS. This medication 
review was carried out by the nursing homes own multidisciplinary team, i.e. 
the responsible physician, the pharmacist and the nurse [20].  
The intervention consisted of three components:    
Component 1) a preparation and education phase that included 
instruction about the practical and organisational aspects of the medication 
review and a training about the efficacy and side effects of psychotropic 
drugs, which were to be attended by physicians, pharmacists and nurses. The 
education was provided by the Dutch Institute for Rational Use of Medicine 
(IVM) and emphasised the adherence to the Guideline for problem behaviour 
of the Dutch Association of Elderly Care Physicians and Social Geriatricians 
(Verenso) [5], the Multidisciplinary guideline Polypharmacy in the elder [23] 
(including the Systematic Tool to Reduce Inappropriate Prescribing (STRIP), 
the Screening Tool to Alert doctors to Right Treatment (START) and the 
Screening Tool of Older Person's potentially inappropriate Prescriptions 
(STOPP) [14]).  
Component 2) the actual medication review, which was conducted at 
0-, 6- and 12-months by the multidisciplinary team. This team prepared the 
medication review with discipline-specific information, including data of the 
patient, pharmaceutical information and information about the patient’s 
current behaviour (obtained by nurses using a checklist) and potential 
psychotropic drug use-related side effects (obtained by physicians using a 
checklist). The medication review focused on the appropriate prescription of 
psychotropic drugs, but also included the review of other drugs. In case of 
multidisciplinary team agreement, medication adjustments were introduced 
after having consulted the patients’ representatives.  
Component 3) an evaluation phase prior to the reviews at 6 and 12 
months. Meetings with all stakeholders, i.e. physician, pharmacist and nurse, 
were organised in order to evaluate the intervention.  
In each nursing home, an intervention coordinator was assigned to 
ensure the planning and organisation of these components. The intervention 
is described extensively elsewhere [20].  
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Assessments and outcomes 
Assessment of appropriateness in this study was limited to antipsychotics, 
anxiolytics, hypnotics/sedatives, antidepressants, antiepileptics and anti-
dementia drugs.  
The appropriateness of psychotropic drug prescriptions was assessed 
using the Appropriate Psychotropic drug use In Dementia (APID) index [17]. 
The APID index was specifically developed for clinical studies evaluating the 
appropriateness of psychotropic drug prescriptions for NPS in patients with 
dementia in nursing homes. Therefore, psychotropic drugs that had a clear 
indication for other psychiatric disorders in the medical record (apart from 
dementia or sleeping disorder or delirium) were excluded from scoring [17]. 
Recommendations from national (Dutch) and international drug formularies 
were applied in order to score information about individual psychotropic 
drugs. The response categories of the seven domains were 0 (appropriate), 1 
(marginally appropriate) and 2 (inappropriate); the domains were weighted 
and incorporated into a sum score. The sum score ranges from 0 (fully 
appropriate) to 102.8 (fully inappropriate) on individual psychotropic drugs 
[17].  
 The primary outcome was the level of appropriateness of psychotropic 
drug use as defined by the Appropriate Psychotropic Drug use In Dementia 
(APID) index sum score.      
 Secondary outcomes were the appropriateness of indication, 
evaluation and therapy duration, defined by the APID index subscores on 
these domains [17]. The theoretical weighted score-ranges for these domains 
of appropriateness are as follows: indication 0-18.8, evaluation 0-19.2 and 
therapy duration 0-12.2.   
The analyses of all psychotropic drug prescriptions combined and per 
psychotropic drug group were performed. Psychotropic drugs were grouped 
using the Anatomical Therapeutic Chemical classification (ATC) [23]. 
Antidepressants, as well as anti-dementia drugs, do not have the maximum 
therapy duration according to Dutch drug formularies [5]. Therefore, these 
psychotropic drugs cannot be scored as inappropriate for therapy duration.  
 
Baseline characteristics 
Other characteristics that were collected at baseline were number of 
dementia special care units, age, sex, duration of nursing home admission and 
type of dementia as documented in the patients’ files. The type of dementia 
was categorised in Alzheimer Dementia (AD), Vascular Dementia (VaD), Mixed 
AD/VaD and other dementia.  
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Statistical analysis 
Descriptive statistics were used to examine the baseline characteristics. When 
more than a 10% difference between the intervention- and control group was 
observed, an independent samples t-test was performed to test the effect of 
this parameter on the primary outcome (APID index sum score).  
At baseline and after 6, 12 and 18 months, the mean APID index sum scores, 
the mean APID index subscores for indication, evaluation and therapy 
duration, including the standard deviations and 95% confidence intervals were 
calculated.  
A linear mixed model for repeated measurements of the outcome 
averaged at dementia special care unit (cluster) levels was used with time and 
treatment (1 in the intervention group at 6, 12 and 18 months and 0 
otherwise) as fixed effects (which is equivalent to a time x treatment 
interaction assuming no systematic difference between groups at baseline 
due to the randomisation) and dementia special care unit as random effect. 
Residuals of the mixed model were checked for trends indicating non-normal 
distribution. The effect in our trial was thus the average effect of the 
intervention versus control, averaged over month 6, 12, and 18. 
First, analyses on all prescriptions taken together were performed, 
followed by analyses per psychotropic drug group. 
 
RESULTS 
Recruitment and flowchart 
Eleven of the 27 long-term care organisations that were contacted decided 
not to take part because of a) lack of time or insufficient staffing (physician or 
nurse) to carry out the project (N=5); b) an ongoing reorganisation (N=3); c) 
involvement in another (research) project (N=2); and d) unit managers who 
were unwilling to participate (N=1). The study was conducted from September 
2012 to July 2014. The 12 long-term care organisations that completed the 
study were equally distributed over various rural and urban parts of the 
Netherlands.  
 The flowchart (Figure 1) provides an overview of the participating 
units and patients during the study.  
Figure 1. Study flowchart for the outcome analysis, please see Appendix C.  
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Baseline characteristics 
Table 1. Baseline characteristics. 
Baseline Characteristics of Nursing Home 
patients  
Intervention 
(n=222) 
Control 
(n= 158) 
Number of dementia special care units (clusters) 15 16 
Mean age (years), [SD] (range) 84 [7.4] (55-99) 83 [7.3] (55-99) 
Sex, female N (%) 173 (77.9%) 114 (72.2%) 
Length of stay at dementia special care unit 
(months), [SD] (range) 
25 [21.8] (0-118) 24.4 [21.7] (0-114) 
Number of psychotropic drugs used in total 
sample at baseline 
114 (51.4%) 88 (55.7%) 
Diagnosis of dementia, N (%)   
Alzheimer’s dementia 90 (40.5%) 37 (23.4%) 
Vascular dementia 27 (12.2%) 29 (18.4%) 
Mixed Alzheimer's/vascular dementia 22 (9.9%) 19 (12.0%) 
Other dementia 83 (37.4%) 73 (46.2%) 
 
Marginal baseline differences (see Table 1) were found between the 
intervention group and the control group for sex (77.9% and 72.2%) and 
number of psychotropic drugs used (51.4% and 55.7%). Although there was a 
difference between the intervention group and the control group in the 
prevalence of types of dementia, an independent sample t-test of the mean 
APID index sum score per patient at baseline revealed no significant 
differences between dementia types (AD, p = 0.264; VaD, p = 0.696; mixed 
AD/VaD, p = 0.200; other dementia, p = 0.811).  
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Table 2. Observed APID index sum score means of all psychotropic drug prescriptions at baseline, 6, 12 and 18 months. 
 
Outcome 
Theoretical 
range 
 
Observed Mean APID index sum score (CI) 
Baseline 
PDs n=329  
Clusters n=31  
After 6 months 
PDs n=306  
Clusters n=29 
After 12 months 
PDs n=278  
Clusters n=28 
After 18 months 
PDs n=272  
Clusters n=29 
APID index 
sum score 
0-120.8 Intervention  29.0 (CI= 26.1: 32.0) 21.1 (CI= 17.6: 24.4) 19.1 (CI=14.4: 23.7) 19.1 (CI= 16.6: 21.6) 
 Control 29.2 (CI= 24.0: 34.4) 28.5 CI 24.1: 32.9) 28.2 (CI 22.7: 33.8) 
Indication 
subscore 
0-18.8 Intervention 11.4 (CI= 10.0: 12.9) 8.4 (CI= 6.5: 10.3) 8.0 (CI= 5.8: 10.2) 7.4 (CI= 5.8: 9.0) 
 Control 11.5 (CI= 8.7: 14.4) 11.9 (CI= 8.6: 15.1) 11.1 (CI= 8.1: 14.0) 
Evaluation 
subscore 
0-19.2 Intervention 8.0 (CI= 6.4: 9.7) 3.6 (CI=1.9: 5.3) 2.8 (CI= 1.2: 4.3) 2.0 (CI= 0.8: 3.3) 
 Control 8.1 (CI=5.1: 11.1) 8.4 (CI= 5.9: 10.9) 8.5 (CI= 5.0: 12.0) 
Therapy 
duration 
subscore 
0-12.2 Intervention 5.8 (CI= 4.9: 6.8) 4.9 (CI= 3.4: 6.3) 5.1 (CI= 3.8: 6.3) 5.7 (CI= 4.7: 6.8) 
 Control 7.0 (CI= 5.5:  8.6) 6.0 (CI= 4.2: 7.8) 6.3 (CI= 4.4: 8.1) 
APID= Appropriate Psychotropic drug use In Dementia, PDs= psychotropic drugs, CI= 95% confidence interval  
 
Outcomes measures 
The average improvement over 6, 12, and 18 months of the mean APID index sum score for all psychotropic drug 
prescriptions together over time (as shown in Table 2) was significantly greater (as shown in Table 3) in the intervention group 
than the control group (-5.28, p = 0.005). This was also the case for the evaluation subscore (-2.26, p = 0.008). The mean APID 
index subscore for therapy duration declined significantly less in the intervention group (-1.65, p = 0.020). The indication 
subscore (-1.91, p=0.150) did not show differences (Table 3).  
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Table 3. Effect of structural medication reviews on the APID index sum score, indication score, evaluation score and therapy 
duration score of psychotropic drug prescriptions.¹  
 
Parameter 
n at 
baseline/ 
number of 
clusters 
Sum score 
TR 0-102.8 
Indication 
TR 0-18.8 
Evaluation 
TR 0-19.2 
Therapy duration 
TR 0-12.2 
APID index all 
prescriptions 
329/ 31 -5.28 (CI = -8.87: -1.69 
and p= 0.005*) 
 -1.91 (CI= -4.55:      -
0.75 and p=0.150) 
-2.26 (CI= -3.86:    -
0.65 and p=0.008*) 
-1.65 (CI= -3.03:        -
0.28 and p=0.020*) 
Specified per psychotropic drug group 
APID index 
antipsychotics 
85/ 31 -6.64 (CI= -13.51: -0.22 
and p=0.057) 
-0.68 (CI= -3.24: 1.88 
and p=0.585) 
-0.07 (CI= -3.78: 
3.65 and p=0.970) 
-1.44 (CI= -2.83:         -
0.05 and p=0.043*) 
APID index anxiolytics 54/ 31 -10.85 (CI= -17.17:       -
4.53 and p=0.002*) 
-10.09 (CI= -14.16:  -
6.03 and p<0.001*) 
-2.39 (CI= -5.47: 
0.69 and p=0.123) 
-0.31 (CI= -1.03: 0.41 
and p=0.379) 
APID index 
hypnotics/sedatives 
49/ 31 -4.07 (CI= -9.53: 1.39 
and p=0.135) 
 0.62 (CI= -3.40: 4.64 
and p=0.749) 
-7.49 (CI= -10.83: -
4.15 and p<0.001*) 
-2.94 (CI= -4.73:         -
1.16 and p=0.003*) 
APID index 
antidepressants 
90/ 31 -5.33 (CI= -10.11:         -
0.56 and p=0.030*) 
-2.94 (CI= -5.72:       -
0.16 and p=0.039*) 
-5.31 (CI= -7.72:    -
2.89 and p<0.001*) 
n.a. 
APID index anti-
dementia drugs 
38/ 31  3.77 (CI= -6.09: 13.64 
and p=0.430) 
-2.83 (CI= -9.91: 4.25 
and p=0.411) 
 4.27 (CI= 0.36: 
8.18 and p=0.038*) 
n.a. 
*= significant influence on regression p<0.05, CI= 95% confidence interval, n.a. = not applicable, TR = theoretical range.  
¹Analyses were performed on cluster-level. Analyses on antiepileptics were excluded, considering the small sample size (n=13 at baseline). Adjacent small 
dementia special care units sharing staff and corridors that had few participating patients, i.e. ≤ 3 patients participating on each unit at one or more of the 
measurement points, were grouped.  This was the case for three different nursing homes: two, three, five and five dementia special care units, respectively, 
with shared staff and corridors were grouped into larger clusters encompassing at least nine patients participating at baseline, after 6, 12 or 18 months.  
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Outcomes specified per psychotropic drug group 
More specifically, the APID index sum score and indication subscore for 
anxiolytics (-10.85, p = 0.002 and -10.09, p = 0.000) and antidepressants (-
5.33, p = 0.030 and 2.94, p = 0.039) showed a statistically significant greater 
improvement in the intervention group compared to the control group. For 
hypnotics/sedatives (-7.49, p < 0.001) and antidepressants (-5.31, p < 0.001) 
the evaluation subscore showed a significantly greater improvement in the 
intervention group compared to the control group, and a negative effect was 
found on the evaluation subscore for anti-dementia drugs (4.27, p = 0.038). 
Therapy duration subscore showed a significantly greater improvement in the 
intervention group compared to the control group for antipsychotics (-1.44, p 
= 0.043) and hypnotics/sedatives (-2.94, p = 0.003) (Table 3).  
 
DISCUSSION 
Main findings 
This innovative study demonstrated that the appropriateness of psychotropic 
drug prescriptions for NPS improved by structurally reviewing the 
prescriptions of nursing home patients with dementia every six months. 
Regarding all psychotropic prescriptions combined, overall appropriateness 
improved; on the level of domains, the evaluation and the therapy duration 
improved.     
In addition, in the control group, the overall appropriateness, 
indications and evaluations also improved, which could be due to the current 
societal attention for psychotropic drug prescriptions in nursing homes [25] 
and increased awareness as a result from participation in this study.   
 
To summarise, a biannual multidisciplinary review approach and attention for 
psychotropic drug prescriptions for NPS in dementia improves the efficacy of 
the evaluation and therapy duration, but changing to indications that are 
more appropriate may need a different approach and more attention on this 
domain during medication reviews.  
 
Strengths and limitations  
One of the strengths of our study was its multidisciplinary team approach; the 
presence of the nurses, which makes it possible to have more detailed 
information on the patients’ present condition in terms of NPS, in 
combination with the side effects associated with psychotropic drug use, 
monitored by physicians, and pharmaceutical information, provided by 
pharmacists. Furthermore, we used a newly developed instrument to assess 
inappropriate psychotropic drug use rated by researchers, independent from 
the opinion of the treating physician. 
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A limitation is the low participation rate in some dementia special care units, 
resulting in a few small clusters. Additionally, the overall sample size of some 
psychotropic drug groups was small; therefore, group specific reports should 
be interpreted carefully. Another limitation may be that the outcome 
measurement, the APID index, is partly based on Dutch drug formularies, 
implying for instance that some psychotropic drugs cannot be scored as 
inappropriate for therapy duration. Further, it uses patient records.  As a 
result, the score may be affected by suboptimal recordkeeping. However, 
good recordkeeping can be considered as an indispensable prerequisite for 
judging the appropriateness of prescription; physicians need good 
recordkeeping to evaluate the psychotropic drug prescriptions [17].  
 
Clinical implications 
The clinical use of off-label prescriptions is widespread [26]; many different 
psychotropic drugs are prescribed to individual patients with similar NPS 
[19][27]. Psychotropic drug prescriptions for NPS in dementia were rated as 
appropriate when guidelines recommended these specific prescriptions for a 
NPS, but even when there is maximum guideline adherence, there still is 
limited evidence for the efficacy of treatment [25] and, therefore, 
psychotropic drugs should be regularly evaluated. Additionally, antipsychotics, 
anxiolytics and hypnotics/sedatives are used too long [8][19]. 
Improvement of guideline recommended indications, appropriate 
evaluations of effects and therapy duration, could be facilitated with a 
psychotropic drug prescription monitor, based on the APID index, that is 
suitable for daily practice. This instrument could increase the awareness of 
inappropriate prescriptions of psychotropic drugs for NPS and, consequently, 
facilitate the implementation of the medication review.  
This study was performed in the Netherlands with trained elderly care 
physicians as the responsible physician, the pharmacist and the nurse. The 
structure of a medication review service may differ worldwide, however, since 
the appropriateness of psychotropic drug prescriptions is a worldwide 
challenge and similar interventions (including pharmacists and physicians) on 
reducing (the appropriateness of) psychotropic drug use were performed in 
other countries [14][28][29][30], the results may very well be generalisable to 
other countries. 
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INTRODUCTION 
There is an ever increasing interest in reducing psychotropic drug (PD) use for 
neuropsychiatric symptoms (NPS) in institutionalized patients with dementia. 
While initiatives focus on reducing the frequency (prevalence), the 
appropriateness of these prescriptions has received less attention. However, 
that could be key for beneficial PD use, consequently improving its 
effectiveness and reducing side effects.  
The first part of this thesis (PROPER I) focuses on the development of the 
APID, an index to objectify the construct appropriateness of PD use for NPS in 
dementia, measure the current appropriateness with this index and 
determine factors associated with appropriateness.  
The second part of this thesis (PROPER II) focuses, based on the 
abovementioned exploration of appropriateness, on the improvement of 
potentially inappropriate prescriptions.  
 
Prior to discussing the performed studies and their results, a summary of the 
findings is given according to the thesis’ research questions on PD 
prescriptions for NPS among nursing home patients with dementia: 
 
1. How to measure appropriateness of psychotropic drug prescriptions? 
2. How appropriate are psychotropic drug prescriptions for 
neuropsychiatric symptoms? 
3. What factors are associated with the appropriateness of psychotropic 
drug prescriptions? 
4. How to improve the appropriateness of PD prescriptions? 
 
Second, the methodological considerations, the clinical implications, the 
societal impact and recommendations for future research are discussed. 
 
SUMMARY OF FINDINGS 
How to measure appropriateness of psychotropic drug prescriptions? 
Chapter 3 describes the development of an index that is suited for clinical 
studies evaluating appropriateness of PD prescriptions for NPS in nursing 
homes patients with dementia and to test its reliability and validity; the design 
is described in chapter 2.  
The Medication Appropriateness index (MAI) [1] is an index that was 
developed to measure appropriateness of drug use in general, but it is not 
specifically aimed at assessing appropriateness of PD prescriptions for NPS in 
dementia. In addition, the MAI does not fit specific drug utilization 
formularies, which is preferable when drug utilization reviews are applied. 
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Therefore, an index was developed, derived from the items of the MAI, that is 
specifically suited for clinical studies evaluating the appropriateness of PD 
prescriptions for NPS in nursing homes patients with dementia. An expert 
panel reviewed the MAI items; five existing MAI items were found suitable, 
the MAI item ‘indication’ was adjusted, a new item ‘evaluation’ was added, 
and scoring rules were based on guideline recommendations, to create the 
Appropriate Psychotropic drug use In Dementia (APID) index. A second 
independent expert panel determined that all items contributed to the 
construct ‘appropriateness’. This resulted in an index that encompasses seven 
(different) domains of appropriateness, i.e. indication, evaluation, dosage, 
drug-drug interactions, drug-disease interactions, duplications and therapy 
duration. An interrater reliability study was conducted, and a summated index 
score, based on weighted item scores, was developed to enhance the use in 
clinical studies. The APID index score is calculated using information about 
individual PDs from patients' medical records. Construct validity was explored 
using a representative sample of 560 medical records. Information from PD 
prescription guidelines and the summary of product characteristics from the 
medication evaluation board [2], which was retrieved by Dutch databases for 
drug prescriptions, was integrated into the seven items of the APID index for 
each PD [3][4].  
The results of this study showed that the APID index is reliable and 
valid for measuring the appropriateness of PD prescriptions for NPS in nursing 
home patients with dementia in clinical studies.   
 
How appropriate are psychotropic drug prescriptions for neuropsychiatric 
symptoms? 
Chapter 4 describes the exploration of the status of the appropriateness of PD 
prescriptions for NPS in nursing home patients with dementia; the design is 
described in chapter 2.       
 A cross-sectional study among 559 patients with dementia residing on 
Dementia Special Care Units (DSCUs) in Dutch nursing homes was conducted. 
Appropriateness of PD prescription was assessed using the APID index. A total 
of 578 PDs were used for NPS by 60% of the patients. Of the seven APID index’ 
items it appeared that indication, evaluation and therapy duration contributed 
the most to inappropriate use. The minority of the PDs, only 10%, scored fully 
appropriate according to the APID index sum score, 36% scored fully 
appropriate for ‘indication’, 46% scored fully appropriate for ‘evaluation’, and 
58% scored fully appropriate for ‘therapy duration’. Antidepressants were 
used the most appropriately, and antiepileptics the most inappropriately. 
Appropriateness was not associated with the number of PDs used per patient, 
the percentage of use on the DSCUs, nor the percentage of prescription of the 
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individual physicians (i.e. the number of their patients with one or more PD 
prescriptions).   
The results imply that there is room for improvement of the PD prescriptions 
for NPS in patients with dementia and that it should be optimized with a 
clinical focus on the appropriateness of indication, evaluation, and therapy 
duration, which guided us to focus on these domains in the exploration of the 
appropriateness of different individual and groups of PDs. 
What factors are associated with the appropriateness of psychotropic drug 
prescriptions? 
Chapter 5 describes the cross-sectional study on patient and non-patient 
factors associated with (in) appropriate PD prescription as measured with the 
APID index sum score; the design of a conceptual framework about potential 
associations is described in chapter 2.      
 The sample consisted of 559 patients that used 147 antipsychotics, 
167 antidepressants, 85 anxiolytics and 76 hypnotics/sedatives. Various 
measurements were carried out for patient and non-patient factors (e.g. NPS, 
NPS related nurses’ stress, attitude to dementia care of caregivers, physicians’ 
experience, time available per patient) using questionnaires, assessment 
instruments and patient records.    
Linear multilevel regression analysis was used to identify factors that 
are associated with APID index sum scores. Analyses were performed for four 
groups of PDs separately, i.e. antipsychotics, antidepressants, anxiolytics and 
hypnotics/sedatives. It was found that older age and more severe aggression, 
agitation, apathy and depression were associated with more appropriate 
prescriptions.        
 Less appropriate prescriptions were found to be associated with more 
severe anxiety and non-Alzheimer’s dementias. Several non-patient related 
factors were also associated with less appropriate PD prescriptions (more 
patients per physician and higher nurses’ workload) and some of these 
findings were counter-intuitive (more physician time available per patient, 
more years of experience of the physician).  
 
How to improve the appropriateness of PD prescriptions? 
Chapter 7 describes the efficacy of a multi-centre cluster randomised 
controlled trial on implementing biannual structured medication reviews to 
improve the appropriateness of PD prescriptions for NPS in nursing home 
patients with dementia. The design is described in chapter 6.   
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The PROPER II intervention consists of a structured and repeated 
multidisciplinary medication review supported by education and biannual 
evaluation. It was conducted by pharmacists, physicians, and nurses and 
consisted of three components: 1) preparation and education, 2) conduct, and 
3) evaluation and guidance. The primary outcome was the appropriateness of 
PD prescriptions defined by the APID index sum score, lower scores indicating 
more appropriate use. 
During this eighteen-month randomised controlled trial, the patients’ 
medical files were assessed every six months. At baseline, 380 patients were 
included, of which 222 were randomised to the intervention group. Compared 
to the control group, the APID index sum score in the intervention group 
improved significantly for all PD prescriptions combined. This was also the 
case for the subscore ‘evaluation’ and the subscore ‘therapy duration’. The 
subscore ‘indication’ did not show a significant difference.   
        
More specifically, per PD group, the APID index sum score and indication 
subscore for anxiolytics and antidepressants showed a statistically significant 
greater improvement in the intervention group compared to the control 
group. For hypnotics/sedatives, antidepressants and anti-dementia drugs the 
evaluation subscore improved significantly in the intervention group 
compared to the control group. The therapy duration subscore also improved 
significantly in the intervention group compared to the control group for 
antipsychotics and hypnotics/sedatives.   
Based on these results, the implementation of a structured repeated 
medication review for PD prescriptions into daily practice is recommended, 
with the essential roles of pharmacist, physician and nurse. 
METHODOLOGICAL CONSIDERATIONS 
Study population/response rate 
For PROPER I 13 long-term care organisations (LTCOs) were recruited, located 
throughout the Netherlands. In the Netherlands, nursing homes are part of 
LTCOs and have Dementia Special Care Units (DSCUs) that differ in size 
between 5 and 30 patients. A random selection of the DSCUs that participated 
in PROPER I (see chapter 2) was included in PROPER II (see chapter 6), which 
resulted in the absence of selection bias.  
The PROPER I sample consisted of 559 patients, 338 used one or more 
PDs, living in 44 different DSCUs of 12 Dutch LTCOs. Only few (<10) objected 
to participation. The mean age was 84 years (range 62-100) and 73.8% was 
female. These findings were similar to the results found in other studies 
[9][5][6]. Therefore, the sample was considered as a good representation of 
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Dutch long-term care patients residing on DSCUs; the sample had good 
external validity. 
The PROPER II sample at baseline consisted of 222 patients residing on 
15 DSCUs in the intervention group and 158 patients residing on 16 DSCUs in 
the control group. Again only few (<10) objected to participation. Baseline 
differences were found between the intervention group and the control group 
for sex (77.9% and 72.2%), number of PDs used (51.4% and 55.7%) and 
percentage of Alzheimer’s dementia (40.5% and 23.4%). Although differences 
between the intervention group and the control group in the prevalence were 
found, independent sample t-testing of the mean APID index sum score 
between the groups at baseline revealed no significant differences. Moreover 
the mean APID index sum score was found independent from prevalence 
(chapter 4), therefore, we did not correct for this in the final analyses.  
The participation rate in some DSCUs was limited, although sample 
size calculation was performed prior to recruitment for PROPER II (chapter 6) 
and new patients were recruited during the study period to compensate for 
patients who died or were discharged from the DSCU. The limited 
participation rate resulted in a few small clusters during the study period, see 
chapter 7. Additionally, the sample size of some PD groups was small; 
therefore, PD group specific reports should be interpreted carefully. 
Nevertheless, the samples were sufficient to detect significant differences. 
 
Study design 
In this thesis the status of the appropriateness of PD prescriptions for NPS in 
Dutch patients with dementia residing in LTCOs was explored by using the 
APID index, see chapter 4. Prior to that measurement, the major part 
participated in the development and validity study of the APID index. 
However, uncertainty exists about the generalisability of the status of the 
appropriateness to other samples, which could be considered as a limitation 
of the study design. Therefore, the APID index should be used on other 
samples to test the external validity of the results from the study on the status 
of the appropriateness (chapter 4). 
To our knowledge chapter 5 describes the first study that was 
performed to identify potential associations with the appropriateness of PD 
prescription for NPS in patients with dementia specifically. Primarily patient 
factors were associated with the appropriateness of PD prescriptions, which 
implies that physicians should pay more attention to the appropriateness 
when NPS are less severe. The search for associations is complex. Different 
factors have been mentioned in the literature, e.g. the presence of 
behavioural symptoms and female sex have been found to be associated with 
more appropriate indications of benzodiazepines[7]. We developed a 
conceptual framework of factors associated with the appropriateness of PD 
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prescriptions (chapter 2), we assumed that appropriate prescription of PDs 
has a similar multifactorial nature as it has for the frequency of PD 
prescription [8]. The statistical limitations in searching for the most important 
of these associations have once again been confirmed in this thesis; there are 
too many potential associations even for reasonably large samples [9]. The 
assumed multifactorial nature of PD prescriptions in dementia care resulted in 
that we collected too many factors, see chapter 2, whereas including all 
possibly relevant factors could lead to an overfit of statistical models[9]. 
Therefore, it can be considered as a limitation of the PROPER I study design 
and made the authors decide to make a selection of factors potentially 
associated with appropriate PD prescription. This selection was based on the 
existing knowledge about the factors associated with PD prescriptions and the 
clinical expertise of the authors. Due to this selection, relevant but still 
unknown factors might have been missed.  
 
The construct ‘appropriateness’ 
In this thesis the development and validation of the first medication index 
specified to measure the appropriateness of PD prescriptions for NPS in 
nursing home residents with dementia was described. All seven newly 
developed APID index items had good content validity and no multicollinearity 
was found between the items. However, considering that the construct 
‘specified to measure the appropriateness of PD prescription for NPS in 
dementia’ was newly developed, there is no gold standard to validate the 
index as a good measure for this construct. The issues faced with this new 
construct are discussed here:   
Literature on appropriateness indicators [10][11][12] shows that the 
items ‘indication’, ‘evaluation’ and ‘duration of therapy’ have a large 
contribution to inappropriateness of PD prescriptions. These results are in line 
with results of a multi-intervention study on all drugs used by elderly patients 
which found that the items indication, duration and expense where most 
inappropriate using the MAI [13], and also with our second expert panel’s 
highest mean weighting for the items ‘indication’ and ‘evaluation’.  
 The abovementioned findings are consistent with the results of 
chapter 4, which also found that ‘indication’, ‘evaluation’ and ‘therapy 
duration’ contributed the most to the mean summated index score, thus the 
overall inappropriateness. In relation to this issue, one might argue that 
especially the items indication and evaluation were bound to contribute more 
to the overall inappropriateness considering the weight given; the mean 
weights for indication, evaluation, dosage, drug-drug interactions, drug-
disease interactions, duplications and therapy duration were respectively; 9.4, 
9.6, 6.7, 5.8, 6.6, 7.2 and 6.1.  However, this only partly explains the large 
contribution of these items as their unweighted means (range 0-2 for all seven 
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items) were 1.07, 0.89, 0.19, 0.01, 0.11, 0.09 and 0.83 respectively (table 6, 
chapter 3). 
The results show that the other four items, i.e. dosage, drug-drug 
interactions, drug-disease interactions and duplications, score more 
appropriate. These items can be considered ‘pharmaceutical’ items. 
Potentially, this can be attributed to the recent development in the use of 
electronical prescription systems that control for and thereby prevent drug-
drug interactions, drug-disease interactions and duplications in patients’ 
digital medical files. Therefore, these are less dependent on human action and 
more on electronical systems, which are implemented fairly well in Dutch 
nursing homes.  
Although the absence of multicollinearity and attributions of the 
independent items to the inappropriateness are promising considering the 
validity of the index, further analysis must indicate the extent of the 
constructs’ validity by accumulating evidence when hypotheses about the 
appropriateness of PD prescriptions for NPS in dementia are rejected or 
confirmed [14] [15]. For example, two more steps, next to multicollinearity 
analysis, can be taken in the study of nomological validity: 1) the degree to 
which a construct should behave in relation to other constructs and 2) the 
construct in isolation measured by reflective measures instead of depicted in 
the described formative model [15], e.g. by measuring the amount of 
medication reviews, new indications and evaluations in a year. In addition, in 
future research other instruments, like the MAI, could very well be used to 
investigate discriminant validity [15]. However, in that case different 
outcomes by different instruments should be taken into account; a recent 
study on discriminant validity on general drug appropriateness measures 
found that there are differences in reported appropriateness between 
measures, i.e. Beers criteria 2003, the Screening Tool of Older Person’s 
Potentially Inappropriate Prescriptions (STOPP) and Beers 2012[16][17], which 
could be due to differences in the definition of the constructs. 
Finally, it should be taken into account that the APID index’ content, 
i.e. the formularies for medication prescription[18] and the summary of 
product characteristics [2], are subject to revisions [19]. If formularies and the 
SPCs are revised, the APID index should also be updated before a research 
trial.   
 
Reliability of the APID index 
To consistently measure the new construct, it is imperative to have good 
intra- and interrater reliability, which is a prerequisite for good- research and 
clinical instruments. Results of the interrater reliability analyses described in 
chapter 3 show promising agreement on the individual items; the ICCs for 
agreement of the items are moderate to almost perfect. However, it should 
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be taken into account that this is not the same as the ‘absolute’ agreement 
between raters [20], which varied between the items from 61% to 98%. 
Therefore, the cause of disagreement between two raters was also studied. 
The results show that inter-individual differences in information extraction 
from the patients’ files are the major cause of disagreement. If one individual 
rater extracts information from medical files, the extraction of information 
from these files is likely to be more identical, which implies that results of 
intrarater reliability analysis are bound to be higher [21]. However, if the APID 
index or items from the index are used in clinical practice, a study on the 
intrarater reliability is recommended. 
 
Medical file research 
Given that the APID index uses medical record reports, the extraction of 
information from the records is an important factor in interrater reliability, as 
described above. Next to a medical record extraction bias, the results could be 
biased by the reporting quality.   
The independent reliability study reported in chapter 3 found minimal 
differences between the practising elderly care physician’s and the 
researcher’s administration of the APID index, which supports the concept of 
using medical records for measuring appropriateness; good recordkeeping is a 
prerequisite for evaluating the PD prescriptions. However, the study also 
found that physicians, in comparison to the researcher, have additional 
information about indications. In addition to the information from the medical 
file, the physician had knowledge at hand.         
Another important limitation in relation to medical file research was 
that for practical reasons a selection method had to be made; the medical 
charts were used to search for potential continuous inappropriate PD 
prescriptions with the APID index. That did not account for potential 
prescription omissions and pro re nata prescriptions, see chapter 4. Therefore, 
the inappropriateness measurement is limited to continuous prescriptions. 
 
Improvement of appropriate prescription 
It was found that biannual medication reviews improve the appropriateness of 
PD prescriptions. Medication reviews were carried out by pharmacists, 
physicians and nurses. Pharmacist provided the pharmaceutical information, 
the side effects associated with PD use, were monitored by physicians. The 
participation of the nurses in these reviews, which makes it possible to have 
more detailed information on the patients’ present condition in terms of NPS, 
was considered as one of the strengths. How this interaction added to the 
improvement should be studied by evaluating the process of implementation. 
The item ‘indication’ did not improve significantly by the intervention. This is 
possible due to that once an indication is made or there is a lack of indication, 
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the biannual medication review was insufficient in detecting the initial reason 
for prescription.  
 
Generalisability to other countries 
This study was performed in the Netherlands, on so called DSCUs with trained 
elderly care physicians as the responsible physician. However, the 
appropriateness of PD prescriptions is a worldwide challenge and similar 
difficulties with appropriateness, e.g. guideline non- adherence and non-
patient factors associated with the prescription of PDs, were found in other 
countries [22][23][24][25][26][27]. Therefore, the results can very well be 
generalised to other countries, thus have good external validity.  
 
CLINICAL IMPLICATIONS AND SOCIETAL IMPACT 
Worldwide there is an increasing awareness of the importance of the 
appropriateness of prescriptions [28][29][30][31][32][33][17]. In this thesis 
appropriateness was defined as the extent of the appropriateness of PD 
prescriptions on seven individual items. In other studies we found that 
appropriateness was defined as frequency of use/indications [7] or other 
particular items, i.e. regularly evaluating the prescriptions [34], the 
administration and pharmaceutical aspects like dosage, drug-drug interaction, 
drug-disease interaction and therapy duration[35][36].  
This thesis shows that the frequency and the appropriateness of PD 
prescriptions for NPS in dementia are independent concepts that can be 
explored separately. This thesis contributed to the knowledge of the 
appropriateness, when interpreting these new knowledge new implications 
and recommendations for dementia care arise, which are discussed here: 
 
1) The majority of psychotropic drug prescriptions for neuropsychiatric 
symptoms in dementia are inappropriate 
The clinical use of off-label prescriptions of PDs is widespread and 
persistent[17] [37]; many different PDs are prescribed to patients with similar 
NPS (chapter 4)[38]. The minority of the PD prescriptions is fully appropriate 
and non-patient factors are also associated with inappropriate prescriptions. 
PD prescriptions for NPS in dementia were rated as appropriate when 
guidelines recommended these specific PDs for a NPS, but even when there is 
maximum guideline adherence, there still is limited evidence for the efficacy 
of PD treatment [39] and, therefore, PDs should be regularly evaluated. 
Additionally, antipsychotics, anxiolytics and hypnotics/sedatives are used too 
long (chapter 4)[40]. This thesis strengthens the urge for more appropriate PD 
prescription in dementia.  
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2) Need for improvement of inappropriate psychotropic drug 
prescriptions 
Estimates are that curing/slowing down the degenerative process in dementia 
will take another ten years at the least, in the meantime it is advised to 
address appropriate PD prescriptions [41].  Medication reviews in long-term 
care settings should be performed annually based on the requirements of the 
Dutch Healthcare Inspectorate. However, these are time consuming; to 
increase efficiency a digital support system should be developed/used to 
assist the medication review processes [42]. 
To improve health and wellbeing of patients with dementia a balance 
is needed between effectively treating NPS and taking the negative/side 
effects of PDs into account [43]. Reviewing medication can improve the 
appropriateness of drug prescriptions in patients with dementia. This thesis 
shows that the implementation of structured biannual medication reviews 
(including education about reviewing and involving the nurse) is an effective 
method in improving the appropriateness of psychotropic drug prescriptions. 
Therefore, we recommend the implementation of a structured, repeated 
medication review with the essential roles of pharmacist, physician and nurse, 
into daily practice.   
 
3) What to do next and how to do it? 
The nursing Home Reform Act (OBRA’87) is a federal  American law that sets 
some standards of care and establishes certain rights for elderly persons in the 
United States [44]. In the Netherlands, similar laws, the long term care act and 
the Special Admissions to Psychiatric Hospitals Act (Bopz) [45][46], regulates 
care for psychiatric patients and thus psychogeriatric nursing home care. 
Currently, there is a Dutch bill that introduces a roadmap to promote a 
multidisciplinary approach for voluntary care in regulating NPS in patients 
with dementia, to prevent involuntary psychogeriatric nursing home care [47].     
As mentioned in the introduction of this thesis, the Dutch Healthcare 
Inspectorate monitors the quality and safety of the care for these patients. 
The Inspectorate formulated eight points of attention, i.e. quality indicators 
[48]. These points focus on understanding behaviour and managing behaviour 
by psychosocial interventions in the first place, and more specifically, 
attending the topic of this thesis; if PDs are prescribed these should be 
monitored (by physicians) regularly.      
 A psychotropic drug monitor could facilitate this using the knowledge 
from this thesis; a monitor focussing on proper indications, evaluations and 
therapy durations. The APID index as a research instrument could be adjusted 
to a self –evaluation tool for physicians. Therefore, the development of such a 
tool is advised.     
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If the APID index or items from the APID index are used in clinical practice, 
intra- and interrater bias should be taken into account. In case of clinical 
individual use ‘absolute’ agreement is of importance. If clinicians rate 
individual PD prescriptions, more information about the method they used to 
extract the information from the medical file is necessary, when patients 
transfer to other physicians; to keep clinicians well informed. The results show 
that the physician could have additional information about their patients’ PD 
indications that could influence the index’ score (chapter 3). Additionally, as 
mentioned in the methodological considerations, the intrarater reliability 
should be studied.       
 In relation to the development of a self-evaluation tool an important 
issue was attended in this thesis; the need for a structured way of extracting 
information from patient records. The current status of medical file keeping 
differs between long-term care facilities, i.e. paper files, electronical files or a 
combination of paper and electronic files. Therefore, a protocol could 
facilitate the standardized extraction of information that is suited for and can 
fit different record keeping systems. This protocol should be developed in a 
way that prevents physicians’ bias of self-evaluation; physicians reporting too 
positive or negative about their own prescriptions. Therefore, electronic 
systems for pharmaceutical purposes should be implemented to appropriately 
indicate, evaluate and stop prescriptions in time with, for example, a clinical 
decision support system [49]. Moreover, this tool should be regularly updated 
concerning new guideline recommendations and evidence for appropriate PD 
prescriptions. This updating should be protocolled in time and by a panel 
consisting of expert pharmacists and physicians that work in the (research) 
field of PD prescription in dementia.        
    
Another important quality indicator, and point of attention by the Dutch 
Healthcare Inspectorate, is monitoring the effects of psychosocial and medical 
interventions biannually [48]. In this thesis we attended to the importance of 
enforcing these guidelines regularly and based on the results we suggest the 
development and implementation of a PD self –evaluation tool into clinical 
practise.  
 
RECOMMENDATIONS FOR FUTURE RESEARCH  
Many PDs were prescribed inappropriately, primarily based on off-label and 
missing indications, missing evaluations and long-term prescriptions. 
Potentially, physicians overlook to appropriately indicate, evaluate and 
appropriately stop prescriptions, therefore, determinants of these domains of 
inappropriate prescriptions should be further explored. Additionally, pro re 
nata PD prescriptions were not included in this thesis, considering the 
difficulties in objectifying the rationale of these prescriptions. If PD 
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prescriptions decrease in the future, potentially pro re nata prescriptions 
could increase, therefore, future research should include these prescriptions. 
Considering the limited knowledge there is about associations of 
appropriate PD prescriptions for NPS in dementia specifically, qualitative and 
quantitative research on this topic should be accumulated from other fields of 
research, e.g. associations with the frequency of PD use [50][51][52][53], to 
select potential factors associated with appropriateness of PD prescriptions. 
For example, the factors mentioned in the conceptual framework, chapter 2, 
could be made up to date with current literature on determinants of 
(appropriate) PD prescriptions for NPS in dementia and guide the selection of 
relevant potential determinants of appropriate PD prescriptions in future 
research. The results from this thesis (chapter 5) show that non-patient 
factors like nurse’s attitudes seem to influence appropriateness of 
prescriptions, thus, are we treating patients or staff, or both at the same 
time? Hypothetically, high workloads influence our perception of patients’ 
behaviour and, therefore, result in that caregivers experience patients having 
NPS and hence in inappropriate PD prescription [54][52][53].  
        
In chapter 7 the implementation of a structured, repeated medication review 
with the essential roles of pharmacist, physician, and nurse into daily practice 
is advised to increase the appropriateness, by regularly evaluating the effects 
and stop PD prescriptions in time. Although suggestions have been made in 
the methodological considerations of this discussion, future research could 
give insight into the reason why the appropriateness of indications did not 
improve by biannual medication reviews. Potentially, by attending to this 
topic in the education about medication reviews to the multidisciplinary team, 
this could improve.  
Even when there is maximum guideline adherence and thus 
appropriateness according to the APID index, the evidence for PD 
prescriptions for NPS is marginal. Therefore, future studies could explore to 
what extent NPS are reduced by inappropriate prescriptions in comparison to 
appropriate prescriptions. Moreover, studies have explored the course of NPS 
during long-term care admission [55][56], however, little is known about the 
course of NPS in relation to the appropriateness of PD prescription. 
Longitudinal multicentre studies could potentially lead to insight, for example, 
into how these symptoms appear during nursing home admission without the 
use of PDs.  
The biopsychological model [8] attributes behaviour, and therefore 
NPS, to a genetic and an environmental origin. New developments in nursing 
home care and also new generations of patients with dementia from different 
backgrounds, could influence the extent with which NPS appear. Therefore, a 
meta-analysis of research from different decades could lead to insights in 
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trends, which could lead to new ways to appropriately attend to the needs of 
long-term care patients and focus on the regulation of NPS. 
 Furthermore, research should focus on exploring and strengthening 
the implementation of psychosocial interventions in dementia care and thus 
regulating NPS, considering these are first choice of treating NPS in dementia 
and several have been shown to be effective[57]. To effectively regulate NPS, 
information from patients’ representatives is imperative [53], therefore, 
future implementation studies should address to this topic. 
 
CONCLUDING REMARKS 
In conclusion, this thesis adds important knowledge to the field of appropriate 
dementia care and steps should be taken to implement this knowledge into 
clinical practice: 
- The appropriateness of the prescription of PDs for NPS in nursing 
home patients with dementia is rather poor, and associated with not 
only patient – but also non-patient factors.  
- Regularly reviewing the medication prescriptions improves the 
appropriateness of PD prescriptions and the implementation of tools 
such as the APID index in daily practice, may contribute to increase 
awareness and hence to a reduction of inappropriate PD use.  
 
The minority of the psychotropic drugs are prescribed appropriately for 
neuropsychiatric symptoms in dementia; medication reviews contribute to 
proper treatment. 
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APPENDICES 
Appendix A 
The Appropriate Psychotropic drug use for NPS In Dementia (APID) index, 
example: Haloperidol (N05AD01) 
 
Is there an indication for this drug? 
- In relation to the Psychotropic Drug (PD). 
- For NPS/sleeping disorder/delirium-> score, for other psychiatric disorders-> do not 
score. 
- Find indication from start date to 2 months after / PDs in the history search 6 
months after DSCU admission / past 4 months prior to medical record access (for 
intervention studies). 
 Score 
Agitation + Agression, hallucinations / delusions, delirium in dementia. 0 
Agitation without aggression, restlessness ( no restlessness during the night) 
in dementia. 
1 
No or another indication. 2 
 
Is the PD evaluated? 
- In relation to the PD. 
- Search for evaluation from the start date to 6 months thereafter / PDs prescribed 
before DSCU admission: search 6 months after DSCU admission / in the past 4 
months prior to record access (for intervention studies). 
 Score 
- Evaluation found within two weeks from start date / PDs prescribed before 
DSCU admission: search 6 months after DSCU admission. 
- For intervention studies, past 4 months prior to record access . 
0 
Evaluation between 2 weeks and 6 months after start date. 1 
Evaluation not found /> 6 months after recording current PG at pf from 
history. 
2 
 
Is the current daily dosage correct? 
 
Note: If too low, but if there is a documented reduction effort score 0. Score 
With agitation / aggression / hallucinations / delusions 1mg- 6mg (10-60 gtt. 
of 2mg/ml). Delirium 0.5 mg - 10 mg (5 -100 gtt.). 
0 
Agitation / agression / hallucinations <1 mg (<10 gtt.) / delirium <0.5 mg (<5 
gtt.). 
1 
Agitation / agression / hallucinations> 6 mg (> 60 gtt.) / delirium> 10 mg (> 
100 gtt.). 
2 
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Are there any clinically relevant drug-drug interactions? 
 Score 
No. 0 
Inductors (bosentan, carbamazepine, fenobarbital, fenytoine, primidon, 
rifabutine, rifampicine), ritonavir, lopinavir, efavirenz, etravirine, nevirapine. 
1 
Dopaminergic drugs (amantadine, apomorfine, bromocriptine, levodopa, 
pergolide, pramipexol, rasagiline, ropinirol, rotigotine, selegiline), 
antiarrhythmic agents. 
2 
  
Are there any clinically relevant drug-disease indications? 
 Score 
No. 0 
Epilepsy, liver dysfunction, heart failure, prostatic hyperplasia / trophism, 
sjogren's syndrome, venous thromboembolism. 
1 
Long-qt syndrome, Parkinson. 2 
 
Is there unnecessary (pseudo) duplication of drugs? 
 Score 
No Levomepromazide/ Nozinan, Pipamperon/dipiperon, 
Zuclopentixol/cisordinol, Olanzepine/zyprexa, Risperdon/risperdal, 
Clozapine/leponex, Quetiapine/seroquel. 
0 
Yes, without exceeding the maximum dosage, based on the maximum 
percentage of the dosage. 
1 
Yes, exceeding the maximum dosage, based on the maximum percentage of 
the dosage. 
2 
 
Is the duration of the therapy acceptable? 
Starting from the start date, in case of intermittent use, use the latest start 
date. 
Score 
< 3 months. 0 
> 3 months and <6 months. In case of a documented reduction effort, score 
0. 
1 
> 6 months. 2 
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Appendix B 
The Appropriate Psychotropic drug use for neuropsychiatric symptoms  In 
Dementia (APID) index, example: Risperidone (N05AX08) 
 
Is there an indication for this drug? 
- In relation to the Psychotropic Drug (PD). 
- For Neuropsychiatric Symptoms  (NPS)/sleeping disorder/delirium-> score, for other 
psychiatric disorders-> do not score. 
- Find indication from start date to 2 months after / PDs in the history search 6 
months after Dementia Special Care Unit (DSCU) admission / past 4 months prior to 
medical record access (for intervention studies). 
 Score 
Agitation, agression, hallucinations / delusions, restlessness during the night 
in dementia. 
0 
Delirium in dementia. 1 
No or another indication. 2 
 
Is the PD evaluated? 
- In relation to the PD. 
- Search for evaluation from the start date to 6 months thereafter / PDs prescribed 
before DSCU admission: search 6 months after DSCU admission / in the past 4 months 
prior to record access (for intervention studies). 
 Score 
- Evaluation found within two weeks from start date / PDs prescribed before 
DSCU admission: search 6 months after DSCU admission.  
- For intervention studies, past 4 months prior to record access.  
0 
Evaluation between 2 weeks and 6 months after start date. 1 
Evaluation not found > 6 months after DSCU admission. 2 
 
Is the current daily dosage correct? 
 
Note: If too low, but if there is a documented reduction effort score 0. Score 
With agitation / aggression / hallucinations / delusions / delirium 1mg- 6mg.  
 
0 
Agitation / agression / hallucinations / delusions / delirium <1 mg. 
 
1 
Agitation / agression / hallucinations / delusions / delirium >6 mg. 
 
2 
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Are there any clinically relevant drug-drug interactions? 
 Score 
No. 0 
Inductors (bosentan, carbamazepine, fenobarbital, fenytoine, primidon, 
rifabutine, rifampicine), ritonavir, lopinavir, indinavir, fluoxetine, paroxetine. 
1 
Dopaminergic drugs (amantadine, apomorfine, bromocriptine, levodopa, 
pergolide, pramipexol, rasagiline, ropinirol, rotigotine, selegiline). 
2 
  
Are there any clinically relevant drug-disease indications? 
 Score 
No. 0 
Diabetes Mellitis, epilepsy, hyperlipidemia, heart failure, prostatic 
hyperplasia / trophism, sjogren's syndrome, venous thromboembolism. 
1 
Long-qt syndrome, Parkinson. 2 
 
Is there unnecessary (pseudo) duplication of drugs? 
 Score 
No Levomepromazide/ Nozinan, Pipamperon/dipiperon, 
Zuclopentixol/cisordinol, Olanzepine/zyprexa, Haloperidol/Haldol, 
Clozapine/leponex, Quetiapine/seroquel. 
0 
Yes, without exceeding the maximum dosage, based on the maximum 
percentage of the dosage. 
1 
Yes, exceeding the maximum dosage, based on the maximum percentage of 
the dosage. 
2 
 
Is the duration of the therapy acceptable? 
Starting from the start date, in case of intermittent use, use the latest start 
date. 
Score 
< 3 months. 0 
> 3 months and <6 months. In case of a documented reduction effort, score 
0. 
1 
> 6 months. 2 
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Appendix C 
 
Study flowchart for the outcome analysis. 
LTCO = Long term care organizations 
DSCU = Dementia Special Care Unit  
1. Two LTCOs overruled the randomised selection of DSCUs because the selected DSCUs were covered by the same physician and the 
workload would get too high. 
2. A patient was considered a participant if the primary outcome (the appropriateness of psychotropic drug prescription) was 
collected/assessed. 
3. After baseline, one LTCO randomised to the intervention group discontinued the study because of insufficient staffing of physicians. 
4. One patient dropped out by mistake and was again included at 18 months. 
6 months 
Baseline 
12 months 
18 months 
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NEDERLANDSE SAMENVATTING 
‘Passend psychofarmacagebruik bij dementie’ 
In 2015 waren er wereldwijd ongeveer 46,8 miljoen mensen met dementie. 
Intussen neemt de gemiddelde leeftijd van mensen toe en zijn er jaarlijks 9,9 
miljoen nieuwe gevallen. Hoewel onderzoek zich richt op preventie, 
risicofactoren, ziektemanagement, kwaliteit van leven en van zorg, is er nog 
geen genezing of behandeling die de progressie van de aandoening aanzienlijk 
vertraagt of stopt.  
 Dementie is een progressieve hersenaandoening die resulteert in 
algehele cognitieve achteruitgang en vaak ook gedrag dat als probleem wordt 
ervaren door de persoon zelf of door mensen in diens omgeving. Voor dit 
gedrag wordt ook wel de term neuropsychiatrische symptomen (NPS) 
gebruikt. Voorbeelden van NPS zijn agitatie, agressie, angst, apathie, wanen, 
depressieve symptomen, hallucinaties en slapeloosheid.  
 In Nederland verblijft een groot deel van de mensen met 
vergevorderde dementie op psychogeriatrische afdelingen in verpleeghuizen. 
Zij zijn meestal ernstig beperkt in verschillende hersenfuncties en vertonen 
verschillende NPS.  
  
Psychofarmaca worden vaak voorgeschreven voor de behandeling van NPS. Er 
is echter een toenemende belangstelling voor het verminderen van het 
gebruik van psychofarmaca bij mensen met dementie die wonen in 
verpleeghuizen. Richtlijnen wijzen erop dat psychosociale en psychologische 
interventies, zoals muziektherapie, lichttherapie, snoezelen/ sensorische 
activatie en psychomotorische therapie, de voorkeursbehandeling van NPS 
zijn. Psychofarmaca, zoals antipsychotica, antidepressiva, anxiolytica, 
hypnotica, anti-dementie middelen en anti-epileptica zijn volgens de 
richtlijnen pas geïndiceerd voor NPS als psychosociale interventies 
onvoldoende effectief zijn.  
 Bij de huidige tendens om het aantal voorschriften van 
psychofarmaca te verminderen, lijkt echter weinig aandacht te bestaan voor 
de kwaliteit van het voorschrijven zelf. Verbetering van deze kwaliteit kan 
daarentegen de sleutel zijn voor passend psychofarmacagebruik. Dat wil 
zeggen, passend volgens de indicaties voor het voorschrijven en het gebruik 
ervan volgens de richtlijn probleemgedrag van Verenso, de vereniging voor 
specialisten ouderengeneeskunde. Door passend psychofarmacagebruik te 
verbeteren kan de effectiviteit toenemen en kunnen de bijwerkingen beperkt 
blijven. Passend gebruik van psychofarmaca is het onderwerp van dit 
proefschrift. 
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Het eerste deel van dit proefschrift richt zich op de ontwikkeling van een index 
om het construct ‘passend psychofarmacagebruik voor NPS bij dementie’ te 
operationaliseren. Tevens komt de huidige status van passend 
psychofarmacagebruik aan de orde, evenals relevante factoren die mogelijk 
samenhangen met passend psychofarmacagebruik voor NPS (PROPER I; zie 
hoofdstuk 2 voor het studieprotocol). 
Het tweede deel van dit proefschrift beschrijft een gerandomiseerde 
gecontroleerde trial naar de PROPER-interventie. Deze halfjaarlijkse 
gestructureerde multidisciplinaire medicatiebeoordeling door de arts, 
apotheker en verpleegkundige/verzorgende werd geïntroduceerd in de 
interventiegroep; in de controlegroep werd de gebruikelijke zorg voortgezet. 
Vier maal gedurende 18 maanden werd passend psychofarmacagebruik 
gemeten met de nieuwe index (PROPER II; zie hoofdstuk 6 voor het 
studieprotocol). 
 
PROPER I 
Na een algemene inleiding (hoofdstuk 1) en een weergave van de 
onderzoeksopzet van deel 1 (hoofdstuk 2), beschrijft hoofdstuk 3 de 
ontwikkeling van the Appropriate Psychotropic drugs use In Dementia index, 
de APID-index. Deze is afgeleid van de Medication Appropriateness Index 
(MAI). De MAI is geschikt voor klinische studies naar medicatiegebruik in het 
algemeen. De nieuwe index werd specifiek ontwikkeld voor klinische studies 
naar passend psychofarmacagebruik voor NPS bij bewoners met dementie in 
verpleeghuizen. De betrouwbaarheid en de validiteit (meet de index ook echt 
wat bedoeld is) van deze nieuwe index werden onderzocht. 
  Een panel van deskundigen beoordeelde de MAI items om te bekijken 
welke items geschikt waren en welke dienden te worden toegevoegd aan de 
nieuwe index. Een tweede, onafhankelijk expertpanel bepaalde de 
toepasbaarheid van de nieuwe set van items voor passend 
psychofarmacagebruik. Vijf bestaande MAI items werden gebruikt, het MAI 
item ‘indicatie’ werd aangepast en een nieuw item ‘evaluatie’ werd 
toegevoegd. De score-regels werden gebaseerd op richtlijnen, zoals de 
Verenso richtlijn voor probleemgedrag. Het tweede panel van deskundigen 
kwam tot de conclusie dat alle items bijdragen aan het concept ‘passend 
psychofarmacagebruik voor NPS bij dementie’. Dit resulteerde in een index 
met zeven (verschillende) items van passend psychofarmacagebruik. Deze 
zeven zijn: indicatie, evaluatie (van effectiviteit), dosering, interacties, contra-
indicaties, duplicaties en therapieduur. Een studie naar de 
interbeoordelaarsbetrouwbaarheid (overeenkomst in scores tussen twee 
invullers) werd uitgevoerd. Zodoende werd de APID-index gecreëerd.  
Ook werd er een zogenoemde som score ontwikkeld, gebaseerd op de 
gewogen itemscores, om het gebruik van de index in klinische studies 
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makkelijker toepasbaar te maken. De APID-index som score werd berekend op 
basis van informatie over individuele psychofarmaca uit de medische dossiers 
van bewoners. De validiteit werd onderzocht met behulp van een 
representatieve steekproef van 560 medische dossiers. 
  Uit de resultaten bleek dat alle items en de som score matige tot bijna 
perfecte interbeoordelaarsbetrouwbaarheid hadden en dat de validiteit 
veelbelovend was. De resultaten van deze studie tonen aan dat de APID-index 
betrouwbaar en valide is voor het meten van passend psychofarmacagebruik 
voor NPS bij bewoners met dementie in verpleeghuizen in klinische studies. 
 
Hoofdstuk 4 beschrijft de exploratie van de huidige status van passend 
psychofarmacagebruik voor NPS bij verpleeghuisbewoners met dementie. Een 
eenmalige meting werd uitgevoerd bij 559 bewoners met dementie die waren 
opgenomen op psychogeriatrische afdelingen in Nederlandse verpleeghuizen. 
De mate van passend psychofarmacagebruik werd beoordeeld met behulp 
van de APID-index. 
In totaal werden 578 psychofarmaca gebruikt voor NPS bij 60% van de 
verpleeghuisbewoners. Slechts tien procent van de psychofarmaca scoorden 
volledig passend op basis van de APID-index som score. Als het gebruik niet 
passend was, kwam dit vooral door niet passende indicatie, evaluatie en 
therapieduur; 36% scoorde volledig passend voor wat betreft de indicatie, 
46% scoorde volledig passend voor de evaluatie en 58% scoorde volledig 
passend voor therapieduur. Antidepressiva werden het meest passend 
gebruikt en anti-epileptica het minst.  
  De resultaten impliceren dat psychofarmacagebruik voor NPS bij 
bewoners met dementie kan worden verbeterd met een focus op passende 
indicaties, evaluaties en therapieduur. 
 
Hoofdstuk 5 beschrijft het onderzoek naar bewoner- en niet-bewoner 
gebonden factoren van passend psychofarmacagebruik (zoals ernst van NPS 
bij bewoners, stress bij de verzorgenden, attitude ten opzichte van 
dementiezorg van zorgverleners, ervaring van artsen en beschikbare tijd per 
bewoner). In deze cross-sectionele studie werd de mate van passend gebruik 
onderzocht met behulp van de APID-index som score. Verschillende metingen 
werden uitgevoerd om mogelijke bewoner- en niet-bewoner gebonden 
factoren te identificeren. Data werd verzameld met behulp van vragenlijsten, 
meetinstrumenten en dossiers van bewoners. 
  Met behulp van statistische analyses werd bepaald welke van deze 
factoren verband hielden met de score op de APID-index. De steekproef 
bestond uit 559 bewoners die in totaal 147 antipsychotica, 167 antidepressiva, 
85 anxiolytica en 76 hypnotica gebruikten. Het bleek dat hoe ouder de 
bewoner en hoe ernstiger de agressie, agitatie, apathie en depressie, hoe 
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meer passend het psychofarmacagebruik was. Daarentegen was niet-passend 
psychofarmacagebruik geassocieerd met meer angst bij bewoners, dementie 
van een ander type dan Alzheimer dementie, meer tijd beschikbaar van de 
arts per bewoner, meer bewoners per arts, meer jaren ervaring van de arts, 
en hogere werkdruk van het zorgteam.  
Samenvattend bleek dat meer uitgesproken NPS verband hielden met 
meer passend psychofarmacagebruik. Dit impliceert dat artsen meer aandacht 
moeten besteden aan psychofarmaca voorschriften als de NPS minder 
uitgesproken zijn. Er bleken ook enige niet-bewoner gebonden factoren te zijn 
geassocieerd met de mate van passend psychofarmaca-gebruik. Aangezien 
sommige van deze bevindingen contra-intuïtief zijn, bijvoorbeeld hoe meer 
tijd beschikbaar van de arts per bewoner hoe minder passend het 
psychofarmacagebruik, is meer onderzoek hiernaar nodig. 
 
PROPER-II 
Na de weergave van het studieprotocol in hoofdstuk 6, beschrijft hoofdstuk 7 
de effectiviteit van de PROPER-interventie voor het verbeteren van passend 
psychofarmacagebruik. Tijdens deze studie, met een duur van 18 maanden, 
werden de medische dossiers van de bewoners om de zes maanden 
geëvalueerd. De primaire uitkomstmaat was de mate van passend 
psychofarmacagebruik op basis van de APID-index som score. Bij aanvang van 
de studie waren er 380 deelnemende bewoners, waarvan er 222 op basis van 
toeval werden toegewezen aan de interventiegroep (de groep afdelingen die 
met de medicatiebeoordelingen ging werken). In de controlegroep werd de 
gebruikelijke zorg voortgezet. De APID-index som score verbeterde in de 
interventiegroep significant meer dan in de controlegroep wanneer werd 
gekeken naar alle psychofarmaca voorschriften gezamenlijk. Dit gold ook voor 
de evaluatie van de effectiviteit en voor de therapieduur van psychofarmaca. 
Er was geen significant effect van de interventie op de mate van passende 
indicaties van psychofarmaca voor NPS. 
Als dit per psychofarmaca groep werd bepaald, verbeterden de APID-
index scores voor de indicatie statistisch significant bij anxiolytica en 
antidepressiva. Voor hypnotica/sedativa en antidepressiva verbeterde de 
evaluatie significant. De therapieduur verbeterde significant voor 
antipsychotica en hypnotica/sedativa. 
 
Op basis van deze resultaten wordt het uitvoeren van een halfjaarlijkse 
medicatiebeoordeling in het verpleeghuis geadviseerd, waarbij zowel arts, 
apotheker als een verpleegkundige/verzorgende aanwezig zijn. 
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Slot opmerkingen 
Dit proefschrift voegt belangrijke kennis toe op het gebied van dementiezorg 
die in de praktijk gebracht kan worden (zie hoofdstuk 8 voor een 
beschouwing): 
 
- Psychofarmacagebruik voor NPS bij verpleeghuisbewoners met dementie is 
vaak niet passend en is geassocieerd met kenmerken van bewoners, maar 
ook met kenmerken van hun zorgverleners. 
- Het regelmatig beoordelen van de psychofarmacavoorschriften verbetert 
de kwaliteit van het psychofarmacagebruik. Mogelijk kan de implementatie 
van nieuw te ontwikkelen hulpmiddelen, zoals een voor de dagelijkse 
praktijk geschikte APID-index, bijdragen aan het vergroten van het 
bewustzijn van artsen, apothekers en verpleegkundigen/verzorgenden en 
daarmee aan passend psychofarmacagebruik. 
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DANKWOORD 
Het is ontzettend bijzonder om een aantal jaar aan deze these te hebben 
gewerkt, met de medewerking van vele anderen. Ruim 700 
verpleeghuisbewoners, hun naasten, ruim 100 zorgverleners en mijn collega’s. 
Ik wil met name de bewoners en hun vertegenwoordigers bedanken voor hun 
medewerking en het beschikbaar stellen van hun anonieme gegevens. Dat 
geldt ook voor de 13 verpleeghuizen die op verschillende niveaus meewerkten 
aan de onderzoeken van PROPER I en II. Iedereen heeft zich enorm ingezet en 
een hoop werk is verzet om de kennis over en de zorg voor patiënten met 
dementie te verbeteren. Voor hun enthousiasme en inzet wil ik de 
organisaties, besturen, artsen, apothekers, verpleegkundigen en verzorgers 
bedanken. Ongelofelijk hoe iedereen, naast zijn of haar drukke baan, tijd heeft 
weten te vinden om al onze vragenlijsten en formulieren in te vullen. De 
passie en het enthousiasme die in verpleeghuissetting heerst is 
indrukwekkend. 
 
Mijn naam staat op de voorkant, maar dit proefschrif is een product van een 
projectgroep. Graag wil ik daarom nog de leden van projectgroep individueel 
bedanken. 
 
Debby: zonder je steun, structuur en opbouwende commentaren was het niet 
gelukt. Bladerend door verschillende dankwoorden van proefschriften van 
voorgangers, zie ik wat jou zo uniek en goed in je vak maakt. Je hebt altijd een 
prominente plek in het dankwoord en dat geldt ook voor mijn traject. Ik ken 
weinig mensen die zo slim, bescheiden, warm en tegelijk doortastend kunnen 
zijn. Ik ben zeer verheugd dat je universitair hoofddocent bent geworden. Een 
waardering voor die ongelofelijke inzet die je voor de verpleeghuiszorg levert.  
Raymond: ook al ben je een enorme bezige bij, toch sta je altijd klaar 
voor een inhoudelijk maar bovenal steunend praatje. Je bezit naast een schat 
aan parate kennis, ook mensenkennis, en bent sympathiek en doortastend op 
de juiste momenten. Veel dank daarvoor. 
Sytse: over jouw raamwerk heb ik mij vrij vaak verwonderd; een 
encyclopedie. Je bent met zoveel tegelijk bezig, maar toch waren twee 
woorden genoeg voor jou om te weten waar het over ging. Je kreeg de stoel 
die daar bij past in Groningen. Ik ben zeer vereerd dat je mijn tweede 
promotor bent. De humor en relaxedheid die je daarbij uitstraalt, heeft voor 
mij een meditatief effect. 
Naar aanleiding van een sollicitatie voor onderzoeksassistent bij 
Sandra Zwijsen in Amsterdam, zei Martin ‘jij moet zelf promotieonderzoek 
gaan doen’. Daarna regelde je nog een werkplek voor me bij Gerion, om zo 
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mijn reistijd van Amsterdam naar Nijmegen wat te verlichten. Je hebt zo veel 
voor mij en mijn carrière gedaan, dat ik even niet meer weet hoe ik je daar 
ooit voor kan bedanken. Woorden schieten hier tekort. Je scherpte, 
behulpzaamheid en de rust die je uitstraalt in je, wat mij lijkt, drukke bestaan, 
intrigeert me.  
Steven: duizendmaal dank voor je enorme hulp met de statistiek. Je 
wist vaak complexe statistiek tot jip-en-janneketaal te reduceren, zodat ik het 
ook begreep. Op momenten dat ik even door de bomen het bos niet meer zag, 
wist je een woud aan variabelen te temmen met een overzichtelijke syntax. 
Fijn om iemand in de projectgroep te hebben die zo nuchter blijft.  
Roland: je hebt me het vak van promovendus geleerd. Toen Claudia en 
ik van start gingen, was je net klaar en wist je met wijze levenslessen mij klaar 
te stomen voor een lange intensieve tijd als promovendus. Incasseren, 
tandenknarsen en omzetten in positieve energie om tot mooi gedegen 
onderzoek te komen. Ik ben je daar erg dankbaar voor.  
Marjorie: je was mijn heldin op het gebied van farmaca. Erg fijn om 
iemand bij het project te hebben met zoveel parate farmaceutische kennis. 
Naast de inhoud, hebben we de strategie om de APID index up to date te 
houden aan jou te danken.  
Claudia: het was enorm leuk en vooral ook erg leerzaam met je samen 
te werken. Je had al veel ervaring in het uitvoeren van onderzoek, waardoor ik 
in het begin van het project met je mee kon surfen. Hier heb ik veel van je 
geleerd en daar wil ik je graag voor bedanken. Bedankt ook voor de lol die we 
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